1
Status: Approved ,Date: 31 January 2018Janssen Research & Development *
Clinical Protocol
A Double -blind, Randomized, Placebo -controlled Study to Evaluate the Efficacy and 
Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the 
Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal 
Ideation, in Adult Subjects Assessed to be at Imminent Risk for Suicide
Protocol 54135419SUI3002; Phase 3
AMENDMENT 2
JNJ54135419 (esketamine)
*Janssen Research & Development is a global organization that operates through different legal entities in 
various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development 
studies may v ary, such as, but not limited to Janssen Biotech, Inc.; Janssen Products, LP; Janssen 
Biologics, BV; Janssen -Cilag International NV; Janssen, Inc; Janssen Sciences Ireland UC; or Janssen 
Research & Development, LLC. The term “sponsor” is used throughout th e protocol to represent these 
various legal entities; the sponsor is identified on the Contact [CONTACT_170456].
This compound is being investigated in Phase 3 clinical studie s.
This study  will be conducted under US Food & Drug Administration I NDregulations (21 CFR 
Part 312).
EudraCT NUMBER:         2016 -003992 -23
Status: Approved
Date: 31 January 2018
Prepared by: [CONTACT_12945] & Development, LLC   
EDMS number :EDMS- ERI-132549001, 3.0 
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements . 
Confidentiality Statement
The information in this document contains trade secrets and commercial information that are privileg ed or confidential and may 
not be disclosed unless such disclosure is required by [CONTACT_784]. In any event, persons to whom the 
information is disclosed must be informed that the information is privileged or confidential and may not be f urther disclosed by 
[CONTACT_476]. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as priv ileged or 
confidential.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
2
Status: Approved , Date: 31January 2018TABLE OF CONTENTS
TABLE OF CONTENTS ............................................................................................................................... [ADDRESS_385580] OF IN -TEXT T ABLES A ND FIGU RES ................................................................................................ 5
PROTOCOL A MENDMENTS ....................................................................................................................... 6
SYNOPSIS .................................................................................................................................................. 16
TIME AND EVENTS SCHE DULE .............................................................................................................. 28
SIBAT TIME A ND EVENT S SCHEDULE ................................................................................................... 33
ABBREVIA TIONS ...................................................................................................................................... 35
1. INTRODUCTION ................................................................................................................................ 37
1.1. Background .................................................................................................................................... 37
1.1.1. Nonclinical Studies ..................................................................................................................... 37
1.1.2. Clinical Studies ........................................................................................................................... 38
[IP_ADDRESS]. Completed and Ongoing Clinical Studies with Intranasal Esketamine .................................... 38
[IP_ADDRESS]. Human Pharmacokinetics and Product Metabolism ................................................................ 39
[IP_ADDRESS]. Efficacy .................................................................................................................................... 40
[IP_ADDRESS]. Safety and Tolerability ............................................................................................................. 41
1.2. Overall Rationale for the Study ...................................................................................................... 43
2. OBJECTIVES , ENDPOINTS, A ND HYP OTHESIS ........................................................................... 44
2.1. Objectives and Endpoints .............................................................................................................. 44
2.1.1. Objectives ................................................................................................................................... 44
2.1.2. Endpoints .................................................................................................................................... 46
2.2. Hypothesis ..................................................................................................................................... 47
3. STUDY DESIGN A ND RA TIONA LE................................................................................................ .47
3.1. Overview of Study Design .............................................................................................................. 47
3.2. Study Design Rationale .................................................................................................................. 49
3.2.1. Study Population ......................................................................................................................... 49
3.2.2. Treatment and Study Duration ................................................................................................... 50
3.2.3. Control, Randomization and Blinding ......................................................................................... 51
3.2.4. Dose ............................................................................................................................................ 52
3.2.5. Efficacy  Measures ...................................................................................................................... 53
[IP_ADDRESS]. Montgomery -Asberg Depression Rating Scale (MADRS) ....................................................... 53
[IP_ADDRESS]. Suicide Ideation and Behavior Assessment Tool (SIBAT) ...................................................... 54
[IP_ADDRESS]. Beck Hopelessness Scale (BHS) ............................................................................................ 56
[IP_ADDRESS]. European Quality of Life (EuroQol) Group, 5- Dimension, 5 -Level (EQ -5D-5L)...................... 56
[IP_ADDRESS]. Quality of Life in Depression Scale (QLDS) ............................................................................ 56
[IP_ADDRESS]. Treatment Satisfaction Questionnai re for Medication (TSQM -9)............................................ 56
3.2.6. Safety Evaluations ...................................................................................................................... 56
3.2.7. Phar macokinetic Assessments ................................................................................................... 57
3.2.8. Biom arker, Pharmacogenomic (DNA), and Expression (RNA) Evaluations .............................. [ADDRESS_385581] POPUL ATION.................................................................................................................. 58
4.1. Inclusion Criteria ............................................................................................................................ 58
4.2. Exclusion Criteria ........................................................................................................................... 61
4.3. Prohibitions and Restrictions ......................................................................................................... 64
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
3
Status: Approved , Date: 31January [ZIP_CODE]. TREA TMENT A LLOCA TION AND BLINDING ................................................................................. [ADDRESS_385582] of Care Antidepressant Treatment ................................................................................. 69
7. TREA TMENT COMPLIA NCE ............................................................................................................ 69
8. PRESTUDY A ND CONCOMI TANT THERA PY................................................................................ 69
9. STUDY EVA LUATIONS .................................................................................................................... 70
9.1. Study Procedures ........................................................................................................................... 70
9.1.1. Overview ..................................................................................................................................... 70
9.1.2. Screening Phase ........................................................................................................................ 71
9.1.3. Double -Blind Treatment Phase .................................................................................................. 72
9.1.4. Posttreatment Phase (Follow -Up).............................................................................................. 74
9.2. Efficacy  Evaluations ....................................................................................................................... 75
9.2.1. Montgomery -Asberg Depression Rating Scale .......................................................................... 75
9.2.2. Suicide Ideation and Behavior Assessment Tool ....................................................................... 75
9.2.3. Beck Hopelessness Scale .......................................................................................................... 76
9.2.4. EuroQol 5 -Dimension 5 -Level .................................................................................................... 77
9.2.5. Quality of Life in Depression Scale ............................................................................................. 77
9.2.6. Treatment Satisfaction Questionnaires fo r Medication ............................................................... 77
9.3. Pharmacokinetics ........................................................................................................................... 77
9.3.1. Evaluations ................................................................................................................................ .77
9.3.2. Analytical Procedures ................................................................................................................. 78
9.3.3. Pharmacokinetic Parameters ..................................................................................................... 78
9.4. Pharmacokinetic/Pharmacodynamic Evaluations .......................................................................... 78
9.5. Biom arker and Pharmacogenomic (DNA) Evaluations .................................................................. [ADDRESS_385583] COMPLETION/D ISCONTINUA TION OF ST UDY TREA TMENT/ WITHD RAWAL 
FROM THE STUDY ........................................................................................................................... 84
10.1. Completion ..................................................................................................................................... 84
10.2. Discontinuation of Study Treatment/ Withdrawal From the Study .................................................. [ADDRESS_385584] Information ........................................................................................................................ 86
11.2. Sample Size Determination ........................................................................................................... 87
11.3. Efficacy  Analyses ........................................................................................................................... 87
11.4. Pharmacokinetic Analy ses............................................................................................................. 89
11.5. Pharmacokinetic/Pharmacodynamic Analyses .............................................................................. 89
11.6. Biom arker and Pharmacogenomic Analyses ................................................................................. 89
11.7. Medical Resource Utilization Analyses .......................................................................................... 90
11.8. Safety Analyses ............................................................................................................................. 90
11.9. Independent Data Monitoring Committee ...................................................................................... 91
12. ADVERSE EVENT REPORT ING...................................................................................................... 91
12.1. Definitions ...................................................................................................................................... 92
12.1.1. Adverse Event Definitions and Classifications ........................................................................... 92
12.1.2. Attribution Definitions .................................................................................................................. 93
12.1.3. Severity Criteria .......................................................................................................................... 93
12.2. Special Reporting Situations .......................................................................................................... 94
12.3. Procedures ..................................................................................................................................... 94
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
4
Status: Approved , Date: 31January 201812.3.1. All Adverse Events ...................................................................................................................... [ADDRESS_385585] Quality ............................................................................ 97
14. STUDY DRUG INFORM ATION......................................................................................................... 97
14.1. Physical Description of Study Drug(s) ........................................................................................... [ADDRESS_385586] ................................................. 102
16.2.3. Informed Consent ..................................................................................................................... 103
16.2.4. Privacy of Personal Data .......................................................................................................... 104
16.2.5. Long- Term Retention of Samples for Additional Future Research .......................................... 105
16.2.6. Countr y Selection ..................................................................................................................... 105
17. ADM INISTRA TIVE REQUI REM ENTS ............................................................................................ 105
17.1. Protocol Amendments .................................................................................................................. 105
17.2. Regulatory Documentation .......................................................................................................... 106
17.2.1. Regulatory Approval/Notification .............................................................................................. [ADDRESS_385587] Identif ication, Enrollment, and Screening Logs .............................................................. 107
17.4. Source Documentation ................................................................................................................. 107
17.5. Case Report Form Completion .................................................................................................... 108
17.6. Data Quality Assurance/Quality Control ...................................................................................... [ADDRESS_385588] Retention ......................................................................................................................... 109
17.8. Monitoring .................................................................................................................................... 109
17.9. Study Com pletion/Termination ..................................................................................................... 110
17.9.1. Study Com pletion/End of Study ................................................................................................ [ADDRESS_385589] OF A TTACHMENTS
Attachment 1: Prohibited Therapi[INVESTIGATOR_014] ................................................................................................ 117
Attachment 2: Anticipated Events .................................................................................................... 119
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
5
Status: Approved , Date: 31January 2018LIST OF IN -TEXT TABLES A ND FIGURES
TABLES
Table 1: Dose Administration of Esketamine 84 mg or Placebo ............................................................ 67
Table 2: Dose Administration of Esketamine 56 mg or Placebo ............................................................ 67
Table 3: Guidance for Blood Pressure Monitoring .................................................................................. 68
Table 4 :Approximate Volume of Blood to be Collected From Each Subject ......................................... 71
FIGURES
Figure 1: Schematic Overview of the Study ............................................................................................. 49
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
6
Status: Approved , Date: 31January 2018PROTOCOL A MENDMENTS
Protocol Version Issue Date
Original Protocol [ADDRESS_385590] recent amendment.
Amendment 2(31 January 2018 )
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union.  
The overall reason for the amendment: The overall reason for the amendment is to remove the interim analysis 
from the 54135419SUI3002 protocol ; to clarify that Module 3 Suicide Ideation and Behavior Assessment Tool 
(SIBAT) is an exploratory objective; to modify the timing of screening procedures in Figure 1 to be consistent with 
the Time and Events Schedule; to clari fy which potential subjects are not excluded from participation in the 
54135419SUI300 2study due to having a positive screening test for prescribed psychostimulants that are permitted 
during the study ; and updated text regarding the presentation of nasal examination data .
Applicable Section(s) Description of Change(s)
Rationale: The interim analysis was removed from the 54135419SUI3002 protocol to ensure that the study has 
sufficient numbers of subjects from key global regions/countries needed to support global health authority 
registration.
Synopsis Overview of 
Study Design ;
3.1. Overview  of Study 
Design; 11.2. Sample 
Size Determination; 
11.3. Efficacy 
AnalysesDeleted text stating that a n interim analysis will be conducted w hen 60% of randomized 
subjects have completed Day 2 of the double -blind phase.
Synopsis Statistical 
Methods; 11. 9. 
Independent Data 
Monitoring Committ eeThe follow ing text was deleted from the Synopsis Statistical Analysis section (Interim 
Analysis subsection):
A 2-stage group -sequential design with 1 interim analysis will be implemented to allow  
for early stoppi[INVESTIGATOR_313247] 60% of the subjects have been randomized and have completed Day 
2 of the double- blind phase. If the study is not stopped based upon the interim analysis, it 
will be continued until the maximum sample size (224 subjects) has been reached. An 
external independent Data Monitoring Committee (IDMC) will provide recommendations 
about stoppi[INVESTIGATOR_313248].
Section 11.3, Interim Anal ysis w as removed. As a result, the numbered headings 
following Section 11.3 w ere updated.
Cross -references to Section 11.3 Interim Analysis (in Sections 3.1 [Overview of Study 
Design] , 11.2 [Sample Size Determination] , 11.3 [Efficacy Analyses] ) were also deleted.
The follow ing text was modified in Section 11.9 Independent Data Monitoring Committee 
(strikeout text deleted):
An external Independent Data Monitoring Committee will be established to monitor data 
on an ongoing basis to ensure the continuing safety of the subjects enrolled in this study.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
7
Status: Approved , Date: 31January 2018Applicable Section(s) Description of Change(s)
In addition, the committee will review 1 interim analysis for efficacy. The committee will 
meet every 6 months to review safety data and will meet once to review  efficacy data after 
the interim analysis has been com pleted . After the reviews, the IDMC will make 
recommendations regarding the continuation of the study or, in the case of the interim 
analysis for efficacy, to either stop the study due to efficacy or futility . The details will be 
provided in a separate IDMC charter.
Synopsis Secondary 
Efficacy Endpoints; 
10.2 Discontinuation 
of Study 
Treatment/Withdrawal 
From  the Study ; 11.3. 
Efficacy AnalysisIn the Synopsis (Secondary Efficacy Endpoints), d eleted text stating that 1 interim 
analysis for efficacy and f utility will be performed.
The follow ing bullet point text w as removed from Section 10.2 Discontinuation of Study 
Treatment/Withdrawal From the Study :
Study is terminated by [CONTACT_313310] 11.4, Efficacy Analysis became Section 11.3 since the Interim Analysis section 
was deleted.
5. Treatment 
Allocation and 
BlindingThe follow ing text was deleted in the Blinding subsection:
How ever, if an interim analysis is specified, the randomization codes and, if required, the 
translation of ran domization codes into treatment and control groups will be disclosed to 
those authorized and only for those subjects included in the interim analysis.
Rationale: Module 3 SIBAT My Current Thinking assessment was changed from a secondary to an exploratory 
objective as Module 3 My Current Thinking was not designed as a stand -alone endpoint .
Synopsis, Objectives, 
Endpoints, Hypothesis, 
Exploratory 
Objectives, Endpoints; 
2.1.1. Objectives; 
2.1.2. Endp oints; 
[IP_ADDRESS]. Suicidal 
Ideation and Behavior 
Assessment Tool 
(SIBAT)Text regarding Module 3 SIBAT Assessment was removed from the secondary objective 
and endpoint subsections and moved to the exploratory objective subsections of the 
54135419SUI300 2protocol.
Rationale: Modified Figure [ADDRESS_385591] dose.
3.1. Overview  of Study 
Design (Figure 1)“24 hours” was replaced w ith “48 hours” in the Screening text box of Figure 1.
Footnote c text was modified as follows (bold text added; strikethrough text deleted):
Screening phase may be extended to up to 48 hours prior to Day 1 intranasal dose. If 
possible, screening should be perform ed within 24 hours prior the Day 1 intranasal 
dose.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
8
Status: Approved , Date: 31January 2018Applicable Section(s) Description of Change(s)
Rationale: Exclusion criterion #[ADDRESS_385592] for prescribed psychostimulants that are permitted 
during the stud y.
4.2. Exclusion Criteria The follow ing text was added to exclusion criterion #8 :
8.[ADDRESS_385593] result at screening due to prescribed psychostimulants 
(eg. amphetamine, methylphenidate, etc) that are permitted during the study in accordance 
with Attachment 1 , are eligible for study participation .
Rationale: Updated text reg arding presentation of nasal examination data.
Synopsis, Safety 
Analyses; 11.8. Safety 
AnalysesThe follow ing text was modified (bold text added; strikethrough text deleted):
Abnormalities observed during the targeted nasal exam inations at screening and 
post-baseline will be summarized and listed by [CONTACT_3227]. Changes in findings 
from the baseline nasal examination (including the upper respi[INVESTIGATOR_4352]/throat) w ill be 
listed by [CONTACT_1570]. Examinations will provide ratings (absent, mild, moderate, or 
severe) that are based on a visual inspection of the nostrils, nasal mucosa, and throat for 
nasal erythema, rhinorrhea, rhinitis, capi[INVESTIGATOR_1396]/blood vessel disruption and epi[INVESTIGATOR_3940]. A shift 
table for changes from baseline in ratings for each examinatio n will be presented by 
[CONTACT_313311].
Rationale: Minor errors w ere noted
Throughout the 
protocolMinor grammatical, formatting, or spelling changes were made.
Amendment 1 (20April 2017 )
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union.  
The overall reason for the amendment: The overall reason for the amendm ent isto update and/or clarify protocol 
content based on feedback received during study initiation activities .
Applicable Section(s) Description of Change(s)
Rationale: Exclusion criterion #[ADDRESS_385594]
Population; 
4.2. Exclusion CriteriaExclusion criterion #5 was revised as follows (bold text added; strikeout text deleted):
Subject has a history of meets the DSM -5 severity criteria for moderate or severe 
substance or alcohol use disorder , as defined by [CONTACT_2681] -5 criteria, (except fornicotine or 
caffeine ),within the6 months before screening.
A history (lifetim e) of ketamine, phencyclidine (PCP), lysergic acid diethylam ide 
(LSD), or 3, 4 -methylenedioxy -methamphetamine (MDMA) hallucinogen -related 
use disorder is exclusionary.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
9
Status: Approved , Date: 31January 2018Applicable Section(s) Description of Change(s)
3.2.1. Study 
PopulationText in this section modified as follows (bold text added) for consistency with exclusion 
criterion #5:
Subjects with a recent history (< 6 m onths) of moderate or severe substance or alcohol 
use disorders will be excluded to ensure the subject’s depression is not attributed to 
substance or alcohol use (ie, substance -induced depressive disorder).
Rationale: The text was updated to amend the duration of hospi[INVESTIGATOR_313249].
9.1.3. Double- blind 
Treatment PhaseText w as rev ised as follows (bold text added; strikeout text deleted):
Subjects will remain in the inpatient psychiatry unit for a recommended duration of [ADDRESS_385595] 
of care . The discharge decision will be made based upon the investigator’s judgment that 
the subject is no longer imminently suicidal and meets standard discharge criteria per local 
practice. Discharge before after less than [ADDRESS_385596] be discussed and approved by [CONTACT_3433] e 
sponsor’s medical monitor. The investigator must discuss in advance the need for 
continued hospi[INVESTIGATOR_60613] 107days and thereafter on a w eekly basis with the 
sponsor’s medical monitor.
Synopsis, Overview 
of Study Design and 
Dosage and 
Administration; 
Time and Events 
Schedule; 
3.1. Overview  of 
Study Design; 
6.1. Intranasal Study 
Drug;The text in these sections and Figure 1 (Schematic Overview of the Study) were revised 
for consistency with the changes described above in Section 9.1.3.
12.3.2. Serious 
Adverse Events The follow ing text was corrected for clarity and consistency with the above text in 
Section 9.1.3 (strikeout text deleted):
Inpatient hospi[INVESTIGATOR_313250] -required recommended   
5days (not due to adverse event, ie, clinical w orsening)
Rationale: A remote contact [CONTACT_313312] [ADDRESS_385597] two weeks (Days 28, 32, 35, and 39) after study 
drug treatment.
Time and Events 
Schedule-A remote contact [CONTACT_313313] 35 (35 RC) for MADRS assessment (recall 
since last assessment) and adverse event collection.
-MADRS assessments at Days [ADDRESS_385598] assessment 
from 7 -day recall.
-Visit numbers for Days 39, 46, 53, 67, and 90 w ere changed to Visits 14, 15, 16, 17, 
and 18, respectively.
-The w indow for the Day 32 visit has been changed to ±1 day from ±3 days (ie, footnote 
for Visit 12 w as changed to “b” from “a”).
-Rows for “Prior and concomitant therapy” and “Adverse events” were modified to 
indicate when these data are reviewed during t he follow -up phase.
SIBAT Time and 
Events ScheduleAn additional column was added for the Day [ADDRESS_385599] and the visit numbers were 
revised for consistency with the main Time and Events Schedule.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
10
Status: Approved , Date: 31January 2018Applicable Section(s) Description of Change(s)
Synopsis, Overview 
of Study Design; 
3.1. Overview  of 
Study Design; 
3.2.2. Treatment and 
Study Duration;
9.1.4. Posttreatment 
Phase (Follow -up)Text has been revised to include the Day [ADDRESS_385600] two weeks (Days 28, 32, 35, and 39) 
after study drug treatment. Subjects will then be followed up w eekly for the next two 
weeks (Days 46 and 53) and every two weeks for the re st of the follow -up period (Days 67 
and 90).
3.1. Overview  of 
Study Design, 
Figure 1Figure 1 has been revised to include remote contacts at Days 28 and 35 during the follow -
up phase.
Rationale: The text regarding discontinuation of study treatment was m odified to add that if the legal status of a 
subject changes during the study and the subject’s participation can no longe r be considered voluntary, then he/she 
will be discontinued from study treatment.
10.2. Discontinuation 
of Study 
Treatment/Withdrawal 
From  the Study  The follow ing bullet point was added to the list of reasons for which a subject ’s study 
treatment will b e discontinued:
Change in the in -patient hospi[INVESTIGATOR_313251] a result 
of a judicial or other legal administrative order
Rationale: The text regarding discontinuation of study treatment was modified to include worsening of underlying 
condition as an example of a safety or tolerability reason which would result in discontinuation of study treatment.
10.2. Discontinuation 
of Study 
Treatment/Withdrawal 
From  the Study  Worsening of underlying condition was added as an example of a safety or tolerability 
reason which would result in discontinuation of study treatment. Bold text added as shown 
below : 
The investigator believes that for safety reasons or tolerability reaso ns (eg, adverse 
event or worsening of underlying c ondition )  it is in the best interest of the subject to 
discontinue study treatment
Rationale: Exclusion criteria were revised to explicitly specify a detailed list of important medical conditions which 
are exclusionary.
Synopsis, Subject 
Population; 
4.2. Exclusion CriteriaExclusion criterion #6 was revised as follows (strikeout text deleted; bold text added):
Subject has any of the following conditions : 
-a history or current signs and symptoms of liver or renal insufficiency or of
-clinically significant cardiac (including unstable coronary artery disease and 
congestive heart failure, tachyarrhythm ias and recent myocardial infarction) ,or
vascular, pulmonary, gastrointestinal, endocrine (including uncontrolled 
hyperthyroidism) , neurologic (including current or pa st history of seizures except 
uncomplicated childhood febrile seizures with no sequelae), hematologic, 
rheumatologic, or metabolic (including severe dehydration/hypovolem ia)disease.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
11
Status: Approved , Date: 31January 2018Applicable Section(s) Description of Change(s)
Synopsis, Subject 
Population; 
4.2. Exclusion CriteriaExclusion criteri on #7 was revised as follows (bold text added):
Subject has uncontrolled hypertension (systolic blood pressure >140 mmHg or diastolic 
blood pressure >90 mmHg) despi[INVESTIGATOR_154867], exercise or a stable dose of anti -hypertensive 
treatment for at least 2 weeks at s creening; or any past history of hypertensive crisis. 
-Subjects with conditions in which the elevation of blood pressure could be a 
serious risk (including unstable heart failure, severe cardiovascular disease, 
recent cerebral injury, increased intracranial pressure / intracranial m ass lesion, 
intracranial bleeding or acute stroke, untreated glaucoma or perforating eye 
injury) are excluded.
-An abnormal blood pressure value at screening can be repeated once after [ADDRESS_385601] eligibility. On Day 1 of the double -blind phase prior to 
randomization, a supi[INVESTIGATOR_1662] -supi[INVESTIGATOR_9219] >140 mmHg or 
diastolic blood pressure >[ADDRESS_385602] 
PopulationCorrections were made to the text of exclusion c riterion #7 shown in the synopsis to 
maintain consistency with the text of exclusion criterion #7 shown in Section 4.2.
Rationale: Exclusion criteria were revised to clarify which subjects are excluded due to a positive urine test result.
4.2. Exclusion Criteria Exclusion criterion #8 was revised as follows (bold text added):
Subject has a positive urine test result(s) for phencyclidine (PCP), cocaine, or 
amphetamines (inclusive of amphetamine, methamphetamine [mAMP], and 3, 4-
methylenedio xy-methamphetam ine[MDMA]) at screening. 
-Subjects who have a positive test due to the appropriate use of prescribed opi[INVESTIGATOR_858], 
benzodiazepi[INVESTIGATOR_1651], or barbiturates may be eligible for study participation per clinician 
judgment. In addition, subjects who have a positive test for opi[INVESTIGATOR_858], benzodiazepi[INVESTIGATOR_1651], 
or barbiturates used w ithout a prescription, may be considered eligible per clinician 
judgment and in consultation with the sponsor’s medical monitor. Subjects known to 
be using heroin should be excluded from the study.
-Subjects who have a positive test due to opi[INVESTIGATOR_858], benzodiazepi[INVESTIGATOR_1651], or barbiturates taken 
in a suicide attempt (eg, overdose) may be eligible for study participation per clinician 
judgment and in consultation with the sponsor’s medical monitor.
Rationale: Exclusion criterion #13 w as revised to clarify that subjects who were previously enrolled in this study or 
the Sponsor’s other studies in this population ([ZIP_CODE] 419SUI3001 and ESKETINSUI2001) are excluded from 
participation in this study.
4.2. E xclusion Criteria Exclusion criterion #13 w as revised as follows (bold text added):
Subject has received an investigational drug (including esketamine, ketamine, or 
investigational vaccines) or used an invasive investigational medical device within [ADDRESS_385603] dose of study drug or is currently enrolled in an investig ational 
study or was previously enrolled in this study or the Sponsor’s other studies in this 
population, 54135419SUI3001 and ESKETINSUI2001 .
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
12
Status: Approved , Date: 31January 2018Applicable Section(s) Description of Change(s)
Rationale: Text w as added to further describe how the effect size of 0.45 for MADRS total score (at [ADDRESS_385604] dose ) was computed in the sample size determination .
Synopsis, Sample Size 
Determination; 
11.2. Sample Size 
DeterminationThe follow ing bold text was added:
The effect size used in this calculation was based on results of the ESKETINSUI2001 
study where the effect size for the change from  baseline to Day 2 was 0.65 (mean 
difference between treatm ent groups of - 7.2 and a pooled SD of 11.02) for MADRS 
total score . Given that the ESKETINSUI2001 study was a Phase [ADDRESS_385605] size of 0.45 to allow for greater variability that can be expected 
for a study conducted globally.
Rationale: The statistical methods w ere revised to add that summary statistics by [CONTACT_313314].
Synopsis, Primary 
Efficacy Endpoint; 
11.4. Efficacy 
Analyses, Primary 
Efficacy EndpointThe follow ing statement has been added:
In addition, descriptive statistics (N, mean, standard deviation, median, minimum and 
maximum) of the primary efficacy variable will be provided by [CONTACT_91294].
Rationale: The statistical methods w ere revised to confirm that treatment differences will be estimated using the 
Hodges -Lehman estimate for the key secondary variable.
Synopsis, Secondary 
Efficacy Endpoints; 
11.4. Efficacy 
Analyses, Secondary 
Efficacy EndpointsThe follow ing statement has been added:
The treatment difference will be estimated using the Hodges -Lehmann estimate, which is 
the median of all possible paired differences for the change from baseline for CGI -SS-R at 
24 hours.
Rationale: Text w as added to state which summary (descriptive) stat istics will be used for continuous variables and 
categorical variables.
Synopsis, Secondary 
Efficacy Endpoints; 
11.4. Efficacy 
Analyses, Secondary 
Efficacy EndpointsThe follow ing statement has been added:
Descriptive statistics (N, mean, standard deviation, median, minimum and maximum) will 
be provided for continuous variables and frequency distributions will be provided for 
categorical variables.
Rationale: The statistical methods have been revised to add descriptions of confidence intervals for treatment 
differences based on analysis of covariance ( ANCOVA) model, mixed model with repeated measures (MMRM), 
andnonlinear mixed -effects model analyses.
Synopsis, Primary 
Efficacy Endpoint ; 
11.4. Efficacy 
Analyses , Primary 
Efficacy EndpointThe follow ing statement has been added:
A point estimate and 95% confidence interval for the treatment difference will be 
provided.
Synopsis, Secondary 
Efficacy Endpoints; 
11.4. Efficacy 
Analyses, Secondary 
Efficacy EndpointsThe follow ing statement has been added:
Point estimates and 95% confidence intervals for the treatment differences will be 
provided.  
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
13
Status: Approved , Date: 31January 2018Applicable Section(s) Description of Change(s)
Synopsis, 
Pharm acokinetic 
Analyses; 
11.5 Pharmacokinetic 
AnalysesThe follow ing statement has been added:
For the parameter estimates, the standard error and 95% confidence interval will be 
provided. This w ill be determined after the population pharmacokinetic modeling of the 
data is completed.
Rationale: Text w as added to emphasize that subjects may participate in the study only if they have adequate 
capacity to give consent and after fully understanding the potential risks, benefits, and potential adverse events of 
the study.
16.1 Study -Specific 
Design ConsiderationsThe follow ing text has been added in the subsection “Selection of Subjects”:
Subjects may participate in the study only if they have adequate capacity to give consent 
and after fully understanding the potential risks, benefits, and potential adverse events of 
the study. Determinatio n of a subject’s decisional capacity will be made by [CONTACT_31821].
Rationale: Time and Events Schedule was clarified to note that the Remote Contact [INVESTIGATOR_106006] 90 is the same for 
subjects who discontinue during double -blind phase and those who discontinue during the follow -up phase.
Time and Events 
Schedule; SIBAT 
Time and Events 
Schedule-Footnote “d” in the Time and Events Schedule and footnote “f” in the SIBAT Time and 
Events Schedule were revised as follows (bold text added; strikeout text deleted):
For subjects who discontinue from double -blind treatment with reasons other than lost 
to follow  up, death, or w ithdrawal of consent, Remote Contact (RC) will be 
implemented [ADDRESS_385606] dose of intranasal study medication (if the date o f the 
DB ET visit is less than [ADDRESS_385607] dose of intranasal study medication) ,and 
on Day 25 and on Day 90 for MADRS assessment and adverse event collection. 
-The follow ing statement was added to footnote “dd” in the Time and Events Schedule 
and footnote “h” in the SIBAT Time and Events Schedule:
Subjects who discontinue during the double- blind treatment phase prior to Day [ADDRESS_385608] on Day 90 for MADRS assessment and adverse event 
collection.
Rationale: Text added to state that subjects should refrain from using alcohol within 24 hours before and after each 
intranasal treatment session. 
4.3. Restrictions and 
Prohibitions ; 
6.1. Intranasal Study 
DrugThe follow ing text was added:
Subjects should refrain from using alcohol within [ADDRESS_385609] appears intoxicated, dosing should not occur (delayed per 
the permitted visit window; see the Time and Events Schedule).
Rationale: Text revised to clarify procedures regarding collection of the Healthcare Resource Use Questionnaire.
9.6. Medical Resource 
UtilizationText w as revised as follows (bold text added; strikeout text deleted):
Medical resource utilization data, associated with medical encounters, will be collected 
using the Healthcare Resource Use Questionnaire (HRUQ) on an ongoing basis 
whenever an encounter occurs ,and will be reviewed as indicated in the Time and Events 
Schedule.
Time and Events 
ScheduleText revised to indicate that medical resource utilization data is collected using the 
Healthcare Resource Use Questionnaire.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
14
Status: Approved , Date: 31January 2018Applicable Section(s) Description of Change(s)
Rationale: The text describing evaluation of pulse oximetry and Modified Observer’s Assessment of 
Alertness/Sedation (MOAA/S) w as corrected to accurately describe when these data are collected.
9.7. Safety 
Evaluations, Pulse 
OximetryThe follow ing text was revised (bold text adde d; strikeout text deleted): 
Pulse oximetry will be used to measure arterial oxygen saturation (SpO 2). On each dosing 
day, the device will be attached to the finger, toe, or ear at approximately [ADDRESS_385610] nasal spray is 
administered (ie, SpO2 w ill be measured at t = - 15 m inutes, 0 [after administration of the 
first intranasal device], 15 minutes, 30 minutes, etc.) . 
9.7. Safety 
Evaluations, Modified 
Observer’s 
Assessment of 
Alertness and 
Sedation (MOAA/S)The follow ing text was revised (strikeout text deleted): 
On each intranasal dosing day, the MOAA/S will be performed every 15 minutes from t =  
15 minutes ( predose )to 1.5 hours postdose (ie, at t= -15 m inutes, 0 [after administration of 
the fir st intranasal device], 15 minutes, 30 minutes, etc.) .
Time and Events 
Schedule-Collection of pulse oximetry and MOAA/S data on Day 1 revised to state “ev ery 
15min” instead of “-15 m in to 1.5 hr”
-Footnotes “r” and “t” revised for consistency with the revisions in Section 9.7 
(described above) regarding evaluation of pulse oximetry and MOAA/S.
Rationale: The restriction o ndrinking before administration of intranasal study medication was revised to clarify .
Synopsis, Dosage and 
Administration; 
4.3. Prohibitions and 
Restrictions; 
6.1. Intranasal Study 
DrugText has been revised as follows (bold text added; strikeout text deleted):
Drinking of water or any other permitted beverage fluids will be restricted at least [ADDRESS_385611] nasal spray on each dosing day.
Rationale: Text w as revised to indicate that biomarker evaluations are not considered optional in this study.
Synopsis, Biomarker 
and 
Pharm acogenomic
(DNA) Evaluations , 
and Overview of 
Study Design ; 
3.1. Overview  of 
Study Design; 
9.1.1. Overview, 
Table 4; 
9.5. Biomarker and 
Pharm acogenomic 
(DNA) EvaluationsStatement s which indicated that site participation in biomarker evaluations is optional 
based on ope rational capabilities have been deleted.
Time and Events 
Schedule-The follow ing text was deleted from footnote “y”:
Optional site participation based on operational capabilities; required for subjects at 
participating sites.
-The follow ing text was deleted from the subheading “Biomarkers” as indicated below  
(strikeout text deleted):
Biomarkers (optional site participation) y
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
15
Status: Approved , Date: 31January 2018Applicable Section(s) Description of Change(s)
9.1.1. Overview, 
Table 4-Deleted row  showing approximate total blood volume for double -blind treatment phase 
without biom arker and pharmacogenomic/epi[INVESTIGATOR_313252].
-Text in footnote “c” was deleted and replaced w ith text in footnote “e”. Footnote “e” 
deleted.
Rationale: Procedure for collection of menstrual cycle information was revised to clarify.
Time and Events 
Schedule-The follow ing text was added to f ootnote “y” (replacing deleted text described above ):
Menstrual cycle information will be collected on these visits.
-Footnote “y” was added at Day 1, Predose and Day 25 in the row  for “Blood sample 
collection (serum and plasma biomarkers)” .
9.5. Biomarker and 
Pharm acogenomic 
(DNA) EvaluationsText w as modifi ed as follows for consistency with revisions to the Time and Events 
Schedule (bold text added; strikeout text deleted):
Information on menstrual cycle (da te of first day of last period, average length of cycle) 
will be recorded at each visit on Day 1 (pre dose) and Day 25 when blood samples for 
biomarker analysis are collected.
Rationale: Text w as revised to clarify procedures for clinical laboratory assessments and electrocardiogram 
recording .
9.7. Safety 
Evaluations, Clinical 
Laboratory TestsText revised to indicate that the urine pregnancy test and urine drug sc reen will be 
performed on -site.
9.7. Safety 
Evaluations,
Electrocardiogram 
(ECG)The follow ing statement was deleted:
If blood sampling or vital sign measurement is scheduled for the same time point as ECG 
recording, the procedures should be performed in the following order: ECG(s), vital signs, 
blood draw .
Rationale: Minor errors w ere n oted
Synopsis, Study 
PopulationLists of key inclusion and exclusion criteria revised to use bullets instead of numbers.
Throughout the 
protocolMinor grammatical, formatting, or spelling changes were made.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
16
Status: Approved , Date: 31January 2018SYNOPSIS
A Double -blind, Randomized, Placebo -controlled Study to Evaluate the Efficacy and Safety of 
Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of 
the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Subjects 
Assesse d to be at Imminent Risk for Suicide
Major depressive disorder (MDD) is the most prevalent mental health condition and the psychiatric 
diagnosis most commonly associated with suicide. Epi[INVESTIGATOR_313253] 60% of those 
who die by [CONTACT_313315], and at least one-half of people who complete suicide 
are depressed at the time of their deaths. Although MDD with imminent risk for suicide is a potentially 
lethal condition that requires immediate intervention, there is no approved treatment. The current standard 
of care is hospi[INVESTIGATOR_313254]. However, hospi[INVESTIGATOR_313255], and the risk for suicide remains high in the weeks after discharge. 
Asstandard antidepressants may take up to [ADDRESS_385612].
Ketamine and esketamine (the S-enantiomer of ketamine) are approved and widely used for the induction 
and maintenance of anesthesia via intramuscular (IM) or intravenous (IV) administration. The anesthetic 
effects of esketamine are attributed to the blockade of ionotropic N-methyl -D-aspartate (NMDA) 
glutamate receptors. Janssen Research & Development (JRD) is developi[INVESTIGATOR_313256]. The mechanism of action of esketamine is distinct from conventional 
monoaminergic antidepressant treatments, and esketamine profoundly affects fast excitatory glutamate 
transmission, increases brain -derived neurotrophic factor (BDNF) release, and stimulates synaptogenesis. 
In addition, a higher NMDA receptor binding affinity of esketamine compared to ketamine allows a lower 
volume of medication to be administered via the n on-invasive and rapi[INVESTIGATOR_375] -absorbed intranasal route.
The current study is being conducted to evaluate the efficacy and safety of intranasal esketamine in 
addition to comprehensive standard of care in subjects with MDD who are at imminent risk for suicide as 
a pi[INVESTIGATOR_9205] [ADDRESS_385613] of care in reducing the sympt oms of MDD, including  
suicidal ideation, in subjects who are assessed to beat imminent risk for suicide, as measured by [CONTACT_313316] -Asberg Depression Rating Scale (MADRS) total score at 
24hours post first dose .
Key Secondary Objective
The key secondary objective is to assess the efficacy of intran asal esketamine compared with intranasal 
placebo in reducing severity of suicidality as measured by [CONTACT_313317] (CGI -SS-R) at [ADDRESS_385614] dose.
Other Secondary Objectives
The other secondary objectives are:
 To evaluate the efficacy of intranasal esketamine compared with intranasal placebo in remission of 
MDD (defined as MADRS total score ≤12) at [ADDRESS_385615] dose, and through the 
end of the double -blind treatment p hase (Day 25).
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
17
Status: Approved , Date: 31January 2018 To evaluate the efficacy of intranasal esketamine compared with intranasal placebo in reducing 
symptoms of MDD as assessed by [CONTACT_313318] [ADDRESS_385616] dose on Day 1, and 
through the end of the double -blind treatment phase (Day 25).
 To assess the efficacy of intranasal esketamine compared with intranasal placebo in reducing 
severity of suicidality as measured by [CONTACT_87791] -SS-R at 4hours post first dose on Day 1, and through 
the end of the double- blind treatment phase (Day 25).
 To assess the efficacy of intranasal esketamine compared with intranasal placebo in achieving 
resolution of suicidality as measured by [CONTACT_313319] 0 (normal, not at all suicidal) or 1 (questionably 
suicidal) of the CGI -SS-R at [ADDRESS_385617] dose, and through the end of the double-
blind treatment phase (Day 25).
 To assess the efficacy of intranasal esketamine compared with intranasal placebo in reducing 
imminent suicide risk as measured by [CONTACT_313320] 
(CGI -SR-I) at [ADDRESS_385618] dose, and through the end of the double -blind treatment 
phase (Day 25).
 To assess the impact of intranasal esketamine compared with intranasal placebo on the following 
patient -relevant concepts through the end of the double -blind treatment phase (Day 25)
 Hopelessness as measured by [CONTACT_313321] (BHS)
 Health related quality of life and health status, using the European Quality of Life (EuroQol) 
Group, 5- Dimension, 5- Level (EQ -5D-5L)
 Health rela ted quality of life using the Quality of Life in Depression Scale (QLDS)
 Treatment satisfaction using the Treatment Satisfaction Questionnaire for Medication (TSQM -9)
 Patient- reported suicidality using the Suicidal Ideation and Behaviors Assessment Tool 
(SIBAT), including Module 5 My Risk, Question 3 (patient -reported frequency of suicidal 
thinking)
 To assess the safety and tolerability of intranasal esketamine during the double -blind treatment phase 
and the follow -up phase, with special attention given to the following assessments:
 Potential effects on suicidal ideation and behavior using the SIBAT
 On dosing days:
o Effect on heart rate, blood pressure, respi[INVESTIGATOR_697], and blood oxygen saturation 
o Effect on alertness and sedation using the Modified Observer 's Assessment of 
Alertness/Sedation (MOAA/S) scale
o Treatment -emergent dissociative symptoms using theClinician Administered Dissociative 
States Scale (CADSS)
 To assess the pharmacokinetics of intranasal esketamine.
Exploratory Objectives
The exploratory o bjectives are:
 To evaluate the efficacy of intranasal esketamine compared with intranasal placebo in reducing 
symptoms of MDD as assessed by [CONTACT_313322] -up phase (Day 90).
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
18
Status: Approved , Date: 31January 2018 To assess the efficacy ofintranasal esketamine compared with intranasal placebo in reducing 
severity of suicidality as measured by [CONTACT_87791]-SS-R through the end of the follow -up phase 
(Day 90).
 To assess the efficacy of intranasal esketamine compared with intranasal placebo in reducing 
imminent suicide risk as measured by [CONTACT_87791]-SR-Ithrough the end of the follow -up phase 
(Day 90).
 To assess the impact of intranasal esketamine compared with intranasal placebo through the end of 
the follow -up phase (Day 90) on the following patient -relevant concepts:
 Hopelessness (BHS)
 Health related quality of life and health status (EQ -5D-5L)
 Health related quality of life (QLDS)
 Subject treatment satisfaction (TSQM -9)
 To assess the effect of intranasal esketamine compared with intranasal placebo on the SIBAT 
Module 3 My Current Thinking through the double -blind treatment (Day 25) and follow -up (Day 90) 
phases.
 To assess medical resource utilization as measured by [CONTACT_313323] 
(HRUQ) of intranasal esketamine compared wi th intranasal placebo through the end of the follow -up 
phase (Day 90), including 30-day and 60-day readmission, and emergency room visits related to 
MDD and suicidality. 
 To evaluate whether pretreatment concentrations or post-treatment change in MDD -related 
biomarkers (eg, hypothalamic -pi[INVESTIGATOR_2117] -adrenal [HPA] axis function, immune system activation, 
growth factors, metabolic markers) correlate with clinical response or non-response as measured by 
[CONTACT_199189], following intranasal administration of esketamine .
Endpoints
The primary efficacy endpoint will be the change from baseline (Day 1, predose) to [ADDRESS_385619] 
dose in depressive symptoms, as measured by [CONTACT_170468].
The key secondary efficacy endpoint will be the change from baseline (Day 1, predose) at 24hours post 
first dose in severity of suicidality, as measured by [CONTACT_87791] -SS-R.
The other secondary endpoints are:
 MADRS
 Remission rate (MADRS ≤12) at [ADDRESS_385620] dose, and through the end of 
the double -blind treatment phase (Day 25)
 Change from baseline of MADRS total score at [ADDRESS_385621] dose and through the end of 
the double -blind treatment phase (Day 25)
 CGI-SS-R
 Change from baseline at [ADDRESS_385622] dose and through the end of the double -blind 
treatment phase (Day 25).
 Proportion of subjects achieving resolution of suicidality (CGI -SS-R score of 0 or 1) at [ADDRESS_385623] dose, and through the end of the double -blind treatment phase (Day 25)
 CGI-SR-I: Change from baseline at [ADDRESS_385624] dose, and through the end of the 
double -blind treatment phase (Day 25)
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
19
Status: Approved , Date: 31January 2018 BHS: Change from baseline through the end of the double -blind treatment phase (Day 25)
 EQ-5D-5L: Change from baseline through the end of the double -blind treatment pha se (Day 25)
 QLDS: Change from baseline through the end of the double -blind treatment phase (Day 25)
 TSQM -9: Scores through the end of the double -blind treatment phase (Day 25)
 SIBAT: Change from baseline in Module 5 My Risk, Question 3 (patient -reported frequency of 
suicidal thinking), through the end of the double -blind treatment phase (Day 25)
 Pharmacokinetics: Plasma esketamine and noresketamine concentrations will be summarized; 
plasma concentrations of esketamine (and noresketamine concentrations, ifwarranted) will be 
included in a population analysis
 Safety endpoints will be evaluated throughout the study:
 Monitoring of treatment emergent adverse events (TEAEs)
 Clinical laboratory tests, physical examination, nasal examination, 12-lead electrocardio gram 
(ECG), and vital signs
 SIBAT
 On dosing days: MOAA/S, CADSS, and pulse oximetry
The exploratory endpoints include:
 Change from baseline in MADRS, CGI-SS-R, CGI-SR-I, BHS, QLDS, and EQ-5D-5L through the 
end of the follow -up phase (Day 90)
 TSQM -9scores , medical resource utilization, and biomarkers through the end of the follow -up phase 
(Day 90)
 SIBAT: Change from baseline in Module 3 My Current Thinking through the end of the double -
blind (Day 25) andfollow -up (Day 90) phases
Hypothesis
The primary hypothesis is that, in addition to comprehensive standard of care, intranasal esketamine 
84mg is superior to intranasal placebo in rapi[INVESTIGATOR_313257], including suicidal 
ideation, as assessed by [CONTACT_313324] [ADDRESS_385625] dose in 
subjects who are assessed to be at imminent risk for suicide.
OVERVIEW OF STUDY DESIGN
This is a randomized, double -blind, placebo -controlled, multicenter study . A target of 224 male and 
female subjects , 18 to 64 years of age, with MDD presenting to an emergency room (ER) or other 
permitted setting and assessed to be at imminent risk for suicide will be enrolled in this study . 
The study will consist of a screening evaluation performed within 48 hours prior to the Day 1 intranasal 
dose (if possible, screening should occur within 24 hours prior to the Day 1 intranasal dose) , immediately 
followed by a 25-day double -blind treatment phase (Day 1 to 25), and a 65-day follow -up phase (Day 26 
to Day 90). The total study duration for each subject will be approximately 13 weeks. 
On Day 1 of the double -blind treatment phase, approximately 224 subjects will be randomized in a 1:1 
ratio to 1 of 2 treatments: intranasal esketamine 84 mg (n = 112) or intranasal placebo (n = 112), 
admini stered two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25). Randomization will 
be stratified by [CONTACT_313325]’s assessment of the subject’s need of standard of care 
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
20
Status: Approved , Date: 31January 2018antidepressant treatment (ie, antidepressant monotherapy or an antidepressant plus augmentation therapy); 
the standard of care will be determined prior to randomization on Day [ADDRESS_385626] clinical 
care, including hospi[INVESTIGATOR_313258], which will be 
determined by [CONTACT_1963](s). The standard of careantidepressant treatment will be initiated or 
optimized for all subjects on Day 1. 
After the first dose (ie, starting with the Day 4 dose or later), a one-time dose reduction to intranasal 
esketamine [ADDRESS_385627] is unable to tolerate the intranasal 
esketamine 84 mg or placebo dose assigned at randomization. No further dose adjustment is allowed 
during the double -blind treatment phase.
Dose titration/adjustments of newly initiated or optimized standard of care antidepressant treatment 
should occur during the first 2 weeks of double -blind treatment (ie, by [CONTACT_2006] 15), with doses remaining 
stable thereafter through the end of the double -blind phase (Day 25). During the follow -up phase, the 
antidepressant treatment will be managed based on clinician’s judgment.
Subjects will remain in the inpatient psychiatry unit for a recommended duration of [ADDRESS_385628] be discussed and approved by [CONTACT_456]’s medical monitor. Following discharge from the 
inpatient psychiatric unit, subsequent visits for the double -blind treatment phase will be conducted twice -
weekly at an outpatient psychiatric facility through Day 25. During the follow -up phase, subjects will be 
monitored twice weekly for the first two weeks (Day s 28, 32, 35, and 39) after study drug treatment. 
Subjects will then be followed up weekly for the next two weeks (Days 46 and 53) and every two weeks 
for the rest of the follow -up period (Days 67 and 90). 
Efficacy , safety , pharmacokinetic, biomarker , and pharmacogenomic evaluations will be performed as 
described in the Time and Events Schedule. 
The primary efficacy evaluation is the MADRS, the keysecondary evaluation isCGI-SS-R, and other 
efficacy evaluations include the SIBAT, BHS, EQ -5D-5L, QLDS, and TSQM -9.
Safety evaluations include monitoring and collection of adverse events and concomitant therapi[INVESTIGATOR_014], 
physical examination, nasal examination, body weight, height, vital signs, 12-lead ECG, pulse oximetry, 
respi[INVESTIGATOR_697], clinical laboratory tests, SIBAT, MOAA/S, and C ADSS . 
Blood samples will be collected for measurement of plasma concentrations of esketamine, noresketamine, 
and other metabolites if warranted.
Blood samples will be collected for biomarker evaluations.
Pharmacogenomic blood samples will be collected from subjects who consent separately to this 
component of the study (where local regulations permit). Subject participation in pharmacogenomic 
research is optional.
An Independent Data Monitoring Committee will be commissioned for this study.
SUBJECT POPULATION
The key inclusion and exclusion criteria for enrolling subjects in this study are described below.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
21
Status: Approved , Date: 31January 2018Key Inclusion Criteria
 Subject must be a man or woman, 18 to 64 years of age, inclusive.
 Subject must meet Diagnostic and Statistical Manual of Mental Disorders (5th edition) (DSM -5) 
diagnostic criteria for MDD, without psychotic features, based upon clinical assessment and 
confirmed by [CONTACT_313326] ( MINI ).
 Subjects must have current suicidal ideation with intent, confirmed by a “Yes” response to Question 
B3 [Think (even momentarily) about harming or of hurting or of injuring yourself: with at leas t some 
intent or awareness that you might die as a result; or think about suicide (ie ,about killing yourself)?] 
AND Question B10 [Intend to act on thoughts of killing yourself?] obtained from the MINI. Note: 
the response to B3 must refer to the present, whereas the response to B10 may reflect the past 
24hours. Ifthe screening period is longer than [ADDRESS_385629] be 
repeated prior to randomization to confirm eligibility .
 In the physician’s opi[INVESTIGATOR_1649], acute psychiatric hospit alization is clinically warranted due to subject’s 
imminent risk of suicide.
 Subje ct has a MADRS total score of > 28 predose on Day 1.
 As part of standard of care treatment, subject agrees to be hospi[INVESTIGATOR_313259] a 
recommended period of 5 days after randomization (may beshorter or longer if clinically warranted 
in the investigator’s opi[INVESTIGATOR_1649]) and take prescribed non-investigational antidepressant therapy(ies) for 
at least the duration of the double -blind treatment phase (Day 25) .
Key Exclusion Cri teria
 Subject has a current DSM -5 diagnosis of bipolar (or related disorders) ,antisocial personality 
disorder , or obsessive compulsive disorder .
 Subject currently meets DSM- 5 criteria for borderline personality disorder. 
 Subjects not meeting full DSM -5 criteria for borderline personality disorder but exhibiting 
recurrent suicidal gestures, threats, or self- mutilating behaviors should also be excluded.
 Subject has a current clinical diagnosis of autism, dementia, orintellectual disability 
 Subject has a current or prior DSM -5 diagnosis of a psychotic disorder, or MDD with psychotic 
features .
 Subject meets the DSM -5 severity criteria for moderate or severe substance or alcohol use disorder 
(except for nicotine or caffeine) within the 6 months before screening.
 A history (lifetime) of ketamine, phencyclidine (PCP), lysergic acid diethylamide (LSD), or 3, 
4-methylenedioxy -methamphetamine (MDMA) hallucinogen- related use disorder is 
exclusionary.
 Subject has any of the following conditions : 
 a history or current signs and symptoms of liver or renal insufficiency 
 clinically significant cardiac (including unstable coronary artery disease and congestive heart 
failure, tachyarrhythmias and recent myocardial infarction) orvascular, pulmonary, 
gastrointestinal, endocrine (including uncontrolled hyperthyroidism) , neurologic (including 
current or past history of seizures except uncomplicated childhood febrile seizures with no 
sequelae) , hematologic, rheumatologic, or metabolic (including severe 
dehyd ration/hypovolemia ) disease .
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
22
Status: Approved , Date: 31January 2018 Subject has uncontrolled hyperten sion (systolic blood pressure >140 mmH g or diastolic blood 
pressure > 90 mmHg) despi[INVESTIGATOR_154867], exercise or a stable dose of anti -hypertensive treatment for at least 
2 weeks at screening ; or any pas t history of hypertensive crisis. 
 Subjects with conditions in which the elevation of blood pressure could be a serious risk 
(including unstable heart failure, severe cardiovascular disease, recent cerebral injury, increased 
intracranial pressure / intracr anial mass lesion, intracranial bleeding or acute stroke, untreated 
glaucoma or perforating eye injury) are excluded.
 An abnormal blood pressure value at screening can be repeated once after [ADDRESS_385630] eligibility. On Day 1 of the double -blind phase prior to randomization, a 
supi[INVESTIGATOR_1662] -supi[INVESTIGATOR_9219] >140 mmHg or diastolic blood pressure
>90mmHg is exclusionary.
DOSAGE AND ADMINISTRATION
Intranasal Study Medication
All intranasal doses of study medication will be self-administered under the direct supervision of the 
investigator or designee. On Day 1, subjects will be randomized to treatment with either intranasal 
esketamine [ADDRESS_385631] has nasal congestion on the dosing day, an intranasal decongestant can be used to reduce 
congestion, or with the exception of the Day 1 dose, the dosing day may be delayed (per the permitted 
visit window; see the Time and Events Schedule). If an intranasal decongestant is used to reduce 
congestion, it cannot be used within [ADDRESS_385632] not be transferred from the ER to the inpatient psychiatric unit after the 
postdose assessments (approximately 4 hours in length) are completed. Subjects who have been admitted 
directly into the inpatient psychiatric unit due to immi nent risk for suicide or transferred from a medical 
unit (following medical stabilization for recent suicide attempt) will receive their first dose of study 
medication in the inpatient psychiatric unit. 
Subjects will remain in the inpatient psychiatry unit for a recommended duration of [ADDRESS_385633] is ready for discharge per clinician’s assessment. The minimum time 
required for postdose monitoring is 1.5hours. Subjects should be accompanied when released from the 
clinical study site. Subjects must not drive a car or work with machines for 24 hours after study drug 
dosing.
On each dosing day: Subjects will self-administer 1 spray into each nostril (ie, a total of 2 sprays using 
1intranasal device) at each of the following 3 time points: t = 0, 5 minutes and 10 minutes; time = [ADDRESS_385634] 100-μL spray. Subjects will use a separate intranasal device at each of 
these 3 time points (ie, a total of 3 devices). Sprays to each nostril should be de livered in rapid succession 
at the scheduled time points .
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
23
Status: Approved , Date: 31January 2018After the first dose (ie, starting with the Day 4 dose or later), if required due to tolerability issues, a one-
time dose reduction to intranasal esketamine [ADDRESS_385635] clinical care, including 
hospi[INVESTIGATOR_313258], which will be determined by 
[CONTACT_1963](s) based on clinical judgment and practice guidelines. The standar d of care 
antidepressant treatment (antidepressant monotherapy or antidepressant plus augmentation therapy) will 
be initiated or optimized for all subjects at the time of randomization on Day 1. Subjects who are on 
antidepressant monotherapy from Day 1 should remain on antidepressant monotherapy through the end of 
double -blind phase (Day 25) whereas subjects who are on antidepressant plus augmentation therapy from 
Day 1will remain on antidepressants plus augmentation therapy through the end of double -blind phase 
(Day 25). Eligible subjects may or may not be receiving antidepressants at the time of study entry. Dose 
titration/adjustments of newly initiated or optimized standard of care antidepressant treatment should 
occur during the first 2 weeks of double -blind treatment (ie, by [CONTACT_2006] 15), with doses remaining stable 
thereafter through the end of the double -blind phase (Day 25). Subjects who are currently taking a 
recently initiated antidepressant treatment at screening (initiated <2 weeks prior) may continue taking the 
antidepressant at the current dose or at an optimized dose (dose adjustment is allowed during the first 
2weeks of double -blind treatment) through the end of the double -blind phase (Day 25), if deemed 
clinically appropriate by [CONTACT_093] .During the double -blind treatment phase, the investigator needs 
to consult with the sponsor’s medical monitor in advance if additional changes on antidepressant 
treatment are clinically indicated. During the follow -up phase, the antidepressant treatment will be 
managed based on the clinician’s judgment. 
EFFICACY EVALUATIONS
The primary efficacy evaluation will be the MADRS total score. The assessment will be performed using 
the Structured Interview Guide for the MADRS. 
The other secondary and exploratory efficacy evaluations include the SIBAT, BHS, QLDS, EQ-5D-5L, 
TSQM -9, and HRUQ.
PHARMACOKINETIC EVALUATIONS
Venous blood samples will be collected for measurement of plasma concentrations of esketamine , 
noresketamine, and other metabolites if warranted. Plasma collected for pharmacokinetic (PK) evaluation
may additionally be used to evaluate safety or efficacy aspects that address concerns arising during or 
after the study period.
BIOMARKER AND PHARMACOGENOMIC (DNA) EVALUATIONS
Blood samples will be collected for exploratory analysis of biomarkers (protein, metabolites, and RNA) 
related to immune system activity, HPA axis activation, neurotrophi c and metabolic factors. Exploratory 
analyses may be performed for additional biomarke rs as well. 
A pharmacogenomic blood sample will be collected to allow for pharmacogenomic research, as necessary 
(where local regulations permit) .Subject participation in the pharmacogenomic research is optional.
MEDICAL RESOURCE UTILIZATION
Medical resource utilization data, associated with medical encounters, will be collected using the
Healthcare Resource Use Questionnaire (HRUQ). The HRUQ includes information regarding utilization 
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
24
Status: Approved , Date: 31January 2018of healthcare services (including the timing and type of serves), enabl ing changes in level and quantity of 
services to be considered as a variable in economic models.
SAFETY EVALUATIONS
Safety evaluations include monitoring and collection of adverse events and concomitant therapi[INVESTIGATOR_014], 
physical examination, body weight, height, vital signs, 12-lead ECG, pulse oximetry, clinical laboratory 
tests, and nasal examination . 
Although the SIBAT will be an efficacy evaluation, it will also inform the safety evaluation to detect 
potential effects on suicidal ideation and behavior throughout the study.
The CADSS will be administered to assess treatment -emergent dissociative symptoms , andthe MOAA/S 
will be used to measure treatment -emergent sedation.
STATISTICAL METHODS
Subject Information
The primary efficacy and safety analysis se ts are defined below.
 Full analysis set: The full analysis set will include all randomized subjects who have received at least 
one dose of double -blind study medication and have both a baseline and a post dose evaluation for 
the MADRS total score.
 Safety analysis set: The safety analysis set will include all randomized subjects who receive at least 
one dose of double -blind study medication.
Sample Size Determination
The maximum sample size for this study was calculated assuming an effect size of 0.[ADDRESS_385636] dose (Day 2), a one -sided significance level of 0.025, and a drop -out rate 
at 24 hours of 5%. Approximately 112 subjects will need to be randomized to each treatment group to 
achieve 90% power . The effect size used in this calculation was based on results of the 
ESKETINSUI2001 study where the effect size for the change from baseline to Day 2 was 0.65 (mean 
difference between treatment groups of -7.2 and a pooled SD of 11.02) for MADRS total score. Given 
that the ESKETINSUI2001 study was a Phase [ADDRESS_385637] to be estimated in the study, is defined by [CONTACT_14504] 3 components:
Population: subjects with MDD who are at imminent risk of suicide
Endpoint: change fro m baseline to [ADDRESS_385638] dose (Day 2) in the MADRS total score 
Measure of Intervention: the effect of the initially randomized treatment that would have been observed 
had all subjects remained on their treatment until Day 2 of the double -blind ph ase. 
The primary analysis will be based on the full analysis set and the MADRS total scores collected at 
Day 2.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
25
Status: Approved , Date: 31January 2018Primary Efficacy Endpoint
The primary efficacy variable, change from baseline in MADRS total score at [ADDRESS_385639] dose 
(Day 2), will be analyzed using an analysis of covariance (ANCOVA) model. The model will include 
factors for treatment, center, standard of care antidepres sant treatment (ie, antidepressant monotherapy or 
an antidepressant plus augmentation therapy), and baseline MADRS total score as a covariate. A point 
estimate and 95% confidence interval for the treatment difference will be provided. Since subjects are 
hospi[INVESTIGATOR_313260], it is anticipated that missing data will be infrequent . 
However, if a subject has a MADRS total score at a time earlier than [ADDRESS_385640] the 24 hour value, the earlier value will be used for the primary efficacy analysis .In addition, 
descriptive statistics (N, mean, standard deviation, median, minimum and maximum) of the primary 
efficacy variable will be provided by [CONTACT_91294].
Secondary Efficacy Endpoints
The analysis of th e key secondary efficacy endpoint, change from baseline for CGI -SS-R at [ADDRESS_385641] dose (Day 2), will be performed using an ANCOVA model on the ranks of change with factors for 
treatment, center, standard of care antidepressant treatment (ie, antidepressant monotherapy or an 
antidepressant plus augmentation therapy) and baseline CGI-SS-R (unranked) as a covariate .The 
treatment difference will be estimated using the Hodges -Lehmann estimate, which is the median of all 
possible paired differences for the change from baseline for CGI -SS-R at [ADDRESS_385642] to testing multiple endpoints (the primary and the key secondary) will be 
controlled by a fixed sequence testing procedure, ie, the key secondary hypothesis will be tested only after 
the null hypothesis for the primary endpoint is rejected.
The secondary efficacy endpoints, proportion of subjects with remission (MADRS total score ≤12) and 
the proportion of subjects achieving resolution of suicidality (CGI -SS-R score of 0 or 1) at each visit 
during the double -blind phase will be analyzed using a Cochran -Mantel- Haenszel chi-square test 
adjusting for center and standard of care antidepressant treatment (ie, antidepressant monotherapy or 
antidepressant plus augmentation therapy). Subjects who discontinue treatment prior to the particular visit 
of the double -blind phase will not be considered to have remission or resolution of suicidality.
Changes from baseline over time in MADRS total score, BHS, and QLDS total scores will be analyze d 
based on last observation carried forward (LOCF) data using an ANCOVA model with treatment, center, 
and standard of care antidepressant treatment (ie, antidepressant monotherapy or an antidepressant plus 
augmentation therapy) as factors and baseline valu e as a covariate. Additionally, the change from baseline 
in MADRS total score at Day 25 will be analyzed using a mixed model for repeated measures (MMRM)
analysis with baseline MADRS total score as a covariate, and treatment, center, standard of care
antidepressant treatment (ie, antidepressant monotherapy or antidepressant plus augmentation therapy), 
day, and day-by-treatment interaction as fixed effects, and a random subject effect. Comparison of 
esketamine versus placebo will be performed using the appro priate contrast. Point estimates and 95% 
confidence intervals for the treatment differences will be provided. Missing data will be closely 
monitored and additional sensitivity analyses will be specified in the SAP, if necessary.
Ranks ofchanges from basel ine over time for CGI-SS-R and CGI-SR-Iwill be analyzed based on LOCF 
data using an ANCOVA model with treatment, center, and standard of care antidepressant treatment (ie, 
antidepressant monotherapy or an antidepressant plus augmentation therapy) as facto rs and baseline value 
(unranked) as a covariate.
SIBAT Module 5 My Risk, Question 3 (patient reported frequency of suicidal thinking) , TSQM -9, 
dimension scores of EQ -5D-5L data, and health status index will be summarized over time.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
26
Status: Approved , Date: 31January 2018Additionally, scores of all efficacy endpoints will be summarized for all visits. Descriptive statistics (N, 
mean, standard deviation, median, minimum and maximum) will be provided for continuous variables 
and frequency distributions will be provided for categorical variables.
Pharmacokinetic Analyses
Plasma esketamine and noresketamine concentrations will be listed for all subjects. All concentrations 
below the lowest quantifiable concentration or missing data will be labeled as such in the concentration 
database. All subjects and samples excluded from the analysis will be clearly documented in the study 
report.
Population PK analysis of plasma concentration- time data of esketamine may be performed using  
nonlinear mixed -effects modeling. Data may be combined with those of other selected studies to support a 
relevant structural model. Available baseline subject characteristics (demographics, laboratory variables, 
genotypes, race, etc.) will be tested as potential covariates affecting PK parameters. For the parameter 
estimates, the standard error and 95% confidence interval will be provided. This will be determined after 
the population pharmacokinetic modeling of the data is completed. Details will be given in a population 
PK analysis plan and the results of the population PK analysis will be presented in a separate report.
Pharmacokinetic/Pharmacodynamic Analyses
The relationship between MADRS total score (and possibly selected adverse events and additional 
pharmacodynamic parameters), and PK metrics of esketamine may be evaluated. The results of the 
pharmacokinetic /pharmacodynamic analyses may be reported separately.
Biomarker and Pharmacogenetic Analyses
Biomarkers will be tabulated by [CONTACT_313327]. Posttreatment 
changes in biomarkers over time will be summarized by [CONTACT_1570]. Associations between baseline 
levels and changes from baseline in selected biomarkers and clinical endpoints will beexplored. 
Exploratory analyses may include comparison of biomarker measures between the treatment groups and 
correlation with baseline and change from baseline biomarker values in the efficacy and other measures. 
Exploratory analyses may be performed for additional biomarkers. In addition, all biomarker data 
obtained from this study may also be included in an ongoing cross -study analysis to investigate the 
relationship between depression severity, phenotypes, and biomarkers.
Pharmacogenomic analyses may include candidate gene analyses or genome -wide association analyses in 
relation to treatment response, non-response, and MDD. Expression analyses may include testing of 
known messenger RNA/microRNA (mRNA/miRNA) transcripts or transcriptome -wide analysis in 
relationship to antidepressant treatment response and MDD. Additional exploratory analyses may be 
performed.
Details of the analysis plan and summary of results from both biomarker and pharmacogenomic analyses 
will be reported separately.
Medical Resource U tilization Analys is
Medical resource utilization data will be descriptively summarized by [CONTACT_1570].
Safety Analyses
Safety data will be analyzed for the double -blind phase using the safety analysis set. The safety data from 
the follow -up phase will be summarized separately.
The verbatim terms used in the electronic case report form (eCRF) by [CONTACT_154923] (MedDRA). All reported 
adverse events with onset during each phase will be included in the analysis. For each adverse event, the 
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
27
Status: Approved , Date: 31January 2018percentage of subjects who experience at least 1occurrence of the given event will be summarized by 
[CONTACT_1570]. Subjects who die, who discontinue treatment due to an advers e event, or who experience 
a serious adverse event will be summarized separately.
The TEAEs of special interest will be examined separately grouped in the following categories: drug 
abuse, dependence and withdrawal (standardized MedDRA queries [SMQ]), transient dizziness/vertigo, 
impaired cognition, anxiety, cystitis, and suicidality. The adverse event s of special interest will be further 
listed in the SAP.
Laboratory data will be summarized by [CONTACT_154924]. Reference ranges and markedly abnormal 
results will be used in the summary of laboratory data. Descriptive statistics will be calculated for each 
laboratory analyte at baseline and for observed values and changes from baseline at each scheduled time 
point. Frequency tabulat ions of the abnormalities will be provided. A listing of subjects with any 
markedly abnormal laboratory results will also be provided.
The ECG data will be sum marized by [CONTACT_105292] . Descriptive statistics will be calculated at baseline  
and for observed values and changes from baseline at each scheduled time point. Frequency tabulations of 
the abnormalities will be made. All clinically relevant abnormalities in ECG waveform that are changes 
from the baseline readings will be reported.
Descriptive statist ics of temperature, pulse/heart rate, respi[INVESTIGATOR_697], pulse oximetry measurements, 
body weight measurements, and blood pressure (systolic and diastolic) values and changes from baseline 
will be summarized at each scheduled time point. The percentage of subjects with values beyond 
clinically important limits will be summarized.
Abnormalities observed during the targeted nasal examinations at screening and post-baseline will be 
summarized and listed by [CONTACT_1570].
Sedation data from the MOAA/S and dissociative symptoms data from the CADSS will be summarized 
descriptively at each scheduled visit by [CONTACT_1570].
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
28
Status: Approved , Date: 31 January 2018TIME A ND EVENTS SCHE DULE 
Phase Screening Double -blind Treatment Follow Up
Visit Number 1 2 3 4b5b6b7b8b9b10b- - - 11b12b13b14a15a16a17a18a-
Week 1 2 3 4 4 5 5 6 7 810 13
Day -c1 2ff4 8 11 15 18 22 25 D/CuDB 
ETdDB 
RCd28 
RCii3235 
RCii3946 53 6790/ FU
ETdd90 
RCdd
-Pre
dose0 
hr40
min1
hr1.5 
hr4
hree
Study Procedures
Setting
Emergency Room (ER) 
or other permitted setting e X X X X X X Xf
Inpatient psychiatric unit gX X
Outpatient psychiatric unit X X X X X X - - X X X X X X
Screening/Administrative
Informed consent X
Informed consent for optional 
genetic research samplesX
Inclusion/exclusion criteria X X
Medical history, psychiatric 
history, and demographicsX
Standard of care 
antidepressants assignmenthh X X
Urine pregnancy test for 
women of childbearing 
potential iX X X
Urine drug screen iX X X
Mini International Psychiatric 
Interview (MINI) j X
Question B3 and B10 from 
MINI (current status) j, k X
Study Drug Administration
Practice session for use of 
intranasal deviceX
Randomization X
Study Drug Administration m
(intranasal esketamine or 
placebo)X X X X X X X X
Safety Assessments
Physical examination X X X X
Nasal examination X XhX
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
29
Status: Approved , Date: 31 January 2018Phase Screening Double -blind Treatment Follow Up
Visit Number 1 2 3 4b5b6b7b8b9b10b- - - 11b12b13b14a15a16a17a18a-
Week 1 2 3 4 4 5 5 6 7 810 13
Day -c1 2ff4 8 11 15 18 22 25 D/CuDB 
ETdDB 
RCd28 
RCii3235 
RCii3946 53 6790/ FU
ETdd90 
RCdd
-Pre
dose0 
hr40
min1
hr1.5 
hr4
hree
Vital signs nX XoXoXoXoXoXoXoXoXoXoXoX X
12-lead ECG XpXqXqXqX
Pulse oximetry rX (every 15 min ) X X X X X X X
Body weight X XhX X
Height X
Modified Observer's 
Assessment of 
Alertness/Sedation 
(MOAA/S)j, tX (every 15 min ) X X X X X X X
Clinician Administered 
Dissociation States Scale 
(CADSS)j, sX X X X X X X X X X
Efficacy Assessments
Suicide Ideation and 
Behavior Assessment Tool 
(SIBAT) wX X X XhXhXhXhXhXhXhX X X X X X X X
Montgomery Asberg 
Depression Rating Scale 
(MADRS) (Recall: 7 days)jX X X X X X
MADRS (Recall: since last 
assessment) j XhXhXhXhXhXhXhX X X X X X X
MADRS (Recall: 4 hours) j, eeXv,zXv,z
MADRS (Recall: 24 hours) jX
Beck Hopelessness Scale 
(BHS) (Recall: Last 7 days) l X XhXhX X X
Quality of Life in Depression 
Scale (QLDS)l X X XhXhX X X
EQ-5D-5LlX X XhXhX X X
Treatment Satisfaction 
Questionnaire for Medication 
(TSQM -9)lXhXhX X X
Clinical Laboratory Assessments
Hematology, Chemistry XxXhX
Urinalysis XxXhX
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
30
Status: Approved , Date: 31 January 2018Phase Screening Double -blind Treatment Follow Up
Visit Number 1 2 3 4b5b6b7b8b9b10b- - - 11b12b13b14a15a16a17a18a-
Week 1 2 3 4 4 5 5 6 7 810 13
Day -c1 2ff4 8 11 15 18 22 25 D/CuDB 
ETdDB 
RCd28 
RCii3235 
RCii3946 53 6790/ FU
ETdd90 
RCdd
-Pre
dose0 
hr40
min1
hr1.5 
hr4
hree
Medical Resource Utilization
Health Resource U se
Questionnaire (HRUQ) j X X X X X
Biomarkers 
Blood sample collection 
(serum and plasma 
biomarkers) aaXyX Xh, yX
Blood sample collection 
(RNA biomarkers) gg X X XhX
Pharmacogenomics (DNA /epi[INVESTIGATOR_7009] ) –Optional
Blood sample collection bbX X XhX
Pharmacokinetics
Blood sample collection ccX X
Ongoing Subject Review
Prior and concomitant 
therapyContinuous X Continuous
Adverse events Continuous X X X X Continuous X
Abbreviations: BHS, Beck Hopelessness Scale; CADSS, Clinician Administered Dissociative States Scale; DB, double -blind; D/C, discharge; DNA, deoxyribonucleic acid ; ECG, 
electrocardiogram; EQ-5D -5L, EuroQol -5 dimension - 5-level; ER, emergency room; ET, early termination; FU, follow-up; HRUQ, Health Resource U seQuestionnaire; ICF, informed 
consent form; MADRS, Montgomery -Asberg Depression Rating Scale; MINI, Mini International Neuropsychiatric Interview; MOAA/S, Modified Observer’s Assessment o f 
Alertness/Sedation; QLDS, Q uality of Life in Depression Scale; RC, remote contact; RNA, ribonucleic acid; SIBAT, Suicide Ideation and Behavior Assessment Tool ; SpO 2, oxygen 
saturation; TSQM -9, Treatment Satisfaction Questionnaire for Medication
Footnotes:
aVisit can be performed ±3days.
bVisit can be performed ±[ADDRESS_385643] should be screened (ie, starting with the signing of the informed consent form) within 48hours prior to intranasal dosing on Day 1 (if possible, the subject should be 
screened within 24 hours prior to the Day 1 intranasal dose). 
dSubjects who discontinue from the double -blind treatment phase prior to completion of the Day [ADDRESS_385644] an Early Termination ( DB ET) visit con ducted at the time of 
discontinuation. For s ubjects who discontinue from double -blind treatment with reasons other than lost to follow up, death, or withdrawal ofconsent ,Remote Contact (RC) will be 
implemented [ADDRESS_385645] dose of intranasal stu dy medication (if the date of the DB ET visit is less than [ADDRESS_385646] dose of intranasal study medication )andon Day [ADDRESS_385647] is appropriately transitioned/followed for any additional care required. 
eNot applicable for subjects who have been admitted directly into the inpatient psychiatric unit due to imminent risk for suic ide or for medical stabilization (following recent suicide 
attempt). These subjects will receive their first dose of study medication in the inpatient psychiatric unit. Other permitted setting is a non -ER setting that has appropriate staffing to 
manage acutely suicid al patients.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
31
Status: Approved , Date: 31 January 2018f For subjects dosed in the ER or other permitted setting, it is recommended that subjects not be transferred from the ER to the inpatient psychiatric unit until after the 4 hour pos tdose 
assessments are completed. 
g Subjects can be admitted directly into the inpatient psychiatric unit due to imminent risk for suicide or for medical stabilization (following recent suicide attempt). These subjects will 
receive their first dose of study medication in the inpatient psychiatric unit. The recomme nded duration of inpatient hospi[INVESTIGATOR_2138] [ADDRESS_385648] of care by [CONTACT_093]’s opi[INVESTIGATOR_1649]. Discharge before [ADDRESS_385649] be discussed and approved by [CONTACT_456]’s medical monitor.
hPerformed predose.
iIn addition to the scheduled time points, additional pregnancy and drug screening can be performed at the investigator ’s discretion during the study.
j Clinician -administered assessment.
k Subjects will be asked to respond to Questions B3 and B10 of the MINI relative to their current state. The response to B3 must refer to the pr esent, whereas the response to B10 may 
reflect the past [ADDRESS_385650]-completed assessment.
m On each dosing day, subjects will self-administer 1 spray into each nostril (ie , 2 sprays per intranasal device) at each of the following 3 time points: t = 0, 5 minutes and 10 minutes, 
where time = [ADDRESS_385651] would receive the decreased dose on all
remaining dosing days. Please see details about study drug administration in Section 6.2.
n Blood pressure, heart rate, respi[INVESTIGATOR_697], and temperature (tympanic recommended). 
o Blood pressure, heart rate, and respi[INVESTIGATOR_313261] t = [ADDRESS_385652] 
eligibility.
q Performed 1 hour postdose. 
rOn each dosing day, pulse oximetry (SpO 2) will be performed every 15 minutes from predose to 1.5 hour postdose ( see Section 9.7for further guidance on timing of pulse oximetry 
assessments). 
sCADSS will be performed on dosing days predose and at 40 minutes and 1.5 hours postdose. If any CADSS items are scored zero at 40 minutes, these items will not be repeated at 
1.5hours postdose.
tMOAA/S will be performed every 15 minutes on dosing days from predose to 1.5 hour postdose, or longer, if necessary ( see Section 9.7for further guidance on MOAA/S 
assessments).
u Discharge (D/C) visit is performed on the actual day of discharge from initial hospi[INVESTIGATOR_313262] .If the actual day of discharge coincides with another scheduled 
study visit, all study procedures for the scheduled visit should be completed and duplicate assessments are not required.
v MADRS performed at [ADDRESS_385653] -reported modules; not all modules are completed at every visit. Refer to the SIBAT Time and Events Schedule for an outline of 
which module(s) will be performed at each scheduled time point.
x Samples will be collected for analysis by [CONTACT_12117] (for eligibility) and central laboratory. If standard of care clinical laboratory tests are performed within 24 hours prior to the 
screening visit (ie, prior to signing of the ICF) the results for laboratory tests required per proto col at screening can be used for determination of subject eligibility. In this case, after the 
subject signs the ICF, a sample(s) for the local laboratory is not required, but samples for the central laboratory are still required. 
yMenstrual cycle infor mation will be co llected on these visits.
z The sleep item will not be assessed at the [ADDRESS_385654].
aaApproximately 20 mL serum and 10 mL pla sma samples will be collected at each time point.
bbA 6mL whole blood sample will be collected at each time point.
ccA 2mL whole blood sample will be collected at each of the following postdose times : 30-[ADDRESS_385655] an Early Termination ( FU ET) visit conducted at the time of discontinuation. For 
subjects who discontinue with reasons other than lost to follow up, death, or withdrawal of consent , Remote Contact (RC) will be implemented on Day [ADDRESS_385656] on Day 90 for MADRS assessment and 
adverse event collection.
eeThe 4-hour assessments at the Day 1 and Day 25 visit should be performed within ±30 minutes of the 4 -hour postdose time point.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
32
Status: Approved , Date: 31 January 2018ffThe 24-hour assessments at the Day 2 visit should be performed within ±[ADDRESS_385657] of care antidepressant treatment (antidepressant monotherapy or antid epressant plus augmentation therapy) will be determined by [CONTACT_1963](s) based on 
clinical judgment and practice guidelines prior to randomization ,and the treatment will be initiated on Day 1. See Section 6.2for further details.
iiRemote contact [CONTACT_313328].
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
33
Status: Approved , Date: 31 January 2018SIBA T TIME AND EVENT S SCHEDULE
Phase Screening Double -blind Treatment Follow Up
Visit Number 1 2 34b5b6b7b8b9b10b- - - 11b12b13b14a15a16a17a18a-
Week 1 2 3 4 4 5 5 6 7 810 13
Day - 1 2j4c8c11c15c18c22c25cD/CdDB
ETfDB
RCf28 
RCg3235 
RCg39 46 53 6790/ FU 
ETh90 
RCh
-Pre
dose0 
hr40 
min1 
hr1.[ADDRESS_385658] Completed Modules
Module 1 About me X
Module 2 My Risk/ 
Protective FactorsX X X X X X X
Module 3 My Current 
ThinkingX X X X X X X X X X X X X X X X X X
Module 4 My Actions X X X X X X X X X X X X X X
Module 5 My Risk X X X X X X X X X X X X X X X X X X
Clinician Completed Modules
Module 6. Clinician Semi-
Structured InterviewX X X X X X X X X X X X X X X X X X
Module 7. Clinical Global 
Impressions e X X X X X X X X X X X X X X X X X X
Module 8. Clinical 
Judgment of optimal 
Suicide ManagementX X X X X X X X X X X
Abbreviations: CGI -SR-I, Clinical Global Impression of Imminent Suicide Risk; CGI -SR-LT, Clinical Global Impression of Long-term Suicide Risk; CGI -SS-R, Clinical Global 
Impression of Severity of Suicidality –Revised; DB, double -blind; D/C, discharge; ET, early termination; FoST, frequency of suicidal thinking; FU, follow -up; RC, remote contact; 
SIBAT, Suicide Ideation and Behavior Assessment Tool
Footnotes:
aVisit can be performed +/ -3days.
bVisit can be performed +/ -1 day. Intranasal treatment sessions should not be given on consecutive days.
cThe SIBAT modules will be performed predose.
dDischarge (D/C) visit is performed at on the actual day of discharge from inpatient hospi[INVESTIGATOR_059] . If the actual day of discharge coincides with another scheduled study visit, the 
SIBAT modules will be performed according to the procedures under D/C column and duplicate assessments are not required.
eModule 7 includes the Clinical Global Impression of Severity of Suicidality –Revised (CGI -SS-R), Clinical Global Impression of Imminent Suicide Risk (CGI -SR-I),Clinical Global 
Impression of Long-term Suicide Risk (CGI-SR -LT), and assessment of frequency of suicidal thinking (FoST) .
fSubjects who discontinue from the double -blind treatment phase prior to completion of the Day [ADDRESS_385659] an Early Termination ( DB ET) visit conducted at the time of 
discontinuation. For subjects who discontinue from double -blind treatment with reasons other than lost to follow up, death, or withdrawal of consent, Remote Contact (RC) will be 
implemented [ADDRESS_385660] dose of intranasal study medication (if the date of the DB ET visit is less than [ADDRESS_385661] dose of intranasal study m edication )andon Day [ADDRESS_385662] is appropriately transitioned/fol lowed for any additional care required.
gRemote contact [CONTACT_313329].
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
34
Status: Approved , Date: [ADDRESS_385663] an Early Termination (FU ET) visit conducted at the time of discontinuation. For 
subjects who discontinue with reasons other than lost to follow up, death, or withdrawal of consent, Remote Contact (RC) will be implemented on Day [ADDRESS_385664] on D ay 90 for MADRS assessment and 
adverse event collection.
iThe 4 -hour assessments at the Day 1 visit should be performed within ±30 minutes of the 4 -hour postdose time point.
jThe 24 -hour assessments at the Day 2 visit should be performed within ±2 hours of the 24 -hour postdose time point.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
35
Status: Approved , Date: [ADDRESS_385665] aspartate aminotransferase
BDNF brain -derived neurotrophic factor
BHS Beck Hopelessness Scale
BUN blood urea nitrogen
CADSS Clinician Administered Dissociative States Scale
CGI-SR-I Clinical Global Impression –Imminent Suicide Risk
CGI-SR-LT Clinical Global Impression –Long -term Suicide Risk
CGI-SS Clinical Global Impression –Severity of Suicidality
CGI-SS-R Clinical Global Impression –Severity of Suicidality -Revised
CGJ-SR Clinical Global Judgment of Suicide Risk
eCRF electronic case report form(s)
CYP hepatic cytochrom e P450
DNA deoxyribonucleic acid
DSM -5 Diagnostic and Statistical Manual of Mental Disorders ( 5th edition)
ECG electrocardiogram
ECT electroconvulsive therapy
eDC electronic data capture
EDTA ethylenediaminetetra acetic acid
ER Emergency Room
GCP Good Clinical Practice
HPA hypothalamic -pi[INVESTIGATOR_2117] -adrenal
HRUQ Healthcare Resource Use Questionnaire
ICD- [ADDRESS_385666] InterSePT Scale for Suicidal Thinking
IV Intravenous
IWRS interactive web response system
LC-MS/MS liquid chromatography/mass spectrometry/mass spectrometry
LSD lysergic acid diethylamide
MADRS Montgomery Asberg Depression Rating Scale
MADRS -SI Montgomery Asberg Depression Rating Scale - Suicidal Thoughts I tem
mAMP methamphetamine
MDD major depressive disorder
MDMA 3, 4-methylenedioxy -methamphetamine
MedDRA Medical Dictionary for Regulatory Activities
MINI Mini International Psychiatric I nterview
miRNA micro ribonucleic acid
MOAA/S Modified Observer’s Assessment of A lertness/S edation
mRNA messenger ribonucleic acid
NMDA N-methyl -D-aspartate
PCP phencyclidine
PD pharmacodynamic(s)
PK pharmacokinetic(s)
PQC Product Quality Complaint
QTc corrected QT
QTcB QT corrected according to Bazett's formula
QTcF QT corrected according to Fridericia's formula
RNA ribonucleic acid
SAP Statistical Analysis Plan
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
36
Status: Approved , Date: [ADDRESS_385667] treatment -resistant depression
USP [LOCATION_002] Pharmacopeia
w/v weight/volume
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
37
Status: Approved , Date: 31 January [ZIP_CODE]. INTRODUCTION
Major depressive disorder (MDD) is the most prevalent mental health condition and the 
psychiatric diagnosis most commonly  associated with suicide.41,65Epi[INVESTIGATOR_313263] y 60% of those who die by [CONTACT_313330], and at least one-half 
of people who complete suicide are depressed at the time of their deaths.2,13,17,51Although MDD 
with imminent risk for suicide is a potentially  lethal condition that requires immediate 
intervention , there is no approved treatment. The current standard of care is hospi[INVESTIGATOR_313264]. H owever, hospi[INVESTIGATOR_313265], and the risk for suicide remain shigh in the weeks after discharge . As 
standard antidepressants may take up to 4-[ADDRESS_385668].24
Ketamine and esketamine (the S-enantiomer of ketamine) are approved and widely  used for the 
induction and maintenance of anesthesia via intramuscular (IM) or intravenous (IV) 
administration. The anesthetic effects of esketamine are attributed to the blockade of ionotropic 
N-methy l-D-aspartate (NMDA) glutamate receptors.78Janssen Research & Development (JRD) 
is developi[INVESTIGATOR_313266] y. The mech anism of action of 
esketamine is distinct from conventional monoaminergic antidepressant treatments, and 
esketamine profoundl y affects fast excitatory  glutamate transmission, increases brain -derived 
neurotrophic factor (BDNF) release, and stimulates synaptogenesis.26In addition, ahigher 
NMDA receptor binding affinit y of esketamine compared to ketamine allows a lower volume of 
medication to be admin istered via the non -invasive and rapi[INVESTIGATOR_2478] y-absorbed intranasal route.
For the most comprehensive nonclinical and clinical information regarding esketamine
(JNJ-54135419), refer to the latest version of the Investigator's Brochure for esketamine .37
The term "sponsor" used throughout this document refers to the entities listed in the Contact 
[CONTACT_23774](s), which will be provided as a separate document.
1.1. Background
1.1.1. Nonclinical Studies
Safety Pharmacology
The effects of ketamine on myocardial contractility  and blood pressure variedwith species and 
experimental conditions.37In these studies , the dog was most predictive of the cardiovascular 
effects of ketamine in man. I n dogs, ketamine produced increase sinarterial blood pressure , heart 
rate and cardiac output as well as a decrease in total peripheral resistance .43Results from animal 
studies suggest that the increase in blood pressure produced by [CONTACT_313331].43
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
38
Status: Approved , Date: 31 January 2018Toxicology
Repeated- dose Toxicity: Repeated- dose toxicity  studies with intranasally  administered 
esketamine were performed in rats for up to [ADDRESS_385669] dose tested.37
Neurotoxicity: The neurotoxic potential of intranasal esketamine has been investigated in rats in 
two single -dose studies and one 14-day study. No neuropathological lesions were noted in the 
esketamine -dosed rats at the highest dose tested in each stud y.[ADDRESS_385670] ive and Developmental Toxicity :In a rat fertility  and earlyembry onic developmental 
study , no adverse effects of intranasal esketamine on the fertility  and reproductive capacities of 
adult males and females were observed.37Rat and rabbit embry o-fetal developmental toxicity  
studies with intranasall y administered racemic ketamine did not reveal evidence of reproductive 
toxicity .37However, when monkey  fetuses were exposed in utero to high dose levels of racemic 
ketamine, neurotoxicity  was observed.37Intranasal esketamine did not affect pre-and postnatal 
development in rats; however, high dose levels of racemic ketamine induced neurotoxicity  in 
early postnatal rat pups.37
Genotoxicity: In vitro and in vivo genotoxicity  studies have been performed with ketamine and 
esketamine, and the overall weight of evidence demonstrates the absence of significant genotoxic 
risk.37
Abuse potential: The results of self -administration and withdrawal experiments in several animal 
models suggest that esketamine would have abuse potential in humans.7,20,21,46,57,83,84
1.1.2. Clinical Studies
[IP_ADDRESS]. Completed and Ongoing Clinical Studies with Intranasal Esketamine
A total of [ADDRESS_385671] been completed but not reported , and atotal 
of 6 Phase 1 studies are ongoing in healthy  subjects, subjects with hepatic impairment, and 
subjects with renal impairment.
One Phase 2 study  has been completed in subjects with MDD who are at imminent risk of 
suicide with 35subjects exposed to intranasal esketamine.16One Phase 2 study  has been 
completed in subjects with treatment -resistant depression (TRD )with [ADDRESS_385672] : 2short -term double -blind, randomized, active -controlled studies, 
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
39
Status: Approved , Date: [ADDRESS_385673] .
Further information about the completed and ongoing studies with esketamine isprovided in the 
Investigator’s Brochure.37
[IP_ADDRESS]. Human Pharmacokinetics and Product Metabolism
Metabolism and Excretion
Ketamine (and esketamine) underg oes extensive metabolism by  [CONTACT_313332] P450 
(CYP). In humans, N-demethy lation to the active metabolite norketamine is a major route of 
metabolism. Norketamine had a half-life in plasma of approximately  5 hours in humans .31The 
major human hepatic cytochromes that catal yze ketamine N-demethylation in vitro were
CYP2B6 and CYP3A4,32,68,82and those that were responsible for the formation of norketamine 
metabolites include dCYP2A6 and CYP2B6.68Pharmacokinetic (PK) results after IV 
administration of racemic ketamine and esketamine to human subjects suggested that inversion 
of esketamine to arketamine (the R -enantiomer of ketamine) doesnot occur.[ADDRESS_385674] been shown to be predominantly  excreted in the 
urine. An average of 91% of a dose of ketamine administered to healthy  subjects was recovered 
in urine.18Less than 3% of an administered dose was excreted in urine as parent drug.[ADDRESS_385675] been characterized in healthy  adult subjects (elderl y and 
younger adults) as well as subjects with a history  of allergic rhinitis, with TRD37,and with MDD 
at imminent risk for suicide. In healthy  adult subjects, intranasal ly-administered esketamine (28 
to 112 mg) was rapi[INVESTIGATOR_2478] y absorbed with measurable concentrations at 7minutes after the first 
spray ; the plasma esketamine maximum concentration and area under the concentration -time 
curve increased in a dose-related manner following intranasal administration, and the mean 
terminal half-life of esketamine ranged from 5.86 to 9.83 h ours (ESKETINTRD1001).37When 
administered in healthy  adult subjects via the intranasal route, esketamine wasrapi[INVESTIGATOR_2478] y absorbed 
and had an absolute bioavailability  of approximately  48%(ESKTINTRD1009) .37In a Phase [ADDRESS_385676] (ESKETINTRD2003), there was a dose-dependent increase in mean 
plasma esketami ne concentrations from subjects in Panel A who were administered 28, 56, or 
84mgdoses of intranasal esketamine .37Furthermore, the mean esketamine concentrations in 
plasma samples collecte d at corresponding timepoints on Days 1, 11 , and 25 were similar 
suggesting that the PK was consistent after repeated intranasal administration.37The PK result s 
from subjects with MDD at imminent risk of suicide (ESKETINSUI2001) who received [ADDRESS_385677].
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
40
Status: Approved , Date: [ADDRESS_385678] edthat subanesthetic doses of ketamine
could improve symptoms of depression within hours even in subjects who responded poorl y to 
conventional antidepressant s.50Further results from Panel A (conducted in the [LOCATION_002] and 
Belgium) in a Phase 2, 2-panel, double -blind, doubly -randomized, placebo -controlled clinical 
study  in subjects with TRD (ESKETINTRD2003) demonstrated that treatment with intranasal 
esketamine (28, 56, and 84 mg) rapi[INVESTIGATOR_313267] [ADDRESS_385679] dose as assessed by  [CONTACT_313333] -Asberg Depression Rating 
Scale (MADRS )total score from baseline.37In addition, after 1 week of treatment the analysis 
showed thatall 3 esketamine dose groups were statistically  superior to the placebo group using a 
one-sided significance level of 0.05 ( least squares mean differences [SE] between each 
esketamine group and theplacebo group were: -4.2 [2.09] , -6.3 [2.07], and -9.0 [2.13] for 
esketamine 28, 56, and 84 mg, respectively ; p=0.021, p=0.001, and p<0.001 for esketamine 28, 
56, and 84 mg, respectively )and that there was a significant relationship between esketamine 
dose and change in MADRS total score (p<0.001) .37The major secondary  analyses of results 
from Panel Aprovided preliminary  evidence suggesting that improvements in depressive 
symptoms resulting from esketamine treatment could be sustained with repeated dosing for 
74days, the duration of the study in Panel A.37In Panel B(conducted in Japan) , subjects were 
treated with placebo or 14 or 56 mg of intranasal esketamine for up to 25 days. Greater 
improvements in MADRS total score were observed in the esketamine 56-mg group compared 
with the placebo group using a one-sided significance level of 0.10 (mean difference [SE]: -3.7 
[2.81]; p=0.096), and a dose response was detected during the first week of treatment
(p=0.097 ).37Although there was a statistically  significant difference between the esketamine 
56-mg and placebo groups during the first week of treatment, the results from Panel B must be 
interpreted with caution due to a significant treatment by [CONTACT_313334] (p=0.052) , where results favored the placebo group for 
subjects with higher baseline MADRS total scores and the esketamine groups for subjects with 
lower baseline MADRS total scores.[ADDRESS_385680] edthat doses of IV 
ketamine could rapid ly decrease suicidal ideation as evaluated by[INVESTIGATOR_13699] s such as the 
MADRS Suicidal Thoughts Item (MADRS -SI).5,38,63Recently , a Phase 2,double -blind, 
randomized, placebo- controlled, proof -of-concept study  (ESKETINSUI2001 ) evaluated the 
efficacy  and safet y of intranasal esketamine for the rapid reduction of the symptoms of MDD, 
including suicidal ideation . Subjects with a diagnosis of MDD assessed to be at imminent risk for 
suicide from the [LOCATION_002] were random ly assigned to treatment with placebo (n=31) or 
esketamine 84 mg (n=35) for up to [ADDRESS_385681] dose (primary 
endpoint; mean difference [SE] between esketamine 84 mg and placebo: -5.3 [2.10]; p=0.015)
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
41
Status: Approved , Date: [ADDRESS_385682] dose (mean difference [SE]: -7.2 [2.85]; p=0.015) , 
andesketamine [ADDRESS_385683] on Day 25(mean 
difference [SE]: -4.5 [3.14]; p=0.159 ).16The change sfrom baseline in suicidal ideation based on 
the MADRS -SI score also favored esketamine 84 mg ; the difference between the esketamine and 
placebo group wasstatistically  significant at [ADDRESS_385684] dose (p=0.002), and the 
differences between esketamine and placebo showed evidence of a potential therapeutic effect at 
approximately  [ADDRESS_385685] dose (p=0.129 )and on Day 25 (p=0.143 ).16Additionally , 
changes from baseline in the Clinical Global Judgment of Suicide Risk (CGJ -SR), which 
summarized the clinician’s overall judgment of suicide risk, provided evide nce of a potential 
therapeutic effect of esketamine 84 mg compared with placebo at both 4 hours (p=0.112 ) and 
24hours (p=0.150) after the first dose.16The results from ESKETINSUI [ADDRESS_385686] s assessed to be at 
imminent risk for suicide. 
[IP_ADDRESS]. Safety  and Tolerability
Ketamine was first introduced as an anesthetic in [ADDRESS_385687] an excellent 
medical safety  profile.30,45,73,76The following adverse reactions arelisted as very common, 
common, or frequent occurrences for ketamine and esketamine when administered as an 
anesthetic : emergence or recovery  reactions, elevated blood pressure and pulse rate, stimulation 
of respi[INVESTIGATOR_1516], nausea, and vomiting.44,[ADDRESS_385688] dose of study  medication.37A 
total of 4 non -fatal serious adverse events (SAEs) occurred in 3 subjects during the study ; 
oesophagitis (during placebo treatment), ectopic pregnancy  (during esketamine treatment , 
leading to treatment withdrawal) , general physical health deterioration (follow -up phase) and 
confusional state (follow -up phase ).37The investigato r assessed the SAE of confusional state as 
probably  related to study  medication and SAEs of esophagitis, ectopic pregnancy , and general 
physical health deterioration, and completed suicide as not related to study medication .In total, 
4subjects experience d treatment -emergent adverse events (TEAEs) which led to withdrawal of 
study  medication while receiving esketamine treatment (ectopic pregnancy [described above] , 
syncope, headache, and dissociative disorder).37The investigator assessed the events of headache 
and dissociative disorder as very likely  related to study  medication. The investigator considered 
theevent of syncope possibly  related to the study medication, and the sponsor considered the
event of syncope not related to the study  medication based on the short half-life of esketamine 
and the onset of the event of sy ncope . 
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
42
Status: Approved , Date: 31 January 2018In Panels A and Bcombined , the common TEAEs (≥10% the total esketamine or placebo 
groups) that occurred more frequently  in the total esketamine group compared with the placebo 
group during the double -blind phase were : dizziness, headache, dissociation, nausea, feeling 
abnormal, and hypoaesthesia.19A majority  ofsubjects in Panels A and B experienced elevations 
in blood pressure measurements after receiving esketamine doses; the maximum elevations from 
predos e in blood pressure measurements on each dosing day were observed in most cases within 
[ADDRESS_385689] dose, with the majority  returning within the normal range by  2 hours postdose.19The 
blood pressure changes observed did not appear to attenuate over time with multiple doses. A 
majority  of subjects in the esketamine treatment groups in Panels A and B experienced an 
increase in dissociative symptoms after dosing as assessed using the Clinician Administered 
Dissociative States Scale (CADSS ).Dissociative symptoms peaked at approximately 40 minutes 
after dosing and typi[INVESTIGATOR_313268] 2  h ours after dosing.19The magnitude of postdose 
dissociative symptoms decreased over time with repeated consecutive doses for all esketamine 
doses.
Short -term Use of Intranasal Esketamine in Subjects with MDD at Imminent Risk for 
Suicide
In the Phase 2 study  in subjects with MDD at imminent risk for suicide (ESKETINSUI2001) , the 
TEAEs reported by[CONTACT_313335] -treated subjects were consistent with the safety  profile of
esketamine observed in earlier studies. Esketamine 84 mg was generall y tolerated, and no new 
safet y signals emerged in this population. There were no deaths during the study . There were 
4SAEs in the double -blind phase, all in the esketamine 84 mg group.16Three of these events 
were related to re-hospi[INVESTIGATOR_313269]-emergence of suicidal ideation (n=2) or 
depression (n=1) in subjects who had improved and had been discharged from the hospi[INVESTIGATOR_307]. In all 
3instances, the subjects recovered and completed both the double -blind and follow -up phases. 
One subject experienced anevent of increased agitation , and the study  medication was 
withdrawn. With the exception of re-emergence of depre ssive symptoms, which was considered 
possibly  related to study medication , none of the other SAEs were considered to be related to 
study  medication by [CONTACT_093]. During the follow -up phase, 5 subjects in the placebo group
experienced SAEs , including suicidal ideation (n=1) and attempted suicide (n=3) and cellulitis 
(n=1), compared with only  1subject in the esketamine group, who experienced suicidal ideation .
One subject in the placebo group and [ADDRESS_385690] s in the esketamine 84 mg group discontinued 
from the double -blind phase due to TEAEs.16Events leading to discontinuation in the esketamine 
group were dizziness, dysgeusia, ventricular extras ystole, nausea, and dyspnea , which were 
considered by [CONTACT_313336]; and aggression 
and agitation , which were considered to be doubtfully  and not related to study  drug, respectivel y.
In total, [ADDRESS_385691] common ( ≥20%) individual TEAEs in the esketamine 84 mg group were nausea, 
dizziness, dysgeusia, headache, and dissociation and vomiting.16A majority  of subjects in the 
esketamin e group experienced elevations in blood pressure measurements after dosing. The 
maximum increases in blood pressure occurred in the esketamine treated subjects at 
approximately  40 minutes postdose.16A greater proportion of subjects in the esketamine group 
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
43
Status: Approved , Date: [ADDRESS_385692] examined cognitive function in ketamine users , 
23,58,60,64; overall , infrequent use didnot appear to be associated with long-term cognitive 
impairment.64The most robust findings were that frequent ketamine users (more than 5 times a 
week) exhibited impairments in both short -and long-term memory .60Although dosages varied, 
the dosages reported by [CONTACT_313337] . The memory 
impairments were not found in ex-users who had been abstinent for at least a year, thus 
impairments may  be reversible .[ADDRESS_385693] cases were in near-daily  recreational ketamine users ; the majorit y of 
cases resolve dafter stoppi[INVESTIGATOR_154852], and one-third remained static. The ketamine dose, 
dosing frequency , and duration of chronic ketamine use at which cystitis may develop are not 
known. Compared with the doses and dosing frequency  of esketamine proposed in this study , the 
equivalent ketamine dose in publi shed reports of interstitial cystitis and bladder -related 
symptoms was typi[INVESTIGATOR_1306] y much higher; ketamine wasdosed more frequently , and often there was
concomitant use of other substances.
Abuse Liability, Dependence and Withdrawal
There are reports of ketamine dependence in the literature but no large -scale studies.35,39,56,59,66
One study  found that ketamine users and ex-users expressed concerns about ketam ine addictio n, 
and t he majorit y of frequent users reported using the drug without stoppi[INVESTIGATOR_154853], 
so compulsi ve patterns of behavior are a concern.62A few published reports describe craving and 
somatic and psychological aspects of anxiety  as symptoms of withdrawal from ketamine ; 
however, a specific ketamine withdrawal s yndrome has not yet been described.22,48,[ADDRESS_385694] of care in subjects with MDD who are at imminent risk 
for suicide as a pi[INVESTIGATOR_9205] 3 study  in support of regulatory  agency  requirements for 
registration of intranasal esketamine.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
44
Status: Approved , Date: [ADDRESS_385695] of care in reducing the symptoms of 
MDD, including suicidal ideation , in subjects who are assessed to be at imminent risk for 
suicide, as meas ured by  [CONTACT_313338] -Asberg Depression Rating 
Scale (MADRS) total score at [ADDRESS_385696] dose.
Key Secondary Objective
The key secondary objective isto assess the efficacy  of intranasal esketamine compared with 
intranasal placebo in reducing severity  of suicidality  as measured by [CONTACT_313339] y of suicidality  revised version (CGI -SS-R) at [ADDRESS_385697] dose.
Other Secondary Objectives
The other secondary  objectives are:
To evalua te the efficacy  of intranasal esketamine compared with intranasal placebo in 
remission of MDD (defined as MADRS total score ≤12) at [ADDRESS_385698] 
dose, and through the end of the double -blind treatment phase (Day  25).
To evaluate the efficacy of intranasal esketamine compared with intranasal placebo in 
reducing symptoms of MDD as assessed by [CONTACT_313318] [ADDRESS_385699] 
dose on Day  1, and through the end of the double- blind treatment phase (Day  25).
To assess the efficacy ofintranasal esketamine compared with intranasal placebo in 
reducing severit y of suicidality  as measured by [CONTACT_87791]-SS-R at 4hours post first dose on 
Day 1, and through the end of the double -blind treatment phase (Day 25).
To assess the efficacy of intrana sal esketamine compared with intranasal placebo in 
achieving resolution of suicidality  as measured by [CONTACT_313319] 0 (normal, not at all suicidal) 
or 1 (questionably  suicidal) of the CGI-SS-R at [ADDRESS_385700] dose, and 
through the end of the double -blind treatment phase (Day  25).
To assess the efficacy of intranasal esketamine compared with intranasal placebo in 
reducing imminent suicide risk as measured by [CONTACT_313340] (CGI -SR-I)at [ADDRESS_385701] dose, and through the end of the 
double -blind treatment phase (Day  25).
To assess the impact of intranasal esketamine compared with intranasal placebo on the 
following patient- relevant concepts through the end of the double -blind treatme nt phase 
(Day  25)
Hopelessness as measured by  [CONTACT_313321] (BHS)
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
45
Status: Approved , Date: 31 January 2018Health related qualit y of life and health status, using the European Quality  of Life 
(EuroQol) Group, 5- Dimension, 5 -Level (EQ -5D- 5L)
Health related quality  of life using the Quali ty of Life in Depression Scale (QLDS)
Treatment satisfaction using the Treatment Satisfaction Questionnaire for Medication 
(TSQM -9)
Patient- reported suicidality  using the Suicidal Ideation and Behaviors Assessment Tool 
(SIBAT ), including Module 5 My Risk,Question 3(patient -reported frequency  of 
suicidal thinking)
To assess the safety  and tolerability  of intranasal esketamine during the double -blind 
treatment phase and the follow -up phase, with special attention given to the following 
assessments:
Potential effects on suicidal ideation and behavior using the SIBAT
On dosing day s:
oEffect on heart rate, blood pressure, respi[INVESTIGATOR_2842], and blood oxy gen saturation 
oEffect on alertness and sedation using the Modified Observer's Assessment of 
Alertness/Sedation (MOAA/S) scale
oTreatment -emergent dissociative symptoms using the Clinician Administered 
Dissociative States Scale (CADSS)
To assess the pharmacokinetics of intranasal esketamine .
Exploratory Objectives
The exploratory  objectives are:
Toevaluate the efficacy  of intranasal esketamine compared with intranasal placebo in 
reducing symptoms of MDD as assessed by [CONTACT_313341]- up phase (Day  90).
To assess the efficacy of intranasal esket amine compared with intranasal placebo in 
reducing severit y of suicidality  as measured by  [CONTACT_87791] -SS-R through the end of the follow -
up phase (Day  90).
To assess the efficacy of intranasal esketamine compared with intranasal placebo in 
reducing imminent suicide riskas measured by [CONTACT_87791]-SR-Ithrough the end of the follow -
up phase (Day  90).
To assess the impact of intranasal esketamine compared with intranasal placebo through the 
end of the follow -up phase (Day  90) on the following patient -relevant concepts:
Hopelessness (BHS)
Health related quality  of life and health status (EQ -5D- 5L)
Health related quality  of life (QLDS)
Subject treatment satisfaction (TSQM-9)
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
46
Status: Approved , Date: 31 January 2018To assess the effect of intranasal esketamine compared with intranasal placebo on the 
SIBAT Module 3 My Current Thinking through the double -blind treatment (Day  25) and 
follow -up (Day  90) phases.
To assess medical resource utilization as measured by [CONTACT_313342] (HRUQ) of intranasal esketamine compared with intranasal placebo through 
the end of the follow -up phase (Day  90), including 30-day and 60 -day readmission, and 
emergency  room visit srelated to MDD and suicidality .
To evaluate whether pretreatment concentrations or post-treatment change in MDD -related 
biomarkers (eg, hypothalamic -pi[INVESTIGATOR_2117] -adrenal [HPA ]axis function, immune system 
activation, growth factors, metabolic markers) correlate with clinical response or non-
response as measured b y the MADRS, following intranasal administration of esketamine.
2.1.2. Endpoints
The primary  efficacy  endpoint will be the change from baseline (Day  1, predose) to [ADDRESS_385702] dose in depressive sy mptoms, as measured by  [CONTACT_170468].
The key secondary  efficacy  endpoint will be the change from baseline (Day  1, predose) at 
24hours post first dose in severit y of suicidalit y, as measured b y the CGI -SS-R.
The other secondary  endpoints are:
MADRS
Remission rate (MADRS ≤12) at [ADDRESS_385703] dose, and through the 
end of the double -blind treatment phase (Day  25)
Change from baseline of MADRS total score at [ADDRESS_385704] dose and through the 
end of the double -blind treatment phase (Day  25)
CGI-SS-R
Change from baseline at [ADDRESS_385705] dose andthrough the end of the double -blind 
treatment phase (Day  25).
Proportion of subjects achiev ingresolution of suicidality  (CGI-SS-R score of 0 or 1) at 
[ADDRESS_385706] dose, and through the end of the double -blind treatment 
phase (Day  25)
CGI-SR-I: Change from baseline at [ADDRESS_385707] dose , and t hrough the end 
of the double -blind treatment phase (Day  25)
BHS: Change from baseline through the end of the double -blind treatment phase (Day  25)
EQ-5D- 5L: Change from baseline through the end of the double -blind treatment phase 
(Day 25)
QLDS: C hange from baseline through the end of the double -blind treatment phase (Day  25)
TSQM -9: Scores through the end of the double -blind treatment phase (Day  25)
SIBAT: Change from baseline in Module 5 My  Risk, Question 3 (patient -reported frequency  
of suicidal thinking) , through the end of the double- blind treatment phase (Day  25)
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
47
Status: Approved , Date: 31 January 2018Pharmacokinetics: Plasma esketamine and noresketamine concentrations will be 
summari zed; plasma concentrations of esketamine (and noresketamine concentrations, if 
warranted) will be included in a population anal ysis
Safety  endpoints will be evaluated throughout the study :
Monitoring of treatment emergent adverse events (TEAEs)
Clinical laboratory  tests, physical examination, nasal examination, 12-lead 
electrocardiogram ( ECG ), and vital signs
SIBAT
On dosing day s: MOAA/S, CADSS , and pulse oximetry
The e xploratory  endpoints include:
Change from baseline in MADRS, CGI-SS-R, CGI-SR-I, BHS, QLDS, and EQ-5D- 5L
through the end of the follow- up phase (Day  90)
TSQM -9scores , medical re source utilization, and biomarkers through the end of the follow -
up phase (Day  90)
SIBAT: Change from baseline in Module 3 My Current Thinking through the end of the 
double -blind (Day  25) and follow -up (Day  90) phases
Refer to Section 9, Study Evaluations for evaluations related to endpoints.
2.2. Hypothesis
The primary  hypothesis is that, in addition to comprehensive standard of care, intranasal 
esketamine [ADDRESS_385708] dose in subjects who are assessed to be at imminen t risk for suicide.
3. STUDY DESIGN A ND RA TIONA LE
3.1. Overview  of Study  Design
This is a randomized, double -blind, placebo -controlled, multicenter study . A target of 224 male 
and female subjects , 18 to 64 years of age, with MDD presenting to an emergency  room (ER) or 
other permitted setting and assessed to be at imminent risk for suicide will be enrolled in this 
study .
The study  will consist of a screening evaluation performed within 48hours prior to the Day 1 
intranasal dose (if possible, screening should occur within 24 hours prior to the Day 1 intranasal 
dose), immediatel y followed by a  25-day double -blind treatment phase (Day  1to 25), and a 
65-day follow -up phase (Day  26 to Day 90). The total study  duration for each subject will be 
approximately 13 weeks. 
On Day  1 of the double -blind treatment phase, approximately  224 subjects will be randomized in 
a 1:1 ratio to 1 of 2 treatments: intranasal esketamine 84 mg (n = 112) or intranasal placebo 
(n=112), administered two times per week for 4 weeks (Day s 1, 4, 8, 11, 15, 18, 22, and 25). 
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
48
Status: Approved , Date: 31 January 2018Randomization will be stratified by [CONTACT_313325]’ s assessment of the 
subject’ s need of standard of care antidepressant treatment (ie, antidepressant monotherap y or an 
antidepressant plus augmentation therap y); the standard of care will be determined prior to 
randomization on Day  1. 
The first dose of study  medication will be administered in the ER or other permitted setting , 
including the inpatient psychiatric unit. All subjects will be treated in the context of 
comprehensive standard clinical care, including hospi[INVESTIGATOR_313270], which will be determined by [CONTACT_1963](s). The standard 
of care antidepressant treatment will be initiated or op timized for all subjects on Day  1. 
After the first dose (ie, starting with the Day 4 dose or later), a one-time dose reduction to 
intranasal esketamine [ADDRESS_385709] is unable to tolerate the 
intranasal esketamine 84 mg or placebo dose assigned at randomization. No further dose 
adjustment is allowed during the double -blind treatment phase .
Dose titration/adjustments of newl y initiated or optimized standard of care antidepressant 
treatment should occur during the first 2 weeks of double -blind treatment (ie, by [CONTACT_2006] 15), with 
doses remaining stable thereafter through the end of the double -blind phase (Day  25). During the 
follow -up phase, the antidepressant treatment will be managed based on clinician’ s judgment.
Subjects will remain in the inpatient psychiatry unit for a recommended duration of [ADDRESS_385710] be discussed and approved by [CONTACT_456]’s medical monitor. 
Following discharge from the inpatient psychiatric unit, subsequent visits for the double -blind 
treatment phase will be conducted twice -weekly  at an outpatient psychiatric facility  through 
Day 25. During the follow -up phase, subjects will be monitored twice weekly  for the first two 
weeks (Day s 28, 32, 35, and 39) after study  drug treatment. Subjects will then be followed up 
weekl y for the next two weeks (Day s 46 and 53) and every  two weeks for the rest of the follow -
up period (Day s 67 and 90).   
Efficacy , safet y, pharmacokinetic, biomarker , and pharmacogenomic evaluations will be 
performed as described in the Time and Events Schedule. 
The primary  efficacy  evaluation is the MADRS, the key secondary  evaluation is CGI-SS-R, 
and other efficac y evaluations include the SIBAT, BHS, EQ -5D- 5L, QLDS, and TSQM -9.
Safety  evaluations include monitoring and collection of adverse events and concomitant 
therapi[INVESTIGATOR_014], physical examination, nasal examination, body  weight, height, vital signs, 12-lead 
ECG, pulse oximetry , respi[INVESTIGATOR_2842], clinical laboratory  tests, SIBAT, MOAA/S, and 
CADSS . 
Blood samples will be collected for measurement of plasma concentrations of esketamine, 
noresketamine, and other metabolites if warranted.
Blood samples will be collected f or biomarker evaluations.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
49
Status: Approved , Date: 31 January 2018Pharmacogenomic blood sample swill be collected from subjects who consent separatel y to 
this component of the study  (where local regulations permit). Subject participation in 
pharmacogenomic research is optional.
AnIndependent Data Monitoring Committee (I DMC) will be commissioned for this study . Refer 
toSection 11.9,Data Monitoring Committee, for details.
A diagram of t he stud y design is provided in Figure 1.
Figure 1: Schematic Overview of the Study
3.2. Study Design Rationale
3.2.1. Study Population
This study  will enroll adult subjects (18 to 64 years) with MDD presenting with suicidal ideation 
who are assessed to be at imminent risk for suicide. Subjects must meet Diagnostic and 
Statistical Manual of Mental Disorders -5th edition (DSM -5)criteria for MDD (without 
psychosis), based on diagn ostic assessment with the Mini International Psychiatric Interview 
(MINI), and subjects must have a MADRS total score >28at baseline. By [CONTACT_313343] a MADRS total score of >28 (representing moderat e to severe depression), the study  may 
reduce placebo response and enhance signal detection.MDD 
subjects 
assessed to 
be at 
imminent 
risk for 
suicide a
(n =224) Intranasal Esketamine 84 mg
on Day 1, 4, 8, 11, 15, 18, 22, 25 
+ 
Standard of Care antidepressant 
treatment b
(n = 112)
Emergency Room
(or other permitted setting) Inpatient 
Psychiatric Unit
(Recommended 5 days) dIntranasal Placebo
on Day 1, 4, 8, 11, 15, 18, 22, 25 
+ 
Standard of Care antidepressant 
treatment bStandard of Care antidepressant 
treatment
Screening
(within 48 hours c
prior to Day 1 dose)Double -blind Treatment
(Day 1 to 25)
(Day 1, 4, 8, 11, 15, 18, 22, and 25) Follow Up
(Day 26 to 90)
(Day 28e, 32, 35e, 39, 46, 53, 67, and 90)
Outpatient Psychiatric Unit (n = 112)
aRandomization will be stratified by [CONTACT_313325]’s assessment of the subject’s need of 
standard of care antidepressant treatment ( ie, antidepressant monotherapy or an antidepressant plus
augmentation therapy); the standard of care will be determined prior to randomization on Day 1.
bStandard of care antidepressant treatment will be initiated or optimized on Day 1.
cIf possible, screening should be performed within [ADDRESS_385711] be discussed and approved by [CONTACT_456]’s medical monitor.
eRemote contact
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
50
Status: Approved , Date: [ADDRESS_385712] also present with suicidal ideation with intent, operationalized by 
[CONTACT_313344] B3 (Think about harming/hurting/ injuring yourself or 
about suicide?) and B10 (Intend to act on thoughts of killing yourself? ). This generally 
corresponds with the level of severity  of suicidal ideation that appears to predict suicidal 
behavior over the short term.69Additionally , in the physician’s opi[INVESTIGATOR_1649], acute psychiatric 
hospi[INVESTIGATOR_313271]’s imminent risk of 
suicide . By[CONTACT_313345], the possibility  of a favorable 
benefit -risk balance for the experimental treatment is enhanced.
The age range of [ADDRESS_385713] rapid and sustained benefit in adults. As higher 
systemic bioavailability  of intranasal esketamine has been previously observed in an elderl y 
population (≥65years) (Studies ESKETI NTRD1003 andESKETI NTRD101237)and the efficacy 
and safet y of esketamine in the elder ly population with MDD is being further evaluated in other 
studies ,elderly  adult subjects will not be enrolled in this study .
Subjects with a recent history  (<6 months) of moderate or severe substance or alcohol use 
disorders will be excluded to ensure the subject’s depression is not attributed to substance or 
alcohol use (ie, substance -induced depressive disorder). Subjects with a current diagnosis of 
bipolar or related disorders will be excluded to allow accurate assessment of efficacy  and/or 
safet y data of the study  drug in the context of MDD .
3.2.2. Treatment and Study  Duration
Patients with MDD with suicidal thoughts and behaviors are at risk for increased suicidalit y both 
in the first several days after initiating treatment with a standard antidepressant40and post-
hospi[INVESTIGATOR_059].12,79Therefore, the dosing regimen in this study  includes administration of 
esketamine twice weekly  for 4 weeks (Day s 1, 4, 8, 11, 15, 18, 22, and 25). This duration of 
repeated dosing is consistent with the timeframe inwhich standard antidepressants take to exert 
their action, and will allow for the evaluation of depression and assessment of suicide risk during 
this period of increased vulnerability . The same dosing regimen and duration of treatment was 
used in the Phas e [ADDRESS_385714] for esketamine in reducing 
the symptoms of depression and suicidality , it also suggested that continue d dosing through 
Day 25 provided an additional therapeutic adva ntage. Indeed, esketamine showed greater 
improvement compared to placebo on the MADRS total score and on the MADRS -SI at the 
double -blind endpoint (Day  25).16This result was further supported by [CONTACT_313346] (at least 
50% improvement in MADRS total score from baseline) and remission rates (MADRS total 
score ≤12) on Day 25, [ADDRESS_385715] dose. At thattimepoint, 20 of 24 (83%) esketamine subjects, 
compared to 15 of 24 (63%) placebo subjects ,were considered responders; similarly , 16 of 24 
(67%) esketamine subjects, compared to 12 of 24 (50%) placebo subjects were considered 
remitters.16The improvements continued throughout the posttreatment follow -up phase; at 
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
51
Status: Approved , Date: 31 January 2018Day 81, remission rates were 63% in the esketamine group compared with 50% in the placebo 
group.[ADDRESS_385716] initial attempt and/or hospi[INVESTIGATOR_059].12,15Specificall y, the follow -up after the 25-day 
treatment period is through Day [ADDRESS_385717] 
two weeks (Day s 28, 32, 35, and 39) after study  drug treatment. Subjects will then be followed 
up weekl y for the next two weeks (Day s 46 and 53) and every  two weeks for the rest of the 
follow -up period (Day s 67 and 90).The MADRS and CGI-SS-R will be completed at each of 
these visits. Additionally, throughout the follow -up period, suicide attempts, hospi[INVESTIGATOR_134577]-
admissions for suicidality , and ER visits will be assessed . 
The short -term treatment course of esketamine in subjects with MDD at imminent risk for 
suicide is expected to provide antidepressant efficacy  during the interval needed for the newl y 
initiated or optimized ora l antidepressant sto become effective.
3.2.3. Control, Randomization and Blinding
A placebo control will be used to establish the frequency  and magnitude of changes in clinical
endpoints that may  occur in the absence of active treatment.
Randomization will be used to minimize bias in the assignment of subjects to treatment groups, 
to increase the likelihood that known and unknown subject attributes (eg,demographic and 
baseline characteristics) are evenly  balanced across treatment groups, and to enhance the validity 
of statistical comparisons across treatment groups. Randomization will be stratified by [CONTACT_313347]’s assessment of the subject’s need of standard of care antidepressant 
treatment (ie, antidepressant monoth erapy or an antidepressant plus augmentation therap y); the 
standard of care will be determined prior to randomization on Day 1. This stratification is aimed 
at balancing treatment groups within the standard of care antidepressant treatment to be initiated 
or optimized on Day 1, as antidepressant monotherapy  and antidepressant plus augmentation 
therap y may be differentially  effective. A similar stratification approach was used successfull y in 
Study  ESKETINSUI2001.
Blinded treatment will be used to reduce potential bias during data collection and evaluation of 
clinical endpoints. Administration of esketamine, however, is associated with a number of 
transient adverse events, including sedation, dissociative symptoms, and elevation of blood 
pressure. To minimize the risk of unblinding the treatment assignment, different raters will 
perform efficacy  and safet y assessments ;clinicians who perform the MADRS and SIBAT 
assessments will be different from those who evaluate vital signs, MOAA/S, CADSS , and 
adverse events .Raters for the MADRS and SIBAT assessments will not be allowed to access or 
to review subject safety records; therefore, they will not provide clinical care for subjects. 
Clinical care of subjects will be perform ed by [CONTACT_313348]. 
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
52
Status: Approved , Date: 31 January [ZIP_CODE].2.4. Dose
The currentl y available nonclinical safety  studies support chronic intranasal administration of 
esketamine in human subjects up to a dose of 84 mg/day .37The treatment groups in the double -
blind treatment phase of this study  are esketamine [ADDRESS_385718] efficacy , and for which titration to an 
effective dose is not warranted. Study  treatment will initially  be administered in a hospi[INVESTIGATOR_313272] y monitored and managed. Finally , a course of treatment 
of esketamine for MDD with imminent risk for suicide is limited to 4 weeks. 
Given the benefit- risk assessment of treatment for a life -threatening condition, the 84 mg dose of 
esketamine (with an option to reduce to the 56 mgdose) was selected to provide the greatest 
opportunity  for rapid onset of efficacy  and longer durability  of activity , with acceptable 
tolerability , in the context of a psy chiatric emergency . 
Efficacy Findings Supporting the 84- mg Dose
Results from the Phase [ADDRESS_385719] dose and at the double -blind endpoint (Day  25), esketamine 84 mg 
demonstrated a rapid and statistically  significant reduction in symptoms of depression (based on 
MADRS total score ) and suicidal ideation (based on the MADRS -SI score) compared to placebo
(refer to Section 1.1.2 .3for details) .Additionally , esketamine demonstrated evidence for a 
potential therapeutic effect based on the CGJ-SR, which summarized clinician overall judgment 
of suicide risk as derived from the SIBAT, at b oth [ADDRESS_385720] ; statistically  significant 
reductions in the MADRS total score were observed in all esketamine groups (28, 56, 84 mg) 
compared with the placebo group after the first week of treatment, with a significant dose-
response relationship detected (refer to Section [IP_ADDRESS] for details).37In addition, for those 
subjects in Panel A who received the same esketamine treatment for both periods and completed 
the double -blind phase, the greatest decrease in MADRS total score was seen with the 84-mg 
dose, followed b y the [ADDRESS_385721] bo group 
received all 8 scheduled doses of the study  medication, and mean treatment durations were 
similar in the esketamine 84 mg group and in the placebo group . Furthermore, only 3 of the 
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
53
Status: Approved , Date: [ADDRESS_385722] common ( ≥20%) TEAEs in the esketamine [ADDRESS_385723] common TEAE in the placebo group was headache. Dissociative symptoms, as 
measured on the CADSS, and transient blood pressure increases observed in the esketamine 
group were consistent with prior studies.
There were no deaths during Study ESKETINSUI2001. There were 4 SAEs in the double -blind
phase, all in the esketamine 84 mg group. Three of these events were related to re -hospi[INVESTIGATOR_313273]-emergence of suicidal ideation (n=2) or depression (n=1) in subjects who had 
improved and had been discharged from the hospi[INVESTIGATOR_307]. In all 3instances, the subjects recovered 
and completed both the double -blind and follow -up phases. One subject experienced an event of 
increased agitation , and the study  medication was withdrawn. Six subjects experienced an SAE 
in the follow -up phase (5 in the placebo group and 1in the esketamine 84 mg group ;
seeSection [IP_ADDRESS] for further details). The SAEs in the placebo group included 3 suicide 
attemp ts (non-fatal), [ADDRESS_385724] from the esketamine group was suicidal ideation .
Six subjects (1 in the placebo group and 5 in the esketamine 84 mg group) discontinued from the 
double -blind phase due to TEAEs. In the esketamine group, events resulting in discontinuation 
were dizziness, dysgeusia, ventricular extrasy stole, nausea and dyspnea, which were considered 
by [CONTACT_313349] y or very likely  related to study drug; and aggression and 
agitation, which were considered to be doubtfull y and not related to stud y drug, respectively .
Overall, the safet y profile of esketamine 84 mg in Study ESKETINSUI2001 was consistent with 
that observed in previous clinical studies of intranasal esketamine. No new safet y signals were 
identified.
3.2.5. Efficacy  Measures
[IP_ADDRESS]. Montgomery -Asberg Depression Rating Scale (MA DRS)
The primary  outcome measure in this study  will be the MADRS (see Section 9.2.1 ).The 
MADRS is considered the gold standard to measure antidepressant treatment response and is 
acceptable to the regulatory  health authorities for useas a primary  endpoint to determ ine 
symptomatic improvement. Further, the MADRS is sensitive to rapid changes in depression 
symptoms and suicidal thoughts, and has been included as a key  outcome parameter in published 
studies of ketamine for depression and suicidal ideation5,25,47,63,70,71as well as in the sponsor’s 
Phase 2 studies of esketamine in MDD with imminent risk for suicide (ESKETINSUI2001) and 
in TRD (ESKETINTRD2003 and the Phase [ADDRESS_385725] ). 
This study  is primarily  aimed at evaluating the rapid reduction of symptoms of MDD, including 
suicidal ideation , in subject s who are assessed to be at imminent risk for suicide. Accordingl y, 
the primary  efficacy  endpoint is the change from baseline (Day  1 predose) in the MADRS total 
score at [ADDRESS_385726] dose. Although therapeutic activity  is observed with esketamine as 
early as 4 hours after administration, it appears that the full benefit is evident after 24 hours , and 
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
54
Status: Approved , Date: [ADDRESS_385727] dose and through the 
end of the double -blind treatment phase. In addition, the MADRS will be used to evaluate the 
exploratory  objective assessing the change from baseline in MADRS total score and the 
remission rate through the end of the follow-up phase (Day  90).
[IP_ADDRESS]. Suicide Ideation and Behavior Assessment Tool (SIBA T)
The development of treatments with the potential for rapid onset of efficacy  as measured by 
[CONTACT_313350] y measure these attributes. However, these requirements 
correspond with specific deficits in existing suicide assessment scales. To address these unmet 
needs ,a new instrument, the SIBAT, has been developed bya team of experts in suicide and 
psychometrics. The SIBAT is a suicide assessment tool that captures suicidal ideati on and 
behavior(s) as reported by [CONTACT_313351]-term 
suicide risk and treatment plans (see Section 9.2.2 ). 
The SIBAT is computerized and organized into [ADDRESS_385728] a wide variet y of demographic, cultural and demographic backgrounds. The 8 modules of 
theSIBAT aredivided into patient -reported (Modules 1-5) and clinician -rated (Modules 6-8) 
sections. This modular structure allows for customization, and the administration of specific 
modules can be adjusted to meet clinical needs. Responses less susceptible to chang e (eg, 
demographics, medical history ) are segregated into modules distinct from those responses more 
likely  to fluctuate over shorter time intervals (eg, current suicidal ideation). In general, the 
patient -reported modules document information regarding the severity  of suicidal ideation and 
risk and protective factors associated with suicide risk and specific suicidal behaviors. 
Information from the patient -reported modules, plus a brief semi- structured clinician in terview in 
Module 6, represent a comprehen sive profile for assessment of theClinical Global Impressions 
in Module 7, which includes the Clinical Global Impression of Severit y of Suicidality –Revised 
(CGI-SS-R ), the Clinical Global Impression of Imminent Suicide Risk (CGI -SR-I),theClinical 
Glob al Impression of Long -Term Suicide Risk, and assessment of the frequency  of suicidal 
thinking. An assessment ofthe Clinical Global Judgment of Optim al Suicide Management is 
included in Module 8 .
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
55
Status: Approved , Date: 31 January 2018The SIBAT builds on prior work used to develop scales which are avail able for assessing 
suicidality ; for example, the InterSePT Scale for Suicidal Thinking (ISST),49a 12-item 
instrument designed for the ass essment of current suicidal ideation in patients with schizophrenia 
and schizoaffective disorders , and the Clinical Global Impression of Severit y of Suicidality 
(CGI -SS). Module 7 (Clinical Global Impressions) of the SIBAT includes a revised version of 
theCGI-SS(CGI -SS-R), which will be used to evaluate the key  secondary  objective in this study
(further details are provided below) , as well as a Clinical Global I mpression of Imminent Suicide 
Risk (CGI -SR-I), which will be used to evaluate secondary  and exploratory  objectives (further 
details are provided below) .In addition, Question 3 (patient -reported frequency  of suicidal 
thinking) in Module 5 (My Risk) from the SIBAT will be used to evaluate the secondary 
objective assessing patient- reported suicida lity through the end of the double -blind treatment 
phase.
Formal testing of inter-and intra-rater reliability  and assessments of construct validity  and 
internal consistency  are being conducted on the SIBAT.
Clinical Global Impression of Severity of Suicidality – Revised (CGI -SS-R)
The CGI-SS was initially created for the International Suicide Prevention Trial (InterSePT), a 
large -scale, long-term prospective study  that evaluated the potential of clozapi[INVESTIGATOR_313274].1,49,53The CGI-SSwas derived from the Clinical Global 
Impression Severity  Scale (CGI -S), a global rating scale that gives an overall measure of the 
severit y of a patient’s illness. The CGI-SS provided an index to quantify an expert's impression 
of severit y of suicidalit y that helped to confirm the validity  ISST. 
Arevised version ofthe CGI-SS (CGI -SS-R) will be used in this study (see Section 9.2.2 ). This 
revision is aligned with the standard CGI-S with which all clinicians are familiar, and has more 
severit y levels than the original version, allowing for greater sensitivity.
The CGI-SS-R, assessed at 24hours post initial dosing, will be used as the key secondary 
endpoint in this study . In addition, the CGI-SS-R will be used to evaluate secondary  objectives 
assessing:
Change in severity  of suicidality  at 4 hours postdose on Day 1 and through the end of the 
double -blind treatment phase
Resolution of suicidality  as measured by [CONTACT_313319] 0 (normal, not at all suicidal) or 1 
(questionably  suicidal) of the CGI -SS-R at 4 hours postdose on Day  1, 24 hours postdose on 
Day 2, and through the end of the double -blind treatment phase 
and exploratory  objectives assessing:
Change in severit y of suicidality  through the end o f the follow -up phase
Clinical Global Impression of Imminent Suicide Risk (CGI- SR-I)
The CGI-SR-I is a scale summarizing theclinician’s best assessment of the likelihood that the
subject will attempt suicide in the next 7 day s(see Section 9.2.2 ).
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
56
Status: Approved , Date: 31 January 2018The CGI -SR-I will be used to evaluate secondary  objectives assessing:
Change in imminent suicide risk at 4 hours postdose on Day 1, 24 hours postdose on Day 2,
and through the end of the double -blind treatment phase
and exploratory  objectives assessing:
Change in imminent suicide risk through the end of the follow- up phase
[IP_ADDRESS]. Beck Hopelessness Scale (BHS)
The Beck Hopelessness Scale (BHS) is a self-reported measure to assess the level of a subject’s 
negative expectations or pessimism regarding the future, and as such, is an important future 
predictor of suicide. Further information about the BHS is provided in Section 9.2.3 .
[IP_ADDRESS]. European Quality  of Life (EuroQol) Group, 5 -Dimension, 5 -Level 
(EQ-5D-5L)
The EQ-5D- 5L is included as a standardized subject -completed instrument for use as a measure 
of health- related quality  of life and health status.27,28Further information about the EQ-5D- 5L is 
provided in Section 9.2.4 .
[IP_ADDRESS]. Quality  of Life in Depression Scale (QLDS)
The QLDS is a disease -specific patient- reported outcome designed to assess health related 
quality  of life in patients with MDD .34,52,77Further information about the QLDS is provided in 
Section 9.2.5 .
[IP_ADDRESS]. Treatment Satisfaction Questionnaire for Medication (TSQM -9)
The TSQM -9is a 9-item generic patient reported outcome instrument to assess patients’ 
satisfaction with medication.4It is derived from the longer TSQM Version 1.411and covers 
domains of effectivene ss, convenience and global satisfaction. Further information about the 
TSQM -9 is provided in Section 9.2.6 .
3.2.6. Safety  Evaluation s
Physical examination, nasal examination, body  weight, vital signs (including measurement of 
blood pressure, heart rate, respi[INVESTIGATOR_2842], and temperature), 12-lead ECG, pulse oximetry , 
clinical laboratory  tests (hematology , chemistry , and urinal ysis), pregnancy  testing (for women 
of childbearing potential), urine drug screen, and evaluation of TEAEs and concomitant therapi[INVESTIGATOR_313275] y. 
The TEAEs of special interest will be examined separately  grouped in the following categories: 
drug abuse, dependence and withdrawal, transient dizziness/vertigo, impaired cognition, anxiety , 
cystitis, and suicidality . The adverse event s of special interest will be further listed in the 
Statistical Analy sis Plan ( SAP).
Given the potential for treatment -emergent transient elevation in systolic and diastolic blood 
pressure, heart rate and blood pressure will be monitored throughout the study  and at multiple 
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
57
Status: Approved , Date: 31 January 2018time points on dosing days. Specific guidance to be followed on intranasal dosing days is 
provided in Section 6.1.1 .
The MOAA/S will be administered to assess the severit y and duration of any sedation , and the
CADSS will be administered to assess treatment -emergent dissociative symptoms . Although the 
SIBAT will be an efficacy  evaluation, it will also be used to inform safety  evaluation to detect 
any worsening of suicidal ideation and behavior throughout the study .
On all outpatient intranasal dosing days, all subjects must remain at the clinical site until study  
procedures have been completed and the subject is ready for discharge per clinician’s 
assessment . The minimum time required for postdos emonitoring is 1.5hours. Subjects should be 
accompanied when released from the clinical study  site. Subjects must not drive a car or work 
with machines for [ADDRESS_385729] of prohibited therapi[INVESTIGATOR_313276] 1for general guidance for the 
investigator; however, this list is not all- inclusive .
3.2.7. Pharmacokinetic A ssessm ents
Blood samples will be collected for measurement of plasma concentrations of esketamine, 
noresk etamine, and other metabolites if warranted.
3.2.8. Biomarker, Pharmacogenomic (DNA ), and Expression (RNA ) 
Evaluations
Blood samples may be collected for the analy sis of one or more candidate genes and/or the 
analysis of genetic and epi[INVESTIGATOR_313277] . In addition,
blood samples will be collected for the exploratory  analysis of biomarkers related to immune 
system activity , HPA axis activation, neurotrophic and metabolic factors. 
It is recognized that genetic variation can be an important contributory  factor to interindividual 
differences in drug distribution and response and can also serve as a marker for disease 
susceptibility  and prognosis. Pharmacogenomic research may help to explain interindividual 
variability  in clinical outcomes and may help to identify  population subgroups that respond 
differentl y to a drug. The goal of the pharmacogenomic component is to collect DNA to allow 
the identification of genetic and/or epi[INVESTIGATOR_313278]
(PK) ,pharmacod ynamics (PD) ,efficacy , safet y,or tolerability of esketamine and to identif y 
genetic factors associated with MDD and suicidality .Specifically , genes and epi[INVESTIGATOR_313279] s relevant to depression (HPA axis, inflammation, growth 
factors, monoamine transporters, ion channels, circadian rhythm) will be evaluated. Expression 
analyses may include testing of known messenger RNA/microRNA (mRNA/miRNA) transcripts 
or transcriptome -wide analy sis in relationship to antide pressant treatment response and MDD.
Increasingl y, it is recognized that psychiatric disorders may be associated with altered 
immune/metabolic activation patterns. Blood samples will be collected to explore biomarkers 
related to immune system activity , HPA axis activation, and neurotropic factors (including but 
not limited to growth factors, inflammation, or endocrine markers). Biomarker samples (plasma, 
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
58
Status: Approved , Date: 31 January 2018serum, and RNA) will be collected to evaluate the mechanism of action of esketamine or help to 
explain interindividual variability  in clinical outcomes or may help to identify population 
subgroups that respond differentl y to a drug. In addition, biomarker samples may be combined 
with samples collected from other sources to understand the biomarker correlates of suicidal 
behavior including but not limited to high ideation state versus low ideation state versus no 
ideation and to understand the MDD disease mechanism.
The DNA, RNA, protein, and metabolic biomarker samples may be used to help address 
emerging issues and to enable the development of safer, more effective, and ultimat ely 
individualized therapi[INVESTIGATOR_014].
3.2.9. Medical Resource Utilization
Treatment of subjects with MDD at immediate risk of suicide with esketamine versus placebo 
may result in lower utilization of services (ie, outpatient visits, ERvisits or hospi[INVESTIGATOR_059]) as 
assessed using the Heath Resource Use Questionnaire (HRUQ). The HRUQ includes information 
regarding utilization of healthcare services, including the timing of services, enabling changes in 
level and quantit y of services to be considered as a variable in econ omic models.
4. SUBJECT POPULA TION
Screening for eligible subjects should be performed within 48hours prior to the first 
administration of intranasal study  drug(if possible, screening should occur within [ADDRESS_385730] administration of intranasal stud y drug ). 
The inclusion and exclusion criteria for enrolling subjects in this study  are described in the 
following [ADDRESS_385731] satisfy all of the following criteria to be enrolled in the study :
1. Subject must be a man or woman, [ADDRESS_385732] meet Diagnostic and Statistical Manual of Mental Disorders (5th edition) 
(DSM -5) diagnostic criteria for MDD, without psychotic features, based upon clinical 
assessment and confirmed by  [CONTACT_42145].
3. Subjects must have current suicidal ideation with intent, confirmed by a “Yes” response 
to Question B3 [Think (even momentarily ) about harming or of hurting or of injuring 
yourself: with at least some intent or awareness that you might die as a result; or think 
about suicide (ie,about killing yourself)?] AND Question B10 [Intend to act on 
thoughts of killing yourself?] obtained from the MINI. Note: the response to B3 must 
refer to the present, whereas the response to B10 may reflect the past [ADDRESS_385733] be 
repeated prior to randomization to confirm eligibility .
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
59
Status: Approved , Date: 31 January [ZIP_CODE]. In the ph ysician’s opi[INVESTIGATOR_1649], acute ps ychiatric hospi[INVESTIGATOR_313280]’s imminent risk of suicide.
5. Subject has a MADRS total score of > 28predose on Day  1.
6. As part of standard of care treatment, subject agrees to be hospi[INVESTIGATOR_313259] a 
recommended period of 5 days after randomization (may  beshorter orlonger if 
clinically  warranted in the investigator’s opi[INVESTIGATOR_1649]) and take prescribed non-
investigational antidepressant therapy (ies) for at least the duration of the double -blind 
treatment phase (Day  25).
7. Subject is comfortable with self-administration of intranasal medication and able to 
follow instructions provided .
8. Subject must be medically stable on the basis of physical examination, medical history , 
vital signs, and 12-lead ECG performed at screening. If there are abnormalities, the 
subject may be included only if the investigator judges the abnormalities to be not 
clinically  significant. This determination must be recorded in the subject's source 
documents and initialed by  [CONTACT_093] .
Note: Subjects recovering from a recent suicide attempt may be eligible provided they 
are medically  stable.
9. Subject must be medically  stable on the basis of clinical laboratory  tests performed by 
[CONTACT_313352] . If the results of the serum chemistry  panel, 
hematology , or urinaly sis are outside the normal reference ranges, the subject may be 
included only if the investigator judges the abnormalities or deviations from normal to 
be not clinically  significant . This determination must be recorded in the subject's source 
docume nts and initialed by [CONTACT_093] .
Incidental exclusionary laboratory  values ("incidental" refers to duplicate 
results from a separate blood sample analy zed at the central laboratory that 
become available after the subject has satisfied the inclusion and exclusion 
criteria based on the local laboratory  values) will be handled on a case-by-case 
basis to determine if the subject should be withdrawn from the stud y.
10. Contraceptive use by [CONTACT_313353].
Before randomization, a woman must be either:
a.Not of childbearing potential defined as:
opostmenopausal (>[ADDRESS_385734] 
12months), permanently sterilized (eg, bilateral tubal occlusion/ligation 
procedures, hysterectomy , bilateral salpi[INVESTIGATOR_1656] , bilateral 
oophorectom y); or otherwise be incapable of pregnancy
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
60
Status: Approved , Date: 31 January 2018b.Of childbearing potential and
opracticing a highl y effective method of contraception (failure rate of <1% 
per year when used consistently  and correctly )
Examples of highly  effective contraceptives include
-user-independent methods:
implantable progestogen -only hormone contraception associated with 
inhibition of ovulation; intrauterine device (IUD); intrauterine 
hormone -releasing s ystem (IUS); vasectomized partner; sexual 
abstinence (s exual abstinence is considered a highly effective method 
only if defined as refraining from heterosexual intercourse during the 
entire period of risk associated w ith the study drug. The reliability of 
sexual abstinence needs to be evaluated in relation to the duration of 
the study and the preferred and usual lifestyle of the subject. )
-user-dependent methods:
combined (estrogen -and progestogen -containing ) hormonal 
contraception associated with inhibition of ovulation: oral, 
intravaginal, and transdermal; progestogen -only hormone 
contraception associated with inhibition of ovulation: oral and 
injectable
Typi[INVESTIGATOR_313281]. Use should be consistent with local regulations regarding the 
use of contraceptive methods for subjects participating in clinical studies.
oagrees to use a highl y effective method throughout the study  and for at 
least [ADDRESS_385735] dose of study  drug.
Note: If the childbearing potential changes after start of the study  or the risk of 
pregnancy  changes (eg, a woman who is not heter osexually  active becomes active ),a 
woman must begin a highly  effective method of contrac eption, as described throughout 
the inclusion criteria.
11. A woman of childbearing potential must have a negative urine pregnancy  test at 
screening .
12. D uring the study  (ie, from Day 1  of the double -blind phase) and fora minimum of 
1spermatogenesis cycle (defined as approximately  90days)after receiving the last dose 
of study  drug , aman who is sexually  active with a woman of childbearing potential
must be practicing a highly  effective method of contraception with his female 
partner from those listed above (see examples of highly  effective methods of 
contraception provided for female subjects).
must use a condom if his partner is pregnant .
must agree not to donate sperm.
Note: If the childbearing potential changes after start of the study , a female partner of a 
male study  subject must begin a highl y effective method of birth control, as described 
above.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
61
Status: Approved , Date: [ADDRESS_385736] sign an infor med consent form (ICF) indicating that he or she 
understands the purpose of and procedures required for the study  and is willing to 
participate in the study .
Note: Subjects with acute alcohol intoxication should not be screened (but can be 
screened once so ber).
15. Each subject must sign a separate informed consent form if he or she agrees to provide 
anoptional DNA sample for research (where local regulations permit). Refusal to give 
consent for the optional DNA research sample does not exclude a subject from 
participation in the study .
4.2. Exclusion Criteria
Any potential subject who meets any  of the following criteria will be excluded from participating 
in the study :
1. Subject has a current DSM -5 diagnosis of bipolar (or related disorders) ,antisocial 
personality  disorder , or obsessive compulsive disorder.
2. Subject currentl y meets DSM -5 criteria for borderline personalit y disorder. 
Subjects not meeting full DSM -[ADDRESS_385737] meets the DSM -5 severit y criteria for moderate or severe substance or 
alcohol use disorder (except for nicotine or caffeine )within the 6 months before 
screening .
A history  (lifeti me) of ketamine, phency clidine (PCP), lysergic acid 
diethy lamide (LSD), or 3, 4 -methy lenediox y-methamphetamine (MDMA) 
hallucinogen -related use disorder is exclusionary .
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
62
Status: Approved , Date: [ADDRESS_385738] has any of the following conditions : 
ahistory  or current signs and sy mptoms of liver or renal insufficiency
clinically  significant cardiac (including unstable coronary  artery  disease and 
congestive heart failure, tachyarrh ythmias and recent myocardial infarction) or
vascular, pulmonary , gastrointestinal, endocrine (including uncontrolled 
hyperthy roidism) , neurologic (including current or past history  of seizures 
except uncomplicated childhood febrile seizures with no sequelae) , 
hematologic, rheumatologic, or metaboli c (including s evere 
dehy dration/hy povolemia ) disease .
7. Criterion modified per Amendment [ADDRESS_385739] has uncontrolled hypertension (systolic blood pressure >140 mmHg or 
diastolic blood pressure >90 mmHg) despi[INVESTIGATOR_154867], exercise or a stable dose of anti-
hypertensive treatment for at least 2 weeks at screening ; or any past history  of 
hypertensive crisis.
Subjects with conditions in which the elevation of blood pressure could be a 
serious risk (including unstable heart failure, severe cardiovascular disease, 
recent cerebral injury , increased intracranial pressure / intracranial mass lesion, 
intracranial bleeding or acute stroke, untreated glaucoma or perforating eye 
injury ) are excluded.
An abnormal blood pressure value at screening can be repeated once after 
5minutes of relaxation for subject eligibility .On Day 1  of the double -blind 
phase prior to randomization, a supi[INVESTIGATOR_1662] -supi[INVESTIGATOR_9219] 
>140 mmHg or diastolic blood pressure >[ADDRESS_385740] result(s) for phency clidine (PCP), cocaine, or 
amphetamines (inclusive of amphetamine, methamphetamine [mAMP], and 3, 4-
methy lenedioxy -methamphetamine [MDMA]) at screening . 
Subjects who have a positive test due to the appropriate use of prescribed 
opi[INVESTIGATOR_858], benzodiazepi[INVESTIGATOR_1651], or barbiturates may  be eligible for study  participation 
per clinician judgment. In addition, subjects who have a positive test for 
opi[INVESTIGATOR_858], benzodiazepi[INVESTIGATOR_1651], or barbiturates used withou t a prescription, may be 
considered eligible per clinician judgment and in consultation with the 
sponsor’s medical monitor. Subjects known to be using heroin should be 
excluded from the study .
Subjects who have a positive test due to opi[INVESTIGATOR_858], benzodiazepi[INVESTIGATOR_1651], or 
barbiturates taken in a suicide attempt (eg, overdose) may be eligible for study 
participation per clinician judgment and in consultation with the sponsor’s 
medical monitor.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
63
Status: Approved , Date: 31 January [ZIP_CODE].2 Criterion modified per Amendment 2
Subjects, who have a positive test result at screening due to prescribed 
psychostimulants (eg. amphetamine, methy lphenidate) that are permitted 
during the study  in accordance with Attachment 1, are eligible for study  
participation.
9. Subject has ahistory  of malignancy  within 5 years before screening (exceptions are 
squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or 
malignancy  that in the opi[INVESTIGATOR_871] , with concurrence with the sponsor's 
medical monitor ,is considered to have minimal risk of recurrence).
10. Subject has any anatomical or medical condition that, per the investigator’s clinical 
judgment based on assessment, may impede delivery  or absorption of intranasal study  
drug.
11. Subject has known allergies, hypersensitivity , intolerance or contraindications to
esketamine or ketamine or its excipi[INVESTIGATOR_840] (refer to Investigator's Brochure for 
esketamine37,Summary  of Product Characteristics42,45,78, US prescribing 
information43,44).
12. Subject hastaken any disallowed therap y(ies) as noted in Section 8, Prestudy  and 
Concomitant Therap y, and Attachment 1.
13.
  Criterion modified per Amendment [ADDRESS_385741] has received an investigational drug (including esketamine, ketamine, or 
investigational vaccines) or used an invasive investigational medical device within 
60days before the planned first dose of study  drug or is currentl y enrolled in an 
investigational study or was previously  enrolled in this study  or the Sponsor’s 
other studies in this population, 54135419SUI [ADDRESS_385742] (eg, compromise the well-
being) or that could prevent, limit, or confound the protocol- specified assessments.
16. Subject is anemploy ee of the investigator or study  site, with direct involvement in the 
proposed study  or other studies under the direction of that investigator or study  site, as 
well as famil y members of the employees or the investigator.
NOTE: Investigators should ensure that all study enrollment criteria have bee n met at screening. 
Section 17.4, Source Documentation, describes the required documentation to support meeting 
the enrollment criteria.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
64
Status: Approved , Date: [ADDRESS_385743] be willing and able to adhere to the following prohibitions and 
restrictions during the course of the stud y to be eligible for participation:
1. Refer to Section 4.1, Inclusion Criteria, for information regarding contraception/birth 
control requirements and sperm donation restrictions.
2. On all outpatient intranasal dosing days, all subjects must remain at the clinical site until 
study  procedures have been completed and the subject is ready  for discharge per 
clinician’s assessment. The minimum time required for postdose monitoring is 1.5hours. 
Subjects should be accompanied when released from the clinic al study  site. Subjects must 
not drive a car or work with machines for 24 hours after study  drug dosing.
3. Refer to Section 8, Prestudy  and Concomitant Therap y and Attachment 1(Prohibited 
Therapi[INVESTIGATOR_014]) for information regarding pr ohibited therapi[INVESTIGATOR_014].
4. Subjects may not receive electroconvulsive therapy  (ECT) during the study . ECT non-
responders at imminent risk for suicide may be included in the study . If an investigator 
were to enroll a subject currentl y receiving ECT, the investigator would have to 
document why it is clinically  appropriate to discontinue the ECT treatments, and to 
ensure that treatment is not changed for the purpose of making the subject eligible.
5. Food will be restricted for at least [ADDRESS_385744] appears intoxicated, dosing should not occur 
(delay ed per the permitted visit window; see the Time and Events Schedule).
8. Agree to follow all requirements that must be met during the study  as noted in the
Inclusion and Ex clusion Criteria (eg, contraceptive requirements ).
5. TREA TMENT ALLOCA TION AND BLINDING
Treatment Allocation and Randomization
Central randomization will be implemented in this study . Subjects will be randomly assigned to 
1 of 2treatment groups in a 1:1 ratio based on a computer -generated randomization schedule 
prepared before the study  by [CONTACT_43754]. The randomization will be 
balanced by [CONTACT_313354]’s assessment of the subject’s need of standard of care antidepressant treatment 
(ie,antidepressant monotherap y or an antidepressant plus augmentation therapy ); the standard of 
care will be determined prior to randomization on Day 1. The interac tive web response system 
(IWRS) will assign a unique treatment code, which will dictate the treatment assignment and 
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
65
Status: Approved , Date: [ADDRESS_385745].
Data that may potentially  unblind the treatment assignment (eg, study  drug plasma
concentrations, treatment allocation ) will be handled with special care to ensure that the integrity  
of theblind is maintained and the potential for bias is minimized. This can include making 
special provisions, such as segregating the data in question from view by [CONTACT_473], 
clinical team, or others as appropriate until the time of database lock and unblinding. To
minimize the risk of unblinding the treatment assignment during the study ,different raters will 
perform efficacy  and safety  assessments. Clinicians who perform MADRS and SIBAT will be 
different than those who evaluate vital signs, MOAA/S, CADSS , and adverse events .Raters for 
the MADRS and SIBAT assessment will not be allowed to access or to review subject safet y 
records; therefore, they will not provide clinical care for subjects. Clinical care of subjects will 
be performed by [CONTACT_313355]-SS-R/SIBAT raters. 
Adherence to this procedure will be monitored and enforced during the study .
Under normal circumstances, the blind should not be broken until all subjects have completed 
the study  and the database is finalized. Otherwise, the blind should be broken only if specific 
emergency  treatment/course of action would be dictated by [CONTACT_313356] t he treatment status of the 
subject. In such cases, the investigator may in an emergency  determine the identity  of the 
treatment by  [CONTACT_23793].It is recommended that the investigator contact [CONTACT_244530], before breaking the blind. Telephone 
contact [CONTACT_97500] 24hours per day, 7days per week. In 
the event the blind is broken, the sponsor must be informed as soon as possible. The date, time,
and reason for the unblinding must be documented in the appropriate section of the electronic 
case report form (eCRF), andin the source document. The documentation received from the 
IWRS indicating the code break must be retained with the subject's source doc uments in a secure 
manner .
Subjects who have had their treatment assignment unblinded should continue to return for 
scheduled earl y termination and follo w-up contacts and visits.
In general, randomization codes will be disclosed fully  only if the study is completed and the 
clinical database is closed. 
To maintain the blinding of intranasal study  medication, the esketamine and placebo intranasal 
devices will be indistinguishable. Please refer to Section 14(Study  Drug Information) for 
information on the phy sical characteristics of the study  drugs and devices.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
66
Status: Approved , Date: [ADDRESS_385746] supervision of 
the investigator or designee. Instructions for use of the device will be provided as a separate 
document (see Section 15, Study -specific Materials ).Details regarding study  drug administration 
will be recorded in the source documents and the eCRF. On all intranasal treatment session day s, 
a site staff member with training in cardiopulmonary resuscitation (eg, Basic L ife Support course 
or equivalent course) that is up to date per local regulations must be present with the subject 
during the intranasal treatment session and the postdose observation period. In addition, 
equipment for supportive ventilation and resuscitation needs to be present. A physical 
description of the stud y drugs is provided in Section 14.1.
On Day 1, subjects will be randomized to treatment with either intranasal esketamine [ADDRESS_385747] has nasal congestion on the dosing day, an intranasal decongestant can 
be used to reduce congestion ,or with the exception of the Day 1 dose, the dosing day may be 
delay ed (per the permitted visit window; see the Time and Events Schedule). If an intranasal 
decongestant is used to reduce congestion , it cannot be used within 1hour prior to intranasal 
study  drug dosing (see Attachment 1for allowed intranasal decongestant ).
The first dose of study  medication will be administered in the ER or other permitted setting that 
has appropriate staffing to manage acutel y suicidal subjects . If the first dose is administered in 
the ER, it is recommended that the subject notbe transferr ed from the ER to the inpatient 
psychiatric unit after the 4-hour postdose assessments are completed. Subjects who have been 
admitted directly  into the inpatient psy chiatric unit due to imminent risk for suicide or transferred 
from a medical unit (followin g medical stabilization for recent suicide attempt) will receive their 
first dose of study medication in the inpatient psychiatric unit.
Subjects will remain in the inpatient psychiatry unit for a recommended duration of [ADDRESS_385748] is ready for discharge per clinician’s 
assessment . The minimum time required for postdose mo nitoring is 1.[ADDRESS_385749] appears 
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
67
Status: Approved , Date: 31 January 2018intoxicated, dosing should not occur (delay ed per the permitted visit window; see the Time and 
Events Schedule).
On each dosing day : Subjects will self -administer 1 spray  into each nostril (ie, a total of 2 spray s 
using 1 intranasal device) at each of the following 3 time points: t = 0, 5 minutes and 10 minutes ;
time = [ADDRESS_385750] 100-μL spray . Subjects will use a separate intranasal 
device at each of these 3 time points (ie, a total of 3 devices). Spray s to each nostril should be 
delivered in rapid succession at the scheduled time points. Table 1describes how esketamine 
84 mg or placebo will be administered in the double-blind treatment phase.
Table 1: Dose Administration of Esketam ine [ADDRESS_385751] intranasal 
device. 
bOne device will be used at each time point. Each individual intranasal device contains 2 sprays. The intranasal 
devices containing esketamine deliver 14 mg per spray, for a total of 28 mg per individual device (ie, 2 sprays) .
After the first dose (ie, starting with the Day 4 dose or later), if required due to tolerability  issues, 
a one-time dose reduction to intranasal esketamine [ADDRESS_385752] would receive the decreased dose at all remaining dosing day s.
Table 2describes how esketamine 56 mg or placebo will be administered in the double -blind 
treatment phase.
Table 2: Dose Administration of Esketam ine [ADDRESS_385753] intranasal 
device. 
bOne device will be used at each time point. Each individual intranasal device contains 2 sprays. The intranasal 
devices containing esketamine deliver 14 mg per spray, for a total of 28 mg per individual device (ie, 2 sprays) .
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
68
Status: Approved , Date: 31 January [ZIP_CODE].1.1. Guidance on Blood Pressure Monitoring on Intranasal Treatment 
Session Days
Given the potential for treatment emergent transient elevation in systolic and diastolic blood 
pressure, the guidance shown in Table 3 should be fol lowed on intranasal dosing day s.
Table 3: Guidance for Blood Pressure Monitoring
Timing of blood 
pressure 
measurementThresholds for elevated blood 
pressure that require further 
guidanceGuidance for dosing, blood pressure m onitoring, or
follow -up assessment
Predose on 
Day 1Refer to exclusion criterion # 7 
(Section 4.2)Refer to exclusion criterion # 7 (Section 4.2).
Predose on any 
dosing day after 
Day 1SBP: >140 mmHg
and/or
DBP: >90 mmHgBlood pressure measurement should be repeated 
after the subject rests in a supi[INVESTIGATOR_1662] -supi[INVESTIGATOR_313282]. 
If SBP and/or DBP remain higher than thresholds, 
dosing should be postponed and re scheduled on the 
following day or within th e given visit window . 
If blood pressure elevation persists atthe next visit, 
the subject w ill be scheduled for a consultation by 
[CONTACT_154908], other specialist, or primary care 
physician prior to further dosing.
At any postdose 
timepoint on any 
dosing daySBP: ≥180 mmHg but <200 mmHg
and/or
DBP: ≥110 mmHg but <120 mmHgFurther intranasal dosing should be interrupted and 
the subject should be referred to a cardiologist, 
other specialist, or primary care physician for a 
follow -up assessment .
After the follow -up assessment, if recommended by 
[CONTACT_313357], the subject may continue 
with intranasal dosing if the pre dose blood pressure 
at the next s cheduled visit is within the acceptable 
range (see above).
At any postdose 
timepoint on any 
dosing daySBP: ≥200 mmHg
and/or
DBP: ≥120 mmHgSubject must discontinue from further dosing .
Subject should be referred to a cardiologist, other 
specialist, or primary care physician for a follow -up 
assessment.
At 90 minutes 
postdose on any 
dosing daySBP: ≥160 mmHg
and/or
DBP: ≥100 mmHgBlood pressure assessments should continue every 
30 minutes until:
oSBP is <160 mmHg and DBP is <100 mmHg, 
or 
oIn the investigator’s clinical judgment, the 
subject is clinically stable and can be 
discharged from the study site, or 
oThe subject is referred for appropriate medical 
care, if clinically indicated.
At 120minutes 
postdose on any 
dosing daySBP: ≥180 mmHg
and/or
DBP: ≥120 mmHgThe subject should be referred for immediate 
medical treatment.
Abbreviations: DBP, diastolic blood pressure; SBP, systolic blood pressure
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
69
Status: Approved , Date: [ADDRESS_385754] clinical care, including 
hospi[INVESTIGATOR_313258], which will be 
determined by [CONTACT_1963](s) based on clinical judgment and practice guidelines. The 
standard of care antidepressant treatment (antidepressant monotherapy  or antidepressant plus 
augmentation therap y) will be initiated or optimized for all subjects at the time of randomization 
on Day 1.Subjects who are on antidepressant monotherap y from Day 1 should remain on 
antidepressant monotherapy  through the end of double -blind phase (Day 25) whereas subjects 
who are on antidepressant plus augmentation therapy  from Day 1will remain on antidepressants 
plus augmentation therapy through the end of double -blind phase (Day  25).Eligible subjects 
may or may not be receiving antidepressants at the time of study  entry. Dose 
titration/adjustments of newly  initiated or optimized standard of care antidepressant treatment 
should occur during the first 2 weeks of double -blind treatment (ie, by [CONTACT_2006] 15), with doses 
remaining stable thereafter through the end of the double -blind phase (Day 25). Subjects who are 
currentl y taking a recently  initiated antidepressant treatment at screening (initiated <2 weeks 
prior) may continue taking the antidepressant at the current dose or at an optimized dose (dose 
adjustment is allowed during the first 2 weeks of double -blind treatment) through the end of the 
double -blind phase (Day 25), if deemed clinically  appropriate by [CONTACT_093] . During the 
double -blind treatment phase, the investigator need sto consult with the sponsor ’s medical 
monitor in advance if additional changes on antidepressant treatment are clinically  indicated. 
During the follow -up phase, the antidepressant treatment will be managed based on the 
clinician’s judgment. 
7. TREA TMENT COMPLIA NCE
All doses of study  medication will be self-administered under the direct supervision of the 
investigator or designee.
The investigator or designa ted study -site personnel will maintain a log of all study  drug 
dispensed and returned. Drug supplies for each subject will be inventoried and accounted for 
throughout the stud y.
8. PRESTUDY AND CONCOMITA NT THERAPY
Prestudy  therapi[INVESTIGATOR_43710] 30daysbefore first dose of study  drug  should be recorded 
at screening. Concomitant therapi[INVESTIGATOR_313283]. Concomitant therapi[INVESTIGATOR_313284], including 
serious adverse events that meet the criteria outlined in Section 12.3.2 ., Serious Adverse Events.
All therapi[INVESTIGATOR_014] (prescription or over-the-counter medications, including vaccines, vitamins, herbal 
supplements; non-pharmacologic therapi[INVESTIGATOR_313285], acupuncture, special 
diets, exercise regimens) different from the study  drug must be recorded in the eCRF .
Modification of an effective preexisting therapy  should not be made for the explicit purpose of 
entering a subject into the study .
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
70
Status: Approved , Date: [ADDRESS_385755] of prohibited therapi[INVESTIGATOR_313276] 1as general guidance for the 
investigator; please note, however, this list is not all inclusive. Please contact [CONTACT_313358][INVESTIGATOR_53301] a subject. 
Subjects must also adhere to the list of prohibitions and restrictions provided in Section 4.3.
Subjects may not receive ECT during the study . ECT non-responders at imminent risk for 
suicide may be included in the study . If an investigator were to enroll a subject currentl y 
receiving ECT, the investigator would have to document why it is clinically  appropriate to 
discontinue the ECT treatments, and to ensure that treatment is not changed for the purpose of 
making the subject eligible.
The sponsor must be notified in advance (or as soon as possible thereafter) of any instances in 
which prohibited therapi[INVESTIGATOR_23730].
9. STUDY EVA LUATIONS
9.1. Study Procedures
9.1.1. Overview
The Time and Events Schedule summarizes the frequency  and timing of efficacy ,PK, biomarker,
pharmacogenomic /epi[INVESTIGATOR_18193] , medical resource utilization, and safet ymeasurements applicable 
to this study .
If multiple assessments are scheduled for the same timepoint, it is recommended that procedures 
be performed in the sequence provided by  [CONTACT_941] s ponsor (see Section 9.1.3 ). Actual dates and times 
of assessments will be recorded in the source documentation and eCRF .
Additional pregnancy  tests may be performed, as determined necessary  by [CONTACT_170492], to establish the absence of pregnancy  at any time during the 
subject's participation in the study .
Additional drug tests may be performed as determined necessary  by [CONTACT_313359].
Medical resource utilization data will be collected. Refer to Section 9.6, Medical Resource 
Utilization for det ails.
The total blood volume to be collected from each subject will be approximately 141mL(seeTable 
4).
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
71
Status: Approved , Date: 31 January 2018Table 4: Approxim ate Volume of Blood to be Collected From  Each Subject
Type of SampleVolume (mL)
per sampleNumber of Samples
per SubjectTotal Volume of 
Blood (mL)a
Screening Phase
Serum chemistry 2.5 2 (1 local, 1 central)b5
Hem atology 2 2 (1 local, 1 central)b4
Approximate total blood volume for screening phase 9
Double -Blind Treatment Phase
Serum chemistry 2.5 1 2.5
Hem atology 2 1 2
Pharm acokinetic evaluation 2 6 12
Blood for biomarker evaluation 30 c3 90
Blood for RNA biomarker evaluation 2.5 3 7.5
Approximate total blood volume for double -blind treatment phase with biomarker samples 114
Pharm acogenomic/epi[INVESTIGATOR_313286]6 3 18
Approximate total blood volume for double -blind treatment phase with biomarker and 
pharmacogenomic/epi[INVESTIGATOR_313252]132
Approxim ate total blood volume for study 141 mL
a Calculated as number of samples multiplied by [CONTACT_313360] d per sample.
b At screening , 2 samples will be collected for analysis –1 sample each for the local laboratory (to have results 
prior to Day 1 dose) and the central laboratory (see Section 9.7for further details) .
cBlood volume for biomarker samples represents volume of several tubes combined.
dBlood sample(s) will be collected only from subjects who have consented to provide an optional sample for 
genetic research .
Note: If desired, a n indwelling intravenous cannula may be used for blood sample collection.
Repeat or unscheduled samples may be taken for safet y reasons or for technical issues with the 
samples.
9.1.2. Screening Phase
Prior to conducting any study  procedure, the investigator (or designated study  personnel) will 
review and explain the written ICF to each potential subject with MDD presenting to an ERor 
other permitted setting and assessed to be at imminent risk for suic ide.
After signing the ICF, potential subjects will be screened under close supervision within 
48hours of intranasal dosing on Day 1  to determine eligibility  for study  participation (if 
possible, potential subject sshould be screened within 24 hours of intranasal dosing on Day 1). 
Subjects who have recently  attempted suicide and are currentl y hospi[INVESTIGATOR_313287], or subjects who have been admitted 
directly  into the inpatient psychiatric unit due to imminent risk for suicide, may also be screened 
to determine eligibility . 
Subject smust meet DSM -[ADDRESS_385756] a MADRS 
total score of >28 predose on Day 1, and in the physician’s opi[INVESTIGATOR_1649], acute psychiatric 
hospi[INVESTIGATOR_313288]’s imminent risk of suicide. Refer to 
Section 4(Subject Population) for all inclusion and exclusion criteria that will be used to 
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
72
Status: Approved , Date: [ADDRESS_385757] of study  procedures that will be 
performed at screening .
Theclinician -administered assessments at screening canbe performed in the order preferred by 
[CONTACT_977]:MINI, Question B3 and B10 from MINI (current status). If thescreening phase 
is longer than 24 hours, Question B3 and B10 from MINI (current status) must be repeated prior 
to randomization to confirm eligibility .
All adverse events and special reporting situations, whether serious or non-serious, will be 
reported from the time a signed and dated ICF is obtained until completion of the subject's last 
study -related procedure (which may  include contact [CONTACT_20687] -up of safety).
9.1.3. Double -Blind Treatment Phase
Following completion of all required screening procedures and confirmation of subject 
eligibility , subjects will enter the double -blind treatment phase.
On Day 1  of the double -blind treatment phase, approximately  224 subjects will be randomly  
assigned to 1 of 2 treatme nt groups in a 1:1 ratio (approximately  112 subjects per group) : 
intranasal esketamine 84 mg or intranasal placebo . Study  drug will beadministered two times 
per week for 4 weeks (Day s 1, 4, 8, 11, 15, 18, 22, and 25). Intranasal treatment sessions should 
not take place on consecutive day s.
Subjects will be admitted toand receive the first dose of study  medication inthe ERor other 
permitted setting ; for example, subjects who have been admitted directly  into the inpatient 
psychiatric unit due to imminent risk for suicide or transferred from a medical unit (following 
medical stabilization for recent suicide attempt) will receive their first dose of study  medication 
in the inpatient psychiatric unit. If the first dose is administered in the ER, it is recomme nded 
that subjects not be transferred from the ER to the inpatient psychiatric unit until after the 
postdose assessme nts are completed (approximately  4  hours after study drug administration) . 
Prior to the first intranasal dose on Day 1, subjects will pract ice spraying (into the air, not 
intranasall y) a demonstration intranasal device that is filled with placebo solution. All subjects 
will self-administer the study  medication under the direct supervision of the investigator or 
designee (Refer to Section 6, Dosage and Administration).
All subjects will be treated in the context of comprehensive standard clinical care, including 
hospi[INVESTIGATOR_313258] (antidepressant 
monotherap y or antidepressant plus augmentation therap y). On Day 1, all subjects will begin 
standard of care treatment and will continue, at least, this treatment through the duration of the 
double -blind treatment phase . The standard of care will be determined by [CONTACT_30780](s) based on clinical judgment and local practi ce at the time of randomization on Day  1.
Any changes to the standard of care treatment, that is different from what was planned at the 
time of randomi zation, should be clearly documented including the reason for the change.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
73
Status: Approved , Date: 31 January 2018The 4-hour assessments at the Day 1 visit should be performed within ±30 minutes of the 4-hour 
postdose time point . The 24 -hour assessments at the Day  2 visit should be performed ±[ADDRESS_385758] of care . The 
discharge decisi on will bemade based upon the investigator’s judgment that the subject is no 
longer imminently  suicidal and meets standard discharge criteria per local practice . Discharge
before [ADDRESS_385759] be discussed and approved by [CONTACT_456] ’s medical monitor . The 
investigator must discuss the need for continued hospi[INVESTIGATOR_313289] 10 days and thereafter on 
a weekly basis with the sponsor ’s medical monitor . Following discharge from the inpatient 
psychiatric unit, subsequent visits for the double -blind treatment phase will be conducted twice -
weekl yat an outpatient psy chiatric facility  through Day  25.
Dose titration/adjustments of newl y initiated or optimized standard of care antidepressant 
treatment should occur during the first 2 weeks of double -blind treatment (ie, by [CONTACT_2006] 15), with 
doses remaining stable thereafter through the end of the double -blind phase (Day  25). Subjects 
who are currentl y taking a recentl y initiated antidepressant treatment at screening (initiated 
<2weeks prior) may continue taking theantidepressant at the current dose or at an optimized 
dose (dose adjustment is allowed during the first 2 weeks of double -blind treatment) through the 
end of the double -blind phase (Day  25), if deemed clinically  appropriate by [CONTACT_093] .The 
invest igator need s to consult with the sponsor’s medical monitor in advance if additional changes 
toantidepressant treatment are clinicall y indicated . 
On all outpatient intranasal dosing days, all subjects must remain at the clinical site until study  
procedures have been completed and the subject is ready for discharge per clinician’s 
assessment. The minimum time required for postdose monitoring is 1.[ADDRESS_385760] a car or work 
with machines for 24 hours after stud y drug dose administration.
Efficacy , safet y, pharmacokinetic, biomarker, pharmacogenomics, and medical resource 
utilization evaluations will be performed as described in the Time and Events Schedule. When 
multiple patient -reported outcomes and clinician -administered assessments are scheduled for the 
predose time point it is recommended they  be performed in the following sequence:
SIBAT
MADRS
Patient- reported outcomes : BHS ,QLDS, EQ -5D- 5L, and TSQM-9
Clinicians who perform the MADRS and SIBAT assessments will be different from those who 
evaluate vital signs, MOAA/S, CADSS , and adverse events.
Subje cts and site staff will complete the clinician -administered assessments and patient-reported 
outcomes using a n electronic tablet device provided for this study or using a paper version (refer 
to Section 15,Study -Specific Materials).
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
74
Status: Approved , Date: [ADDRESS_385761] dose of intranasal study  medication (if 
the date of the Early Termin ation visit is less than [ADDRESS_385762] dose of intranasal study 
medication ), on Day 25,and on Day [ADDRESS_385763] is appropriatel y transitioned/followed for any additional care required.
9.1.4. Posttreatment Phase (Follow -Up)
During the follow -up phase, subjects will be monitored twice weekl y for the first two weeks 
(Days 28, 32, 35, and39) after study  drug treatment . Subjects will then be followed up weekl y 
for the next two weeks (Day s 46 and 53) and every  two weeks for the rest of the follow -up 
period (Day s 67 and 90).
During the follow -up phase, the antidepressant treatment will be managed based on the 
clinician’s judgment. 
Efficacy , safety, and medical resource utilization evaluations will be performed as described in 
the Time and Events Schedule. When multiple patient -reported outcomes and clinician -
administered assessments are scheduled for the same time point it is recommended they be 
performed in the following sequence:
SIBAT
MADRS
Patient- reported outcomes: BHS ,QLDS, EQ -5D- 5L, and TSQM-9
Clinicians who perform the MADRS and SIBAT assessments will be different from those who 
evaluate vital signs, and adverse events.
Subjects and site staff will complete the clinician -administered assessments and patient -reported 
outcomes electronicall y using a device provided for this study  or using a paper version (refer to 
Section 15, Study -Specific Materials).
Any clinicall y significant abnormalities persisting at the end of the study  will be followed by  [CONTACT_313361] a clinicall y stable endpoint is reached. All adverse events 
and special reporting situations, whether serious or non- serious, will be reported until completion 
of the subject's last study -related procedure (which may  include contact [CONTACT_20687] -up of safet y).
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
75
Status: Approved , Date: [ADDRESS_385764] is 
appropriatel y transitioned/followed for an y additional care required.
9.2. Efficacy Evaluations
9.2.1. Montgomery -Asberg Depression Rating Scale
The primary  efficacy  evaluation will be the MADRS total score. The MADRS will be p erformed 
using the Structured Interview Guide for the Montgomery A sberg Depression Rating Scale .[ADDRESS_385765] consists of 
10items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous 
presence of the symptoms), for a total possible score of 60. Higher scores represent a more 
severe condition. The MADRS evaluates apparent sadness, reported sadness, inner tension, 
sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal 
thoughts. The test exhibits high inter-rater reliability . 
The typi[INVESTIGATOR_154881] [ADDRESS_385766].
Whenever possible, all efforts should be made to use the same raters for the MADRS at each site 
to assess the sa me subjects throughout the study . If this is not possible, review of the appropriate 
prior assessments and communication with prior raters should be conducted as needed.
9.2.2. Suicide Ideation and Behavior Assessment Tool
The SIBAT has two major divisions: a patient-rated section and a clinician -rated section. The 
patient -rated section has modules of demographics and suicide history , risk/protective factors, 
suicidal thinking, suicide behavior, and suicide risk. The information generated in this section 
will be summarized and used to support the clinical decision -making of the second section. The 
clinician -rated section has modules for semi -structured interview, clinical global impressions of 
current severity  of suicidality  and imminent suicide risk, clinical global impression of long-term 
suicide risk, and clinical judgment of optimal suicide management. 
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
76
Status: Approved , Date: [ADDRESS_385767] and study  staff during 
the study . Refer to the SIBAT Time and Events Schedule for an ou tline of which modules will be 
performed at each scheduled time point. 
One module of the SIBAT includes a revised version of the Clinical Global Impression –
Severity  of Suicidality . The CGI-SS-R rating is scored on a 7-point scale from 0 (normal, not at 
all suicidal ) to 6 ( among the most extremely  suicidal patients) and will be based on the totality  of 
information available to the clinician, including information from the SIBAT. The CGI-SS-R 
summarizes the clinician ’soverall impression of severit y of suicidality  and will be used to assess 
the key secondary  endpoint in this study  (see Section 2.1.2 ). This rating operate slike numerous 
other CGI-severit y scales that have been used in other psychiatric studies. These instruments 
have shown clinical validity  and sensitivity  to change.
The CGI-SR-I summarizes theclinician’s best assessment of the likelihood that a patient will 
attempt suicide in the next 7 day s.
Whenever possible, all efforts should be made to use the same raters for the SIBAT at each site 
to assess the same subjects throughout the study . If this is not possible, review of the appropriate 
prior ass essments and communication with prior raters should be conducted as needed.
9.2.3. Beck Hopelessness Scale
The BHS is a self-reported measure to assess one’s level of negative expectations or pessimism 
regarding the future . It consists of 20 true -false items that examine the respondent’s attitude over 
the past week by [CONTACT_313362] a pessimistic statement or denying an optimistic statement; 
9are keyed false and 11 are key ed true. These items fall within 3 domains: (1) feelings about the 
future; (2) loss of motivation; and (3) future expectations. For every  statement, each response is 
assigned a score of 0 or 1. The total BHS score is a sum of item responses and can range from 
0to 20, with a higher score representing a higher level of hopelessness . Total scores that range 
from 0 to 3 are considered within the normal range, scores 4 to 8 identify mild hopelessness, 
scores 9 to 14 identify moderate hopelessness, and scores greater than 14 identify  severe 
hopelessness . 
BHS scores of ≥[ADDRESS_385768] a high degree of internal 
consistency  (0.92); the same value of internal consistency was found among a group of 
134subjects with recurrent -epi[INVESTIGATOR_154831].9Among a group of hospi[INVESTIGATOR_313290] s, the 
scale showed a relatively  high correlation with clinical ratings of hopelessness and other self-
administered measures of hopelessness . Test- retest scores of 0.[ADDRESS_385769] ’s state of depression over 
time.10The measure is designed for use in adults aged [ADDRESS_385770] 7 day s.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
77
Status: Approved , Date: 31 January [ZIP_CODE].2.4. EuroQol 5 -Dimension 5 -Level
The EQ-5D- 5L is a standardized instrument for use as a measure of health outcome, primarily 
designed for self -completion by  [CONTACT_170496]. It consists of the EQ -5D- 5L descr iptive sy stem and 
the EQ visual analogue scale (EQ- VAS). The EQ-5D- 5L descriptive system comprises the 
following 5 dimensions: Mobility , self-care, usual activities, pain/discomfort and 
anxiety /depression. Each of the 5 dimensions is divided into 5 levels of perceived problems 
(Level 1 indicating no problem, Level 2 indicating slight problems, Level 3 indicating moderate 
problems, Level 4 indicating severe problems, and L evel 5 indicating extreme problems).27,[ADDRESS_385771] 
matches his or her health “today .” The descriptive system can be represented as a health state. 
The EQ-VAS self-rating records the respondent’s own assessment of his or her overall health 
status at the time of completion, on a scale of [ADDRESS_385772] of depression and its treatment from the 
patient’s perspective .34,52,77The instrument has a recall period of "at the moment", contains 34-
items with "yes"/"no" or “true ”/“not true” response options and takes approximately  5-10 minutes 
to complete. The score range is from 0 (good quality  of life) to 34 (very  poor quality  of life). It has 
been shown to have acceptable psy chometric properties and sensitivit y to change.
9.2.6. Treatment Satisfaction Questionnaires for Medication
The Treatment Satisfaction Questionnaire for Medication (TSQM -9)4is a 9-item generic patient 
reported outcome instrument to assess patients’ satisfaction with medication. It is derived from 
the longer TSQM Vers ion 1.411and covers domains of effectiveness, convenience and global 
satisfaction. The instrument is scored by [CONTACT_313363] 0-100 where a lower 
score indicates lower satisfaction. The recall period is “the last 2-3 weeks”. It takes 
approximately  [ADDRESS_385773] be recorded.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
78
Status: Approved , Date: 31 January [ZIP_CODE].3.2. Analytical Procedures
Plasma samples will be analyzed to determine concentrations of esketamine and noresketamine 
using a validated, specific, and sensitive achiral liquid chromatograph y/mass spectrometry /mass 
spectrometry  (LC-MS/MS) method by  [CONTACT_43754].
If required, some plasma samples may be analy zed to document the presence of circulating 
metabolites using a qualified research method. In addition, plasma PK samples may  be stored for
future analy sis of the metabolite profile.
The bioanaly tical report, including a description of the assay  and a summary  of the assay  
performance data, will be included in the final study report as an addendum.
9.3.3. Pharmacokinetic Parameters
The plasma concent ration -time data of esketamine (and noresketamine, if warranted) will be 
analyzed using population PK modeling. I f conducted, the results of population PK analy ses may 
be reported separatel y.
9.4. Pharmacokinetic/Pharmacody namic Evaluations
The relationship between MADRS total score (and possibly  selected adverse events and 
additional pharmacod ynamic parameters), and PK metrics of esketamine may be evaluated. The 
results of such analy ses may  be reported separately .
9.5. Biomarker and Pharmacogenomic (DNA ) Evaluations
Biomarker Evaluations
Blood samples will be collected as indicated in the Time and Events Schedule for exploratory 
analysis of biomarkers (protein, metabolites, and RNA) related to immune system activity , HPA 
axis activation, neurotrophic and metabolic factors . Exploratory  analyses may be performed for 
additional biomarkers as well . Results may  be presented in a separate biomarkers report.
Biomarkers may be added or deleted based on scientific information or technical innovations 
under the condition that the total volume of blood collected will not be increased. 
All biomarker data obtained during this study  may be included in ongoing cross -study  analyses 
to investigate the relationship between depression severit y and phenot ypes and biomarkers.
Informatio n on menstrual cycle (date of first day of last period, average length of cycle) will be 
recorded on Day 1  (predose) and Day 25when blood samples for biomarker analysis are 
collected.
Pharmacogenomic Evaluations
Subject participation in pharmacogenomic/epi[INVESTIGATOR_313291]. A whole blood 
sample for DNA analyses will be collected from all subjects who provide conse nt for 
pharmacogenomic research at the time points indicated in the Time and Events Schedule .
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
79
Status: Approved , Date: [ADDRESS_385774] s relevant to MDD and suicidality . Additional analy ses may be conducted if it is 
hypothesized that this may help resolve issues with the clinical data.
DNA samples will be used for research related to esketamine or MDD . They  may  also be used to 
develop tests/assay s related to esketamine and MDD . Pharmacogenomic research may consist of 
the analysis of one or more candidate genes or of the analysis of genetic and epi[INVESTIGATOR_313292] (as appropriate) in relation to esketamine or MDD clinical endpoints.
9.6. Medical Resource Utilization
Medical resource utilization data, associated with medical encounters, will be collected using the 
Healthcare Resource Use Questionnaire (HRUQ) on an ongoing basis whenever an encounter 
occurs and will be reviewed as indicated in the Time and Events Schedule . The HRUQ includes 
information regarding utilization of healthcare services (including the timing and ty pe of serves ), 
enabling changes in level and quantity  of services to be considered as a variable in economic 
models.
9.7. Safety  Evaluations
Details regarding the Independent Data Monitoring Committee are provided in Section 11.9.
Any clinically  relevant changes occurring during the study  must be recorded on the Adverse 
Event section of the eCRF .
Any clinically  significant abnormalities persisting at the end of the study/earl y withdrawal will 
be followed b y the investigator until resolution or until a clinically  stable endpoint is reached.
The study  will include the following evaluations of safet y and tolerability  according to the time 
points provided in the Time and Events Schedule :
Adverse Events
Adverse events will be reported by [CONTACT_214442] . Adverse events will 
be followed b y the investigator as specified in Section 12, Adverse Event Reporting.
The TEAEs of special interest will be examined separately (refer to Sections 3.2.6 and 11.8 for 
further details).
Clinical Laboratory Tests
Blood samples for serum chemistry  and hematology  and a random urine sample for urinaly sis
will be collected. The investigator must review the laboratory  results, document this review, and 
record any clinicall y relevant changes occurring during the study  in the adverse event section of 
the eCRF . The laboratory reports must be filed with the source documents.
A local laboratory  will be used at screening to ensure results are available in enough time to 
determine subject eligibility . If standard of care clinical laboratory  tests are performed within 
24hours prior to the screening visit (ie, signing of the ICF), results for those laboratory  tests 
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
80
Status: Approved , Date: [ADDRESS_385775] eligibility . In this 
situation , following signing of the ICF, sample(s) for the local laboratory are not required, but 
sample(s) must be obtained and sent to the central laboratory (see below) .A local laboratory  can 
also be used in any instance where safet y follow up is time-critical and the central laboratory  
results are not expected to be available before actions need to be taken for safet y reasons.
A central laboratory  will be used at screening and during the stud y.
The following tests will be performed:
Hematology  Panel
-hemoglobin -platelet count
-hematocrit
-red blood cell (RBC) count
-white blood cell (WBC) count with differential
Serum Chemistry  Panel
-sodium -alkaline phosphatase
-potassium -creatine phosphokinase (CPK)
-chloride -lactic acid deh ydrogenase (LDH)
-bicarbonate -uric acid
-blood urea nitrogen (BUN) -calcium
-creatinine -phosphate
-glucose -albumin
-aspartate aminotransferase (AST) -total protein
-alanine aminotransferase (ALT)
-gamma -glutam yltransferase (GGT)
-total bilirubin
Urinaly sis
Dipstick Sediment (if dipstick result is
-specific gravit y abnormal)
-pH -red blood cells
-glucose -white blood cells
-protein -epi[INVESTIGATOR_1663]
-blood -crystals
-ketones -casts
-bilirubin -bacteria
-urobilinogen
-nitrite
-leukocy te esterase
If dipstick res ult is abnormal, flow cy tometry will be used to measure sediment. I n case of
discordance between the dipstick results and the flow cy tometric results, the sediment will 
be examined microscopi[INVESTIGATOR_897] .
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
81
Status: Approved , Date: 31 January 2018Specific gravity , pH, glucose, protein, blood, ketones, bilirubin, and urobilinogen will be 
determined using a dipstick. Red blood cells, white blood cells, epi[INVESTIGATOR_1663], crystals, casts, 
and bacteria will be measured using flow cytometry . If there is discordance between the dipstick 
results and the flow cytometric results, the sediment will be examined microscopi[INVESTIGATOR_897] .
The following additional clinical laboratory  assessments will be perfor medon-site:
Urine Pregnancy  Testing (for women of childbearing potential only)
Urine Drug Screen -barbiturates , opi[INVESTIGATOR_858], cocaine, PCP, amphetamines, and 
benzodiazepi[INVESTIGATOR_313293] (ECG)
A single, 12-lead ECG will be performed at each time point specified in the Time and Events 
Schedule.
During the collection of ECGs, subjects should be in a quiet setting without distractions 
(eg,television, cell phones). Subjects should rest in a supi[INVESTIGATOR_1662] -supi[INVESTIGATOR_21683] 
[ADDRESS_385776] eligibility .
Vital Signs ( Temperature, Pulse/Heart Rate, Respi[INVESTIGATOR_13581], Blood P ressure)
Vital signs will be performed per the Time and Events Schedule. Blood pressure and pulse/ heart 
rate measurements will be assessed with a completely  automated device. Manual techniques will 
be used onl y if an automated device is not available.
Blood pressure and pulse/heart rate measurements should be preceded by [CONTACT_2669] [ADDRESS_385777] in a quiet setting without distractions (eg, tel evision, cell phones).
For further details regarding blood pressure monitoring, please see Guidance on Blood Pressure 
Monitoring on Intranasal T reatment Session Day s (Section 6.1.1 ).
Tympanic temperature is recommended. The method used for obtaining temperature should be 
documented.
Physical Examination , Body Weight, and Height
Physical examinations and measurement of body weight and height will be performed per the 
Time and Events Schedule.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
82
Status: Approved , Date: 31 January 2018Nasal Examination
Targeted nasal examinations (including the upper respi[INVESTIGATOR_53121]/throat) will be conducted per 
the Time and Events Schedule. The objective of the examination at screening is to rule out any 
subjects with anatomical or medical conditions that may  impede drug delivery  or absorption. 
Subsequent examination will consist of a visual inspection of the nostrils, nasal mucosa, and 
throat for nasal erythema, rhinorrhea, rhinitis, capi[INVESTIGATOR_1396] /blood vessel disruption and epi[INVESTIGATOR_313294]: none, mild, moderate, or severe. 
Dosing Day Assessments
Pulse Oximetry
Pulse oximetry  will be used to measure arterial oxygen saturation (SpO 2). On each dosing day, 
the device will be attached to the finger, toe, or ear ,and SpO 2will be monitored and documented 
every  15 minutes from predose to 1.5 hours postdose. If oxygen saturation levels are <93% at 
any time during the 1.5hour postdose interval, pulse oximetry  will be recorded every  5 m inutes 
until levels return to 93% or until the subject is referred for appropriate medical care, if 
clinically  indicated.
Modified Observer's Assessment of Alertness/Sedation (MOAA/S)
The MOAA/S will be used to measure treatment -emergent sedation with correlation to levels of 
sedation defined by [CONTACT_313364] y of Anesthesiologists (ASA) continuum.67The 
MOAA/S scores range from 0 (no response to painful stimulus; ASA continuum = general 
anesthesia) to 5 (readil y responds to name [CONTACT_154992] [awake] ; ASA continuum = 
minimal sedation) .
On each intranasal dosing day, the MOAA/S will be performed every  15 minutes from predose
to 1.5 hours postdose .
If the score is ≤3 at any time during the 90 minute postdose interval, the MOAA/S will be 
performed every  5  m inutes until a score of 4 is reached (at which point a frequency  of every  
15 minutes can be resumed until t = 90 minutes postdose). 
If a subject does not have a score of at least 5 at t = [ADDRESS_385778] should 
continue to be monitored. For subjects with a score of 4, the assessment should be repeated every 
15 minutes. And for subjects with a score of ≤3, the assessment should be repeated every 
5minutes until the score returns to [ADDRESS_385779] is referred for appropriate medical care, if 
clinically  indicated.
Clinician -Administered Dissociative States Scale (CADSS)
The CADSS is an instrument for the measurement of present -state dissociative symptoms14and 
will be administered to assess treatment -emergent dissociative symptoms. On each dosing day, 
the CADSS will be performed predose, and at 40 minutes and 1.5 hours postdose.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
83
Status: Approved , Date: 31 January 2018The CADSS consists of 23 subjective items, divided into 3 components: depersonalization 
(items 3 to 7, 20, and 23), derealization (items 1, 2, 8 to 13, 16 to 19, and 21) and amnesia 
(items 14, 15, and 22). The subject’s responses are coded on a 5 -point scale ( from 0=not at all to 
4=extremely ). The CADSS has excellent inter -rater reliability  and internal consistency .
If any CADSS items are scored zero at 40 minutes, these items will not need to be repeated at 
1.5hours postdose.
9.8. Other Evaluations
Mini -International Neuropsychiatric Interview (MINI)
The MINI is a short, structured diagnostic interview developed for the fifth edition of the 
Diagnostic and Statistical Manual of Mental Disorders (DSM -5) and 10th revision of the 
International Statistical Classification of Diseases and Related Health Problems (ICD-10) 
psychiatric disorders. It has an administration time of approximately  15 to 30 minutes and 
provides an accurate structured psychiatric interview for multicenter clinical trials. The MINI is 
used to confirm the diagnosis of MDD with current suicidal ideation and to determine if there are 
other psy chiatric conditions present.
Question s B3 and B10 from the MINI
Current suicidal ideation with intent will beevaluated at screening using Question B3 ( Think 
[even momentarily ] about harming or of hurting or of injuring yourself: with at least some intent 
or awareness that you might die as a result; or think about suicide [ie,about killing yourself] ?)
andQuesti on B10 ( Intend to act on thoughts of killing yourself? ) from the MINI. Subjects will 
be asked to answer these questions (Yes or No) relative to their current status. T he response to 
B3 must refer to the present, whereas the response to B10 may reflect the past 24 hours. Ifthe 
screening phase is longer than 24 hours, Question B3 and B10 from MINI (current status) must 
be repeated prior to randomization to confirm eligibility .
9.9. Sample Collection and Handling
The actual dates and times of sample collection must be recorded in the eCRF or laboratory 
requisition form. If blood samples are collected via an indwelling cannula, an appropriate 
amount (1 mL) of serosanguineous fluid slightly  greater than the dead space volume of the lock 
will be removed from the cannula and discarded before each blood sample is taken. After blood 
sample collection, the cannula will be flushed with 0.9% sodium chloride, [LOCATION_002] 
Pharmacopeia (USP) (or equivalent) and charged with a volume equal to the dead space volume 
of the lock.
Refer to the T ime and Events Schedule for the timing and frequency  of all sample collections.
Instructions for the collection, handling, storage, and shipment of samples are found in the 
laboratory  manua lthat will be provided. Collection, handling, storage, and shipment of samples 
must be under the specified, and where applicable, controlled temperature conditions as indicated 
in the laboratory  manual.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
84
Status: Approved , Date: [ADDRESS_385780] COMPLETION/ DISCONTINUA TION OF STUDY TREATMEN T/ 
WITHDRA WALFROM THE STUDY
10.1. Completion
A subject will be considered to have completed treatment if he or she has completed assessments 
up to and including Day [ADDRESS_385781] completed the study  if he or she has completed assessments 
up to and including Day 90.
10.2. Discontinuation of Study Treatment/ Withdrawal From the Study
Discontinuation of Study Treatment During the Double -blind Phase
A subject will not be automatically  withdrawn from the study  if he or she has to discontinue 
treatment before the end of the double -blind treatment phase .
A subject's study  treatment willbediscontinue d for an y of the following reasons:
Lost to follow -up
Withdrawal of consent
Death
Lack of efficacy , per the investigator’s judgment
The investigator believes that for safety  reasons or tolerability  reasons (eg,adverse event or 
worsening of underl ying condition) it is in the best interest of the subject to discontinue 
study  treatment
The subject becomes pregnant during the double -blind treatment phase
Blind is broken 
Violation ofprotocol procedures, per the investigator’s judgment and in consultation with 
the sponsor
Change in the in-patient hospi[INVESTIGATOR_313295] a result of a 
judicial or other legal administrative order
If a subject discontinues study  treatment for any reason other than lost to follow up, death, or 
withdrawal of consent before the end of the double -blind treatment phase, an Early Termination 
visit will be conducted at the time of discontinuation and the subject will be contact[CONTACT_313365] y 
at [ADDRESS_385782] dose of intranasal study  medication (if the date of the Early Termination 
visit is less than [ADDRESS_385783] dose of intranasal study  medication ), on Day  [ADDRESS_385784] is appropriately transitioned 
and/or followed for an y additional care required.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
85
Status: Approved , Date: [ADDRESS_385785] will be withdrawn from the study  during the follow -up phase for any of the following 
reasons:
Lost to follow -up
Withdrawal of consent
Death
Viola tion of protocol procedures, per the investigator’s judgment and in consultation with 
the sponsor
If a subject withdraws from the study  after the double -blind phase but before the end of the 
follow -up phase for reasons other than lost to follow up, death, or withdrawal of consent, an 
Early Termination visit will be conducted at the time of discontinuation and the subject will be 
contact[CONTACT_313365] y on Day [ADDRESS_385786] is 
appropriatel y transitioned and/or followed for an y additional care required.
If a subject is lost to follow up, every  reasonable effort must be made by  [CONTACT_43757]/withdrawal. This should 
include at least [ADDRESS_385787] numbers (eg, home, work, and mobile phone numbers) as well as other contact 
[CONTACT_3031] (eg, email addresses) from subjects before randomization. In addition , the study  site 
should emphasize the importance of follow -up information to the subject before randomization. 
The measures taken to follow up must be documented.
When a subject withdraws before completing the study , the reason for withdrawal is to be 
docu mented in the eCRF and in the source document. Study  drug assigned to the withdrawn 
subject may  not be assigned to another subject. Subjects who withdraw will notbe replaced. 
Withdrawal of Consent
Every  effort will be made in the study  to ensure withdrawal of consent is not selected as a reason 
for discontinuation when in fact the subject withdrew for an identifiable reason (eg, due to an 
adverse event or lack of efficacy ). 
Subjects who wish to withdraw from the study  should be asked if they are agreeabl e to continue 
to an Early Termination visit and to be contact[CONTACT_313365] y to collect follow -up information at 
3days after the last dose of intranasal study  medication (if the subject discontinued during the 
double -blind phase and the date of the Early Term ination visit is less than [ADDRESS_385788] 
dose of intranasal study  medication ),on Day 25 (if the subject discontinued during the double -
blind phase) and on Day 90. Subjects who are not agreeable to remote follow -up contact [CONTACT_313366] “withdrawal of consent.” Subjects who no longer wish to take study 
drug but agree to provide follow -up information will be withdrawn from the double -blind phase 
with the reason noted as “Other” and will specify  the reason wh y.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
86
Status: Approved , Date: [ADDRESS_385789] withdraw consent in 
writing; if the subject refuses or is physicall y unavailable, the study  site should document and 
sign the reason for the subject’s failure to withdraw consent inwriting and maintain it with the 
subject’s source records. 
The investigator will be responsible for making all required notifications to the Institutional 
Review Board (I RB) or Independent Ethic s Committee (IEC).
10.3. Withdrawal From the Use of Research Sample s
A subject who withdraws from the study  will have the following options regarding the optional
research sample :
The collected sample will be retained and used in accordance with the subject's original 
separate informed consent for optional research samples .
The subject may withdraw consent for optional research sample , in which case the sample 
will be destroy ed and no further testing will take place. To initiate the sample destruction 
process, the investigator must notify  the sponsor study  site contact [CONTACT_244538]. The sponsor study  site 
contact [INVESTIGATOR_1318], in turn, contact [CONTACT_90805]. If 
requested, the investigator will receive written confirmation from the sponsor that the 
sample has been destro yed.
Withdrawal From the Optional Research Samples While Remaining in the Main Study
The subject may  withdraw consent for optional research samples while remaining i n the study . In 
such a case, the optional research sample will be destroy ed. The sample destruction process will 
proceed as described above.
Withdrawal From the Use of Sample s in Future Research
The subject may  withdraw consent for use of sample sfor resea rch (refer to Section 16.2.5 , Long-
Term Retention of Samples for Additional Future Research). In such a case, samples will be 
destroy ed after they are no longer needed for the clinical study . Details of the sample retent ion
for research are presented in the main I CF and in the separate ICF for optional research sample s.
11. STATISTICA L METHODS
Statistical analy sis will be done by [CONTACT_43758]. A general 
description of the statistical methods to be used to anal yze the efficacy  and safet y data is outlined 
below. Specific details will be provided in the SAP.
11.1. Subject Information
The primary  efficacy  and safet y analysis sets are defined below.
Full analysis set: The full analy sis setwill include all randomized subjects who have 
received at least one dose of double -blind study  medication and have both a baseline and a 
post dose evaluation for the MADRS total score.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
87
Status: Approved , Date: 31 January 2018Safety  analysis set: The safet y analysis set will include all randomized subjects who receive 
at least one dose of double- blind study  medication.
11.2. Sample Size Determination
The maximum sample size for this study  was calculated assuming an effect size of 0.[ADDRESS_385790] dose (Day  2), a one-sided significance level of 0.025, 
and a drop -out rate at 24 hours of 5%. Approximately  112 subjects will need to be randomized to 
each treatment group to achieve 90% power . The effect size used in this calculation was based 
on results of the ESKETINSUI2001 studywhere the effect size for the change from baseline to 
Day 2 was 0.65 (mean difference between treatment groups of - 7.2 and a pooled SD of 11.02) for 
MADRS total score. Given that the ESKETINSUI2001 study  was a Phase [ADDRESS_385791] to be estimated in the study , is 
defined b y the following 3 components:
Population: subjects with MDD who are at imminent risk of suicide
Endpoint: change from baseline to [ADDRESS_385792] dose (Day 2)in the MADRS total 
score 
Measure of Intervention: the effect of the initially  randomized treatment that would have 
been observed had all subjects remained on their treatment until Day [ADDRESS_385793] 
dose (Day  2), will be analy zed using an analysis of covariance (ANCOVA) model. The model 
will include factors for treatment ,center, standard of care antidepressant treatment (ie, 
antidepressant monotherapy  or an antidepressant plus augmentation therap y), and baseline 
MADRS total score as a covariate. A point estimate and 95% confidence interva l for the 
treatment difference will be provided. Since subjects are hospi[INVESTIGATOR_313296], it is anticipated that missing data will be infrequent . However, if a subject has a 
MADRS total score at a time earlier than [ADDRESS_385794] the 24 hour 
value, the earlier value will be used for the primary  efficacy  analysis.In addition, descriptive 
statistics (N, mean, standard deviation, median, minimum and maximum) of the primary  efficacy 
variable will be provided by  [CONTACT_313367].
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
88
Status: Approved , Date: [ADDRESS_385795] dose (Day  2), will be performed using an ANCOVA model on the ranks of 
change with factors for treatment ,center, standard of care antidepressant treatment (ie, 
antidepressant monotherapy  or an antidepress ant plus augmentation therapy )and baseline 
CGI-SS-R (unranked) asa covariate. The treatment difference will be estimated using the 
Hodges -Lehmann estimate, which is the median of all possible paired differences for the change 
from baseline for CGI -SS-R at [ADDRESS_385796] to testing multiple endpo ints (the primary  and the key secondary ) 
will be controlled by  a fixed sequence testing procedure, ie, the key secondary  hypothesis will be 
tested only  after the null hy pothesis for the primary  endpoint is rejected.
The secondary  efficacy  endpoint s, propor tion of subjects with remission (MADRS total score 
≤12) and the proportion of subjects achieving resolution of suicidality  (CGI-SS-R score of 0 or 
1)at each visit during the double -blind phase will be analy zed using a Cochran -Mantel -Haenszel 
chi-square test adjusting for center and standard of care antidepressant treatment (ie, 
antidepressant monotherapy  or antidepressant plus augmentation therap y).Subjects who 
discontinue treatment prior to the particular visit of the double -blind phase will not be consi dered 
to have remission or resolution of suicidality .
Changes from baseline over time in MADRS total score, BHS, and QLDS total scores will be 
analyzed based on last observation carried forward (LOCF) data using an ANCOVA model with 
treatment, center, and standard of care antidepressant treatment (ie, antidepressant monotherap y 
or an antidepressant plus augmentation therapy )as factors and baseline value as a covariate. 
Additionally , the change from baseline in MADRS total score at Day  25 will be analy zed u sing a 
mixed model for repeated measures (MMRM) analy sis with baseline MADRS total score as a 
covariate, and treatment, center, standard of care antidepressant treatment (ie, antidepressant 
monotherap y or antidepressant plus augmentation therap y), day, and day -by-treatment
interaction as fixed effects, and a random subject effect. Comparison of esketamine versus 
placebo will be performed using the appropriate contrast. Point estimates and 95% confidence 
intervals for the treatment differences will be provid ed.  Missing data will be closely  monitored 
and additional sensitivity  anal yses will be specified in the SAP , if necessary.
Ranks of changes from baseline over time for CGI-SS-R and CGI-SR-Iwill be analyzed based 
on LOC F data using an ANCOVA model with treatment, center, and standard of care
antidepressant treatment (ie, antidepressant monotherap y or an antidepressant plus augmentation 
therap y)as factors and baseline value (unranked) as a covariate.
SIBAT Module 5 My  Risk , Question 3 (patient reported fre quency  of suicidal thinking) ,TSQM -
9, dimension scores of EQ-5D- 5L data, and health status index will be summarized over time.
Additionally , scores of all efficacy  endpoints will be summarized for all visits. Descriptive 
statistics (N, mean, standard deviation, median, minimum and maximum) will be provided for 
continuous variables and frequency  distributions will be provided for categorical variables.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
89
Status: Approved , Date: [ADDRESS_385797] characteristics 
(demographics, laboratory  variables, genot ypes, race, etc.) will be tested as potential covariates 
affecting PK parameters. For the parameter estimates, the standard error and 95% confidence 
interval will be provided. This will be determined after the population pharmacokinetic modeling 
of the data is completed. Details will be given in a population PK analy sis plan and the results of 
the popula tion PK analy sis will be presented in a separate report.
11.5. Pharmacokinetic/Pharmacody namic A nalyses
The relationship between MADRS total score (and possibly  selected adverse events and 
additional pharmacod ynamic parameters), and PK metrics of esketamine may be evaluated. The 
results of the PK/PD analy ses may  be reported separatel y.
11.6. Biomarker and Pharmacogenomic Analyses
Biomarkers will be tabulated by [CONTACT_313368]. 
Posttreatment c hanges in biomarkers over time will be summarized by [CONTACT_1570]. 
Associations between baseline levels and changes from baseline in selected biomarkers and 
clinical endpoints will be explored. Exploratory  analyses may include comparison of biomarker 
measures between the treatment groups and correlation with baseline and change from baseline 
biomarker values in the efficacy  and other measures. Exploratory  analyses may be performed for 
additional biomarkers. In addition, all biomarker data obtained from this study  may also be 
included in an ongoing cross -study  analysis to investigate the relationship between depression 
severit y, phenot ypes, and biomarkers .
Pharmacogenomic analyses may include candidate gene analy ses or genome -wide association 
analyses in relation to treatment response, non-response, and MDD. Expression analyses may 
include testing of known mRNA/miRNA transcripts or transcriptome -wide analysis in 
relationship to antidepressant treatment response and MDD. Additional exploratory  analyses 
may be performed.
Details of the analy sis plan and summary  of results from both biomarker and pharmacogenomic 
analyses will be reported separately .
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
90
Status: Approved , Date: 31 January 201811.7. Medical Resource Utilization A nalyses 
Medical resource utilization data will be descriptively  summarized by  [CONTACT_1570].
11.8. Safety  Analyses
Safety  data will be analyzed for the double -blind phase using the safety  analysis set. The safet y 
data from the follow -up phase will be summarized separately .
Adverse Events
The verbatim terms used in the eCRF by [CONTACT_23820] (MedDRA). All reported adverse events 
with onset during each phase (ie, treatment -emergent adverse events, and adverse events that 
have worsened since baseline) will be included inthe analy sis. For each adverse event, the 
percentage of subjects who experience at least 1occurrence of the given event will be 
summarized by  [CONTACT_1570] . 
The TEAEs of special interest will be examined separatel y (refer to Section 3.2.6 for further 
details) ; adverse event s of special interest will be further listed in the SAP. Subjects who die, 
who discontinue treatment due to an adverse event, or who experience a serious adverse event
will be summarized separatel y.
Clinical Laboratory Tests
Laboratory  data will be summarized by [CONTACT_23821]. Markedly  abnormal results 
(specified in the SAP) will be used in the summary  of laboratory  data. Descriptive statistics will
be calculated for each laboratory  analyte at baseline and for observed v alues and changes from 
baseline at each scheduled time point. Frequency tabulations of the abnormalities will be 
provided. A listing of subjects with any markedly  abnormal laboratory results will also be 
provided. 
Electrocardiogram (ECG)
The effects on cardiovascular variables will be evaluated by [CONTACT_23822]. These tables will include observed values and changes from baseline 
values.
Electrocardiogram data will be summarized by [CONTACT_105292] . Descriptive statistics will be 
calculated at baseline and for observed values and changes from baseline at each scheduled time 
point. Frequency  tabulations of the abnormalities will be made.
The ECG v ariables that will be analy zed are heart rate, PR interval, QRS interval, QT interval, 
and corrected QT (QTc) interval using the following correction methods: QT  corrected according 
to Bazett's formula (QT cB), QT  corrected according to Fridericia's formula (QTcF).6,33,36,74
Descriptive statistics of QTc intervals and changes from baseline will be summarized at each 
scheduled time point. The percentage of subjects with QTc interval >450 milliseconds, 
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
91
Status: Approved , Date: 31 January 2018>480 milliseconds, or >500 milliseconds will be summarized, as will the percentage of subjects 
with QT c interval increases from baseline >30 milliseconds or >60 milliseconds.
All clinically  relevant abnormalities in ECG waveform that are changes from the baseline 
readings will be reported (eg, changes in T -wave morphology  or the occurrence of U -waves.
Vital Signs , Pulse Oximetry and Body Weight
Descriptive statistics of temperature, pulse/heart rate, respi[INVESTIGATOR_2842], pulse oximetry 
measurements, body  weight measurements, and blood pressure (systolic and diastolic) values
and changes from baseline will be summarized at each scheduled time point. The percentage of 
subjects with values beyond clinically important limits will be summarized.
Nasal Examination
Abnormalities observed during the targeted nasal examinations at screening and post-baseline 
will be summarized and listed by  [CONTACT_1570].
MOAA/S and CADSS
Sedation d ata from the MOAA/S and dissociative symptoms data from the CADSS will be 
summarized descriptively at each scheduled visit by  [CONTACT_1570].
11.9. Independent Data Monitoring Committee
An external Independent Data Monitoring Committee will be established to monitor data on an 
ongoing basis to ensure the continuing safet y of the subjects enrolled in this study . The 
committee will meet every  6months to review safet y data. After the reviews, the IDMC will 
make recommendations regarding the continuation of the study . The details will be provided in a 
separate IDMC charter.
The IDMC will consist of at least one medical expert [INVESTIGATOR_313377]. The IDMC responsibilities, authorities, and procedures will be documented in its 
charter.
12. ADVERSE EVENT REPORT ING
Timely, accurate, and complete reporting and analy sis of safety  information from clinical studies 
are crucial for the protection of subjects, investigators, and the sponsor, and are mandated by 
[CONTACT_23824]. The sponsor has established Standard Operating Procedures in 
conformity  with regulatory  requirements worldwide to ensure appropria te reporting of safet y 
information; all clinical studies conducted by [CONTACT_43765].
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
92
Status: Approved , Date: [ADDRESS_385798] administered a 
medicinal (investigational or non-investigational) product. An adverse event does not necessaril y 
have a causal relationship with the treatment. An adverse event can therefore be any  unfavor able 
and unintended sign (including an abnormal finding), sy mptom, or disease temporally  associated 
with the use of a medicinal (investigational or non-investigational) product, whether or not 
related to that medicinal (investigational or non-investigation al) product. (Definition per 
International Conference on Harmonisation [I CH])
This includes any  occurrence that is new in onset or aggravated in severit y or frequency  from the 
baseline condition, or abnormal results of diagnostic procedures, including laboratory  test 
abnormalities.
Note: The sponsor collects adverse events starting with the signing of the ICF (refer to 
Section 12.3.[ADDRESS_385799] adverse event recording).
Serious Adverse Event
A serious adverse event based on ICH and EU Guidelines on Pharmacovigilance for Medicinal 
Products for Human Use is any  untoward medical occurrence that at an y dose:
Results in death
Is life-threatening
(The subject was at risk of death at the time of the event. It does not refer to an event that 
hypothetically  might have caused death if it were more severe.)
Requires inpatient hospi[INVESTIGATOR_1081]
Results in persistent or significant disability /incapacity
Is a congenital anomal y/birth defect
Is a suspected transmission of an y infectious agent via a medicinal product
Is Medicall y Important*
*Medical and scientific judgment should be exercised in decid ing whether expedited reporting is 
also appropriate in other situations, such as important medical events that may not be 
immediately  life threatening or result in death or hospi[INVESTIGATOR_313297]. 
These should usually  be considered serious.
If a serious and unexpected adverse event occurs for which there is evidence suggesting a causal 
relationship between the study  drug and the event (eg,death from anaph ylaxis), the event must 
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
93
Status: Approved , Date: 31 January 2018be reported as a serious and unexpected suspected adverse reaction even if it is a component of 
the study  endpoint (eg, all -cause mort ality).
Unlisted (Unexpected) Adverse Event/Reference Safety Information
An adverse event is considered unlisted if the nature or severity  is not consistent with the 
applicable product reference safet y information. For esketamine , the expectedness of an adverse 
event will be determined by  [CONTACT_41028] I nvestigator's Brochure. 
Adverse Event Associated With the Use of the Drug
An adverse event is considered associated with the use of the drug if the attribution is possible, 
probable, or very  likel yby [CONTACT_23826] 12.1.2 , Attribution Definitions.
12.1.2. Attribution Definitions
Not Related
An adverse event that is not related to the use of the drug.
Doubtful
An adverse event for which analternative explanation is more likely, eg,concomitant drug(s), 
concomitant disease(s), or the relationship in time suggests that a causal relationship is unlikely .
Possible
An adverse event that might be due to the use of the drug. An alternative explan ation, 
eg,concomitant drug(s), concomitant disease(s), is inconclusive. The relationship in time is 
reasonable; therefore, the causal relationship cannot be excluded.
Probable
An adverse event that might be due to the use of the drug. The relationship in time is suggestive 
(eg,confirmed by [CONTACT_23827]). An alternative explanation is less likely, eg,concomitant 
drug(s), concomitant disease(s).
Very Likely
An adverse event that is listed as a possible adverse reaction and cannot be reasonabl y explained 
by [CONTACT_4867], eg,concomitant drug(s), concomitant disease(s). The relationship 
in time is very  suggestive (eg, it is confirmed b y dechallenge and rechallenge).
12.1.3. Severity Criteria
An assessment of severity  grade will be made using the followin g general categorical 
descriptors:
Mild : Awareness of symptoms that are easily tolerated, causing minimal discomfort and not 
interfering with every day activities.
Moderate : Sufficient discomfort is present to cause interference with normal activity .
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
94
Status: Approved , Date: 31 January 2018Severe : Extreme distress, causing significant impairment of functioning or incapacitation. 
Prevents normal every day activities.
The investigator should use clinical judgment in assessing the severit y of events not directly  
experienced b y the subject (eg, laborat ory abnormalities).
12.2. Special Reporting Situations
Safety  events of interest on a sponsor study  drugthat may require expedited reporting or safet y 
evaluation include, but are not limited to:
Overdose of a sponsor study  drug
Suspected abuse/misuse of a sponsor study  drug
Accidental or occupational exposure to a sponsor study  drug
Medication error involving a sponsor product (with or without subject/patient exposure to 
the sponsor study  drug , eg, name [CONTACT_2976])
Exposure to a sponsor study  drug from breastfeed ing
Special reporting situations should be recorded in the eCRF . Any special reporting situation that 
meets the criteria of a serious adverse event should be recorded on the serious adverse event page 
of the eCRF .
12.3. Procedures
12.3.1. All Adverse Events
All adverse events and special reporting situations, whether serious or non-serious, will be 
reported from the time a signed and dated ICFis obtained until completion of the subject's last 
study -related procedure ,which may include contact [CONTACT_20687] -up o f safety ,with the exception 
of pregnancy  which will be reported up to [ADDRESS_385800] dose of study  medication 
(females) or [ADDRESS_385801] dose of study  medication (partners of male subjects ). Serious 
adverse events, including those spontaneously  reported to the investigator from the time a signed 
and dated ICF is obtained until completion of the subject's last study -related procedure , must be 
reported using the Serious Adverse Event Form. The sponsor will evaluate any safet y 
information that is spontaneously reported by [CONTACT_154972].
All events that meet the definition of a serious adverse event will be reported as serious adverse 
events, regardless of whether they are protocol -specific assessments. Anticipated events will be 
recorded and reported as described in Attachment 2.
All adverse events, regardless of seriousness, severity , or presumed relationship to study  drug, 
must be recorded using medical terminology  in the source document and the eCRF . Whenever 
possible, diagnoses should be given when signs and symptoms are due to a common etiology 
(eg,cough , runny nose, sneezing, sore throat, and head congestion should be reported as "upper 
respi[INVESTIGATOR_23739]"). Investigators must record in the eCRF their opi[INVESTIGATOR_313298] 
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
95
Status: Approved , Date: [ADDRESS_385802] be recorded in the source document and reported according to sponsor 
instructions.
The sponsor assumes responsibility  for appropriate reporting of adverse events to the regulatory  
authorities. The sponsor will also report to the investigator (and the head of the investigational 
institute where required) all suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) . The 
investigator (or sponsor where required) must report S[LOCATION_003]Rs to the appropriate IEC/IRB that 
approved the protoco l unless otherwise required and documented by  [CONTACT_6179]/I RB.A S[LOCATION_003]R will 
be reported to regulatory  authorities unblinded. Participating investigators and IEC/I RB will 
receive a blinded S[LOCATION_003]R summary , unless otherwise specified.
For all studies with an outpatient phase, including open -label studies, the subject must be 
provided with a "wallet (study )card" and instructed to carry  this card with them for the duration 
of the study  indicating the following:
Study number
Statement, in the local language(s), that the subject is participating in a clinical study
Investigator's name [INVESTIGATOR_1238] 24-hour contact [CONTACT_23828]
Local sponsor's name [INVESTIGATOR_1238] [ADDRESS_385803] telephone number (for medical staf f onl y)
Site number
Subject number
Any other information that is required to do an emergency  breaking of the blind
12.3.2. Serious A dverse Events
All serious adverse events occurring during thestudymust be reported to the appropriate sponsor 
contact [CONTACT_9702] b ystudy -site personnel within [ADDRESS_385804] be completed and signed by a physician from the study  site, 
and transmitted to the sponsor within 24 hours. The initial and follow-up reports of a serious 
adverse event should be made b y facsimile (fax) .
All serious adverse events that have not resolved by [CONTACT_2054] , or that have not 
resolved upon discontinuation of the subject's participation in the study , must be follow ed until 
any of the following occurs:
The event resolves
The event stabilizes
The event returns to baseline, if a baseline value/status is available
The event can be attributed to agents other than the study  drug or to factors unrelated to 
study  conduct
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
96
Status: Approved , Date: 31 January 2018Itbecomes unlikely  that any additional information can be obtained (subject or health care 
practitioner refusal to provide additional information, lost to follow -up after demonstration 
of due diligence with follow- up ef forts)
Suspected transmission of an infectious agent by a medicinal product will be reported as a 
serious adverse event. Any event requiring hospi[INVESTIGATOR_059] (or prolongation of hospi[INVESTIGATOR_059]) 
that occurs during the course of a subject's participation in a study  must be reported as a serious 
adverse event , except hospi[INVESTIGATOR_23741]:
Inpatient hospi[INVESTIGATOR_313250] -recommended 5 days (not due to 
adverse event , ie, clinical worsening )
Hospi[INVESTIGATOR_23742] (eg, social reasons 
such as pending placement in long -term care facility )
Surgery  or procedure planned before entry  into the study  (must be documented in the 
eCRF ). Note: Hospi[INVESTIGATOR_23743], and where 
theunderl ying condition for which the hospi[INVESTIGATOR_23744] ,will 
not be considered serious adverse events. Any  adverse event that results in a prolongation of 
the originall y planned hospi[INVESTIGATOR_23745] a new serious a dverse event.
The cause of death of a subject in a study  from the time a signed and dated ICF is obtained until 
completion of the subject's last study -related procedure , whether or not the event is expected or 
associated with the study drug , is considered a serious adverse event.
12.3.3. Pregnancy
All initial reports of pregnancy  in female subjects or partners of male subjects must be reported 
to the sponsor by [CONTACT_1758] -site personnel within 24 hours of their knowledge of the event using 
the appropriate pregnancy notification form. Abnormal pregnancy  outcomes (eg, spontaneous 
abortion, fetal death, stillbirth, congenital anomal ies, ectopic pregnancy ) are considered serious 
adverse events and must be reported using the Serious Adverse Event Form. Any subject who 
becomes pregnant during the study  must promptly discontinue further study  treatment. 
Because the effect of the study  drug on sperm is unknown, pregnancies in partners of male subjects 
included in the study  will be reported as noted above.
Follow -up information regarding the outcome of the pregnancy  and any  postnatal sequelae in the 
infant will be required .
12.4. Contact[CONTACT_23830] (and corresponding telephone numbers) of the individuals who should be contact[CONTACT_23831] y issues or questions regarding the study  are listed in the Contact [CONTACT_23832](s), which will be provided as a separate document.
13. PRODUCT QUA LITY COMP LAINT HA NDLING
A product qualit y complaint (PQC) is defined as any suspi[INVESTIGATOR_1884] a product defect related to 
manufacturing, labeling, or packaging, ie, any dissatisfaction relative to the identity , quality , 
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
97
Status: Approved , Date: [ADDRESS_385805]. T imely , accurate, and complete reporting and 
analysis of PQC information from studies are crucial for the protection of subjects, investigators, 
and the sponsor , and are mandated by [CONTACT_23824]. The sponsor has 
established procedures in conformit y with regulatory  requirements worldwide to ensure 
appropriate reporting of PQC information; all studies conducted by [CONTACT_111168].
13.1. Procedures
All initial PQCs must be reported to the s ponsor by  [CONTACT_1758] -site personnel within [ADDRESS_385806] report the 
PQC to the sponsor according to the serious adverse event reporting timelines (refer to 
Section 12.3.2 , Serious Adverse Events). A sample of the suspected product should be 
maintained for further investigation if reque sted by  [CONTACT_456] .
13.2. Contact[CONTACT_23834] (and corresponding telephone numbers) of the individuals who should be contact[CONTACT_23835](s), which will be 
provi ded as a separate document.
14. STUDY DRUG INFORMA TION
14.1. Physical Description of Study Drug(s)
The esketamine supplied for this study  is available as a clear, colorless intranasal solution of 
esketamine hydrochloride (16.14% weight/volume [w/v]; equivalent to 14% w/v of esketamine 
base) in a nasal spray  pump. The solution will consist of 161.4 mg/mL esketamine hy drochloride 
(equivalent to 140 mg of esketamine base) formulated in 0.12 mg/mL EDTA and 1.5 mg/mL 
citric acid at pH of 4.5. It is provided in a nasal s pray pump, which delivers 16.14 mg esketamine 
hydrochloride (14 mg esketamine base) per 100 μL spray. Each individual nasal spray  pump 
(device) contains a total of 28 mg (ie, 2 spray s).
The placebo solution will be provided as a clear, colorless intranasal solution of water for 
injection with a bittering agent (denatonium benzoate [Bitrex®] at a final concentration of 
0.001 mg/mL) added to simulate the taste of the intranasal solution with active drug. The placebo 
solution will be provided in matching nasal spray  pump devices. Benzalkonium chloride is added 
as a preservative at a concentration of 0.3 mg/mL. Each individual nasal spray  pump (device) 
contains 2 sprays.
Study  drug will be manufactured and provided under the responsibility  of the sponsor .Refer to 
the Investigator's Brochure for a list of excipi[INVESTIGATOR_840].37
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
98
Status: Approved , Date: 31 January 201814.2. Packaging
Study  drug (ie, intranasal esketamine and placebo solution) will be supplied by[CONTACT_104222] a 
bi-dose nasal spray  device. The devices will contain 230 µL(of which ~30 µL is the residual 
volume) . Each device delivers 16.14 mg esketamine hydrochloride (14 mg esketamine base) or 
0.1µg of denatonium benzoate per [ADDRESS_385807] specific 
labeling.
Refer to the pharmacy  manual/ study  site investigational product and procedures manual for 
additional guidance on study  drug preparation ,handling , and storage .
14.5. Drug A ccountability
The investigator is responsible for ensuring that all study  drug received at the site is inventoried 
and accounted for throughout the study . The dispensing of study  drug to the subject, and the 
return of study  drug from the subject (if applicable), must bedocumented on the drug 
accountability  form. Subjects must be instructed to return all original containers, whether empty 
or containing stud y drug. All study  drug will be stored and disposed of according to the sponsor's 
instructions. S tudy-site personnel must not combine contents of the study  drug containers.
Study  drug must be handled in strict accordance with the protocol and the container label, and 
must be stored at the study  site in a limited -access area or in a locked cabinet under appropriate 
environmental conditions. Unused study  drug, and study  drug returned by [CONTACT_423], must be 
available for verification by [CONTACT_456]'s study  site monitor during on -site monitoring visits. The 
return to the sponsor of unused study  drug, or used returned study  drug for destruction, will be 
documented on the drug return form. When the study  site is an authorized destruction unit and 
study  drug supplies are destroy ed on -site, this must also be documented on the drug return form.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
99
Status: Approved , Date: 31 January 2018Potentially  hazardous materials such as used ampules, needles, syringes and vials containing 
hazardous liquids should be disposed of immediately  in a safe manner and therefore will not be 
retained for drug accountability  purposes. 
Study  drug should be dispensed under the supervision of the investigator or a qualified member 
of the study -site personnel, or by a hospi[INVESTIGATOR_307]/clinic pharmacist. Study  drug will be supplied only 
to subjects participating in the study . Returned study  drug must not be dispensed again, even to 
the same subject. Study  drug may not be relabeled or reassigned for use by [CONTACT_23837]. The 
investigator agrees neither to dispense the study  drug from, nor store it at, any site other than the 
study  sites agreed upon with the sponsor.
15. STUDY -SPECIFIC MATERIA LS
The investigator w ill be provided with the following supplies:
Investigator 'sBrochure for esketamine
Pharmacy  manual/ study  site investigational product and procedures manual
Study  medication “Instructions for Use” documents for subject and clinical site staff
Practice/demo nstration intranasal devices and ancillary  supplies
Central l aboratory  manual and materials
ECG manuals and materials
Clinician -administered and subject -completed/patient -reported outcome assessments 
Paper versions if applicable
Electronic devices and associated materials
IWRS Manual
Electronic data capture ( eDC) manual
Information for clinician regarding dosing, switching, and augmenting antidepressant 
treatments
Guidance for minimum requirements for site staff and equipment on dosing day s
Study  aware ness and support materials (ie, to facilitate subject identification and retention)
Any updates to these documents that occur during the study  will also be provided.
16. ETHICA L ASPECTS
16.1. Study -Specific Design Considerations
Clinical Study in Subjects with MDD Assessed to be at Imminent Risk of Suicide
Major depressive disorder is the most prevalent mental health condition and the psychiatric 
diagnosis most commonly  associated with suicide.41,65Epi[INVESTIGATOR_313299] y 
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
100
Status: Approved , Date: 31 January 201860% of those who die by [CONTACT_313330], and at least one-half of people
who complete suicide are depressed at the time of their deaths.2,13,17,[ADDRESS_385808] on reducing suicidal ideation within hours of administration.25,47,71,72,85
Furthermore, a Phase 2 study  (ESKETINSUI2001 )recently  completed by [CONTACT_313369][INVESTIGATOR_2478] y reduced symptoms of depression and suicidality in subjects 
with MDD at imminent risk for suicide and that intranasal esketamine was tolerated in this 
population .
Selection of Subjects
The primary  aim of the study  is to evaluate the efficacy  of intranasal esketamine for the rapid 
reduction of the symptoms of major depressive disorder, including suicidal ideation , in subjects 
assessed to be at imminent risk for suicide. Thus, the study  cannot be completed in health y 
subjects or depressed patients who are not at imminent risk for suicide.
While a patient’s decisional capacity  can be impacted by [CONTACT_313370], this 
becomes an ethical concern when the patient refuses medically  necessary  treatment . However, 
the subjects in this trial will be providing voluntary  consent to participate in the study  of a 
potentially  efficacious treatment, given in the context of standard of care treatment (ie, 
hospi[INVESTIGATOR_313300]) . Subjects may participate in the study  only if they 
have adequate capacity  to give consent and after fully  understanding the potential risks, benefits, 
and potential adverse events of thestudy. Determination of a subject’s decisional capacit y will 
be made by [CONTACT_154976]. Thus, ethical concerns regarding subjects’ decision to 
participate are minimal.
Justification for Using Placebo
Assessment of the potential efficacy  of a new comp ound for the treatment of major depression 
requires adequate and well- controlled clinical studies. Asthere are no approved treatments for 
the rapid reduction of symptoms of MDD, including suicidal ideation , a placebo controlled study 
conducted in the context of comprehensive standard of care treatment (ie, acute psychiatric 
hospi[INVESTIGATOR_059], the initiation of optimization standard of care antidepressant treatment, and close 
outpatient follow up) is ethically  appropriate. Subjects will remain hospi[INVESTIGATOR_80529] a 
recommended period of 5days, which is consistent with the typi[INVESTIGATOR_313301], and may stay shorter or longer if 
clinically  warranted. 
Precautions to Ensure Subject Safety in the Study
Subjects may participate in the study  only if they have adequate capacity  to give consent and 
after fully  understanding the potential risks and giving an informed consent. Determination of 
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
101
Status: Approved , Date: [ADDRESS_385809] of care
antidepressant treatment beginning on Day  1. 
For subjects who do not respond during the study  and are not willing or able to receive additional 
study  drug treatment, clinical care will be arranged between the study  investigator and or their 
physician.
Compensation for any procedure will be fair per local standards and approved by [CONTACT_155120]/ IRBs
for participating sites in order to not offer any  undue incen tive to participate in the study .
The investigator will ensure that subjects who withdraw from the study  prior to completion are 
appropriatel y followed and/or transitioned for an y additional care required.
Only  qualified and experienced investigators will participate in the stud y.
Potential subjects will be fully informed of the risks and requirements of the study  and, during the 
study , subjects will be given any new information that may affect their decision to continue 
participation. They will be told tha t their consent to participate in the study  is voluntary  and may  be 
withdrawn at any time with no reason given and without penalt y or loss of benefits to which they 
would otherwise be entitled. Only subjects who are fully able to understand the risks, benefits, and 
potential adverse events of the study , and provide their consent voluntaril y will be enrolled.
The total blood volume to be collected is considered to be an acceptable amount of blood to be 
collected over this time period fr om the population in t his study  and will be less than a Red Cross 
blood donation.3
16.2. Regulatory  Ethics Compliance
16.2.1. Investigator Responsibilities
The investigator is responsi ble for ensuring that the study  is performed in accordance with the 
protocol, current ICH guidelines on Good Clinical Practice (GCP), and applicable regulatory  and 
country -specific requirements.
Good Clinical Practice is an international ethical and scient ific qualit y standard for designing, 
conducting, recording, and reporting studies that involve the participation of human subjects. 
Compliance with this standard provides public assurance that the rights, safety , and well -being of 
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
102
Status: Approved , Date: [ADDRESS_385810]
Before the start of the study , the investigator (or sponsor where required) will provide the 
IEC/IRB with current and complete copi[INVESTIGATOR_23747] (as required by [CONTACT_13125]) :
Final protocol and, if applicable, amendments
Sponsor -approved ICF(and any  other written materials to be provided to the subjects)
Investigator's Brochure (or equivalent information) and amendments/addenda
Sponsor -approved subject recruiting materials
Information on compensation for study -related injuries or payment to subjects for 
participation in the study , if applicable
Investigator's curriculum vitae or equivalent information (unless not required, as 
documented b y the IEC/IRB)
Information regarding funding, name [CONTACT_8152], institutional affiliations, other potential 
conflicts of interest, and incentives for subjects
Any other documents that the I EC/IRB requests to fulfill its obligation
This study will be undertaken only after the IEC/I RB has given full approval of the final 
protocol, amendments (if any, excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study  conduct , unless required locall y), the ICF, applicable 
recruiting materials, and subject compensation programs, and the sponsor has received a copy of 
this approval. This approval letter must be dated and must clearl y identify the IEC/IRB and the 
documents being approved.
Approval for the collection of optional samples for research and for the corresponding ICFmust 
be obtained from the IEC/IRB. Approval for the protocol can be obtained independent of this 
optional rese arch component .
During the study  the investigator (or sponsor where required) will send the following documents 
and updates to the IEC/IRB for their review and approval, where appropriate:
Protocol amendments (excluding the ones that are purel y administra tive, with no 
consequences for subjects, data or study  conduct)
Revision(s) to ICFand any  other written materials to be provided to subjects
If applicable, new or revised subject recruiting materials approved b y the sponsor
Revisions to compensation for study-related injuries or payment to subjects for participation 
in the study , if applicable
New edition(s) of the Investigator's Brochure and amendments/addenda
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
103
Status: Approved , Date: 31 January 2018Summaries of the status of the study at intervals stipulated in guidelines of the IEC/IRB (at 
least annuall y)
Reports of adverse events that are serious, unlisted/unexpected, and associated with the 
study  drug
New information that may adversel y affect the safet y of the subjects or the conduct of the 
study
Deviations from or changes to the protocol to eliminate immediate hazards to the subjects
Report of deaths of subjects under the investigator's care
Notification if a new investigator is responsible for the study  at the site
Development Safet y Update Report and Line Listings, where applicable
Any other requirements of the IEC/I RB
For all protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study conduct) , the amendment and applicable ICFrevisions 
must be submitted promptly  to the IEC/I RB for review and approval before implementation of 
the change(s).
At least once a year, the IEC/I RB will be asked to review and reapprove this study , where 
required.
At the end of the study , the investigator (or sponsor where required) will notify  the IEC/I RB 
about the study  completion (if applicable, the notification will be submitted through the head of 
investigational institution) .
16.2.3. Informed Consent
Each subject must give written consent according to local requirements after the nature of the 
study  has been fully  explained. The ICF(s) must be signed before performance of any study -
related activity . The ICF(s) that is/areused must be approved by [CONTACT_170510]/I RB and be in a language that the subject can read and understand. The informed 
consent should be in accordance with principles that originated in the Declaration of Helsinki, 
current ICH and GCP guidelines, applicable regulatory  requirements, and sponsor policy .
Before enrollment in the study , the investigator or an authorized member of the study -site 
personnel must explain to potential subjects the aims, methods, reasonably anticipated benefits, 
and potential hazards of the study ,and any discomfort participation in the study  may entail. 
Subjects will be informed that their participation is voluntary  and that they may withdraw 
consent to participate at any time. They  will be informed that choosing not to participate will not 
affect the care the subject will receive for the treatment of his or her disease. Finally , they  will be 
told that the investigator will maintain a subject identification register for the purposes of long-
term follow up if needed and that their records may be accessed by [CONTACT_313371], to the extent 
permitted by [CONTACT_6983](s) or regulations. By [CONTACT_313372] , which includ espermission to obtain information about his or her survival status. It 
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
104
Status: Approved , Date: [ADDRESS_385811]'s personall y dated signature. After having obtained the consent, a copy  of 
the ICFmust be given to the subject.
Subjects will be asked for consent to provide optional samples for research (where local 
regulations permit). After informed consent for the study  is appropriatel y obtained, the subject
will be asked to sign and personall y date a separate ICFindicating agreement to participate in the 
optional research component . Refusal to participate in the optional research will not result in 
ineligibility  for the stud y.A cop y of this signed ICF will be given to the subject.
16.2.4. Privacy of Personal Data
The collection and processing of personal data from subjects enrolled in this study will be 
limited to those data that are necessary  to fulfill the objectives of the study .
These data must be collected and processed with adequate precautions to ensure confidentialit y 
and compliance with applicable data privacy  protection laws and regulations. Appropriate 
technical and organizational measures to protect the personal data against unauthorized 
disclosures or access, accidental or unlawful destructio n, or accidental loss or alteration must be 
put in place. Sponsor personnel whose responsibilities require access to personal data agree to 
keep the identit y of subjects confidential.
The informed consent obtained from the subject includes explicit consent for the processing of 
personal data and for the investigator /institution to allow direct access to his or her original 
medical records (source data/documents) for study -related monitoring, audit, IEC/IRB review, 
and regulatory  inspection. This consent also addresses the transfer of the data to other entities 
and to other countries.
The subject has the right to request through the investigator access to his or her personal data and 
the right to request rectification of any data that are not correct or complete. Reasonable steps 
will be taken to respond to such a request, taking into consideration the nature of the request, the 
conditions of the study , and the applicable laws and regulations.
Exploratory  DNA, biomarker , andPK research is not conducted under standards appropriate for 
the return of data to subjects. In addition, the sponsor cannot make decisions as to the 
significance of any findings resulting from exploratory  research. Therefore, exploratory  research 
data will not be returned to subjects or investigators, unless required by [CONTACT_23844] . 
Privacy  and confidentiality  of data generated in the future on stored samples will be protected by  
[CONTACT_43778].
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
105
Status: Approved , Date: 31 January 201816.2.5. Long -Term Retention of Samples for Additional Future Research
Samples collected in this study  may be stored for up to 15 years (or according to local 
regulations) for additional research. Samples will only be used to understand esketamine , to 
understand depression, to understand differential drug responders, and to develop tests/assay s 
related to esketamine and depression. The research may  begin at any  time during the study  or the 
post-study  storage period. 
Stored samples will be coded throughout the sample storage and analysis process and wi ll not be 
labeled with personal identifiers. Subjects may withdraw their consent for their samples to be 
stored for research (refer toSection 10.3, Withdrawal From the Use of Samples in Future 
Research .
16.2.6. Country Selection
This study  will only be conducted in those countries where the intent is to launch or otherwise 
help ensure access tothe developed product if the need for the product persists , unless explicitly  
addressed as a specific ethical consideration in Section 16.1, Study -Specific Design 
Considerations.
17. ADMINISTRA TIVE REQUI REMENTS
17.1. Protocol A mendments
Neither the investigator nor the sponsor will modify  this protocol without a formal amendment 
by [CONTACT_456]. All protocol amendments must be issued by  [CONTACT_456], and signed and dated by 
[CONTACT_093]. Protocol amendments must not be implemented without prior IEC/IRB 
approval, or when the relevant competent authority  has raised any grounds for non-acceptance, 
except when necessary to eliminate immediate hazards to the subje cts, in which case the 
amendment must be promptly  submitted to the IEC/I RB and relevant competent authority . 
Documentation of amendment approval by  [CONTACT_23846]/IRB must be provided to the 
sponsor. When the change(s) involves only logistic or administrative aspects of the study , the 
IEC/IRB ( where required) only  needs to be notified.
During the course of the study , in situations where a departure from the protocol is unavoidable, 
the investigator or other physician in attendance will contact [CONTACT_307510] (s), which will beprovided as a separate
document . Except in emergency  situations, this contact [CONTACT_23848]. In all cases, contact [CONTACT_233869]. The data recorded 
in the eCRF and source documents will reflect any departure from the protocol, and the source 
documents will describe this departure and the circumstances requiring it.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
106
Status: Approved , Date: 31 January 201817.2. Regulatory  Documentation
17.2.1. Regulatory  Approval/Notification
This protocol and any amendment(s) must be submitted to the appropriate regul atory  authorities 
in each respective country , if applicable. A study may not be initiated until all local regulatory 
requirements are met.
17.2.2. Required Prestudy  Documentation
The following documents must be provided to the sponsor before shipment of study  drugto the 
study site:
Protocol and amendment(s), if an y, signed and dated by [CONTACT_458]
A copy of the dated and signed (or sealed, where appropriate per local regulations) , written 
IEC/IRB approval of the protocol, amendments, ICF, any recrui ting materials, and if 
applicable, subject compensation programs. This approval must clearly  identify  the specific 
protocol by [CONTACT_23850] (or sealed, where appropriate per local 
regulations) by [CONTACT_23851].
Name [CONTACT_23875]/IRB, including a current list of the IEC/IRB members and 
their function, with a statement that it is organized and operates according to GCP and the 
applicable laws and regulations. If accompanied by a  letter of explanation, or equivalent, 
from the IEC/I RB, a general statement may be substituted for this list. If an investigator or a 
member of the study -site personnel is a member of the IEC/IRB, documentation must be 
obtained to state that this person did not participate in the deliberations or in the 
vote/opi[INVESTIGATOR_23748] .
Regulatory  authority  approval or notification, if applicable
Signed and dated statement of investigator (eg, Form FDA 1572), if applicable
Documentation of investigator qualifications (eg, curriculum vitae)
Completed investigator financial disclosure form from the principal investigator, where 
required
Signed and dated clinical trial agreement, which includes the financial agreement
Any other documentation required by  [CONTACT_43782]:
Completed investigator financial disclosure forms from all subinvestigators
Documentation of subinvestigator qualifications (eg, curriculum vitae)
Name [CONTACT_313378] , and a dated copy  of 
current laboratory  normal ranges for these tests, if applicable
Local laboratory  documentation demonstrating competence and test reliability 
(eg,accreditation/license), if applicable
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
107
Status: Approved , Date: [ADDRESS_385812] be available for the following: 
subject identification, eligibility , and study  identification; study  discussion and date of signed 
informed consent; dates of visits; results of safety and efficacy  parameters as required by [CONTACT_313373]; record of all adverse events and follow -up of adverse events; concomitant medication; 
drug receipt/dispensing/return records; study  drugadministration information ; and date of study 
completion and reason for early discontinuation of study  drug or withdrawal from the study , if 
applicable. 
The author of an entry  in the source documents should be identifiable.
Specific details required as source data for the study  and source data collection methods will be 
reviewed with the investigator before the study  and will be described in the monitoring 
guidelines (or other equivalent document).
The minimum source documentation requirements for Section 4.1,Inclusion Criteria and 
Section 4.2, Exclusion Criteria that specify  a need for documented medical history  are as 
follows:
Referral letter from treating ph ysician or
Complete history  of medical notes at the site
Discharge summaries
Inclusion and exclusion criteria not requiring documented medical history must be verified at a 
minimum by [CONTACT_41047] (eg, physical examinatio n, 
laboratory  assessment) and documented in the source documents.
An electronic source system may be utilized, which contains data traditionally  maintained in a 
hospi[INVESTIGATOR_23749] (eg, electronic source documents) as well as
the clinical study -specific data fields as determined by [CONTACT_760]. This data is electronicall y 
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
108
Status: Approved , Date: [ADDRESS_385813].
Electronic data capture (eDC) will be used for this study . The study  data will be transcribed by 
[CONTACT_3449] -sitepersonnel from the source documents onto an eCRF , and transmitted in a secure 
manner to the sponsor within the timeframe agreed upon between the sponsor andthe study  site. 
The electronic file will be considered to be the eCRF.
Worksheets may be used for the capture of some data to facilitate completion of the eCRF . Any 
such worksheets will become part of the subject's source document s. Data must be entered into 
eCRF in English. The eCRF must be completed as soon as possible after a subject visit and the 
forms should be available for review at the next scheduled monitoring visit.
All subjective measurements (eg, scale information or oth er questionnaires) should be completed 
by [CONTACT_66890].
The investigator must verify  that all data entries in the eCRFs are accurate and correct. All eCRF 
entries, corrections, and alterations must be made by [CONTACT_204286] -
site personnel. If necessary , queries will be generated in the eDC tool. If corrections to a eCRF
are needed after the initial entry  into the eCRF , this can be done in either of the following ways:
Investigator and study-site personnel can make corrections in the eDC tool at their own 
initiative or as a response to an auto query  (generated by  [CONTACT_66832]) .
Sponsor or sponsor delegate can generate a query  for resolution by [CONTACT_23858] -site personnel.
17.6. Data Quality  Assurance/Quality  Control
Steps to be taken to ensure the accuracy  and reliability  of data include the selection of qualified 
investigators and appropriate study  sites, review of protocol procedures with the investigator and 
study -site personnel before the study , periodic monitoring visits by [CONTACT_456], and direct 
transmission of clinical laboratory  data from a central laboratory  into the sponsor's data base. 
Written instructions will be provided for collection, handling, storage, and shipment of samples. 
Guidelines for eCRF completion will be provided and reviewed with study -sitepersonnel before 
the start of the stud y.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
109
Status: Approved , Date: 31 January 2018The sponsor will review eCRF for accuracy  and completeness during on-site monitoring visits 
and after transmission to the sponsor; any discrepancies will be resolved with the investigator or 
designee, as appropriate. After upload of the data into the study database they  will be verified for 
accuracy  and consistency with the data sources. 
17.7. Record Retention
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all eCRF
and all source documents that support the data collected from each subject, as well as all study 
documents as specified in ICH/GCP Section 8, Essential Documents for the Conduct of a 
Clinical Trial, and all study  documents as specified by [CONTACT_23859](s). 
The investigator/institution will take measures to prevent accidental or premature destruction of 
these documents.
Essential documents must be retained until at least 2years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing 
applications in an ICH region or until at least 2years have elapsed since the formal 
discontinuation of clinical development of the investigational product. These documents will be 
retained for a longer period if required by [CONTACT_43785]. It is the responsibility  of the sponsor to inform the 
investigator/institution as to when these documents no longer need to be retained.
If the responsible investigator retires, relocates, or for other reasons withdraws from the 
respons ibility  of keepi[INVESTIGATOR_13274], custody  must be transferred to a person who will 
accept the responsibility . The sponsor must be notified in writing of the name [CONTACT_23877]. Under no circumstance shall the investigator relocate or dispose of any study  
documents before having obtained written approval from the sponsor .
If it becomes necessary  for the sponsor or the appropriate regulatory  authority  to review any 
documentation relating to this study , the investigator /institution must permit access to such 
reports.
17.8. Monitoring
The sponsor will perform on-site monitoring visits as frequentl y as necessary . The monitor will 
record dates of the visits in a study  site visit log that will be kept at the study site. The first post-
initiation visit will be made as soon as possible after enrollment has begun. At these visits, the 
monitor will compare data entered into the eCRF with the source documents (eg, 
hospi[INVESTIGATOR_307]/clinic/phy sician’s office medical records) ; a sample may be reviewed. The nature and 
location of all source documents will be identified to ensure that all sources of original data 
required to complete the eCRF are known to the sponsor and study -site personnel and are 
accessible for verification by [CONTACT_43786] -site contact. If electronic records are maintained 
at the study site, the method of verification must be discussed with the study -site personnel . 
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
110
Status: Approved , Date: [ADDRESS_385814] access to source document s(medical records) must be allowed for the purpose of 
verify ing that the recorded data are consi stent with the original source data. Findings from this 
review will be discussed with the study -site personnel . The sponsor expects that, during 
monitoring visits, the relevant study -site personnel will be available, the source document swill 
be accessible, and a suitable environment will be provided for review of study -related 
documents. The monitor will meet with the investigator on a regular basis during the study to 
provide feedback on the study conduct.
In addition to on-site monitoring visits, remote contacts can occur. It is expected that during 
these remote contacts, study -site personnel will be available to provide an update on the progress 
of the study  at the site. 
Central monitoring will take place for data identified by  [CONTACT_70467].
17.9. Study Completion/Termination
17.9.1. Study Completion /End of Study
The study  is considered completed with the last study  assessment for the last subject 
participating in the study . The final data from the study site will be sent to the sponsor (or 
designee) after completion of the final subject assessment at that study  site, in the time frame 
specified in the Clinical Trial Agreement.
17.9.2. Study Termination
The sponsor reserves the right to close the study site or terminate the study  at any time forany 
reason at the sole discretion of the sponsor .Study sites will be closed upon study  completion. A
study site is considered closed when all required documents and study  supplies have been 
collected and a study -site closure visit has been performed.
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.
Reasons for the earlyclosure of astudy site by [CONTACT_11004]:
Failure of the investigator to comply  with the protocol, the requirements of the IEC/I RB or 
local health authorities, the sponsor's procedures, or GCP guidelines
Inadequate recruitment of subjects by  [CONTACT_093]
Discontinuation of further study  drug development
17.10. On-Site A udits
Representatives of the sponsor's clinical quality  assurance department may visit the study  site at 
any time during or after completion of the study  to conduct an audit of the study  in compliance 
with regulat ory guidelines and company  policy . These audits will require access to all study 
records, including source documents, for inspection. Subject privacy  must, however, be 
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
111
Status: Approved , Date: 31 January 2018respected. The investigator and study -site personnel are responsible for being present and 
available for consultation during routinely  scheduled study -site audit visits conducted by [CONTACT_170192]. 
Similar auditing procedures may also be conducted by [CONTACT_23865], either as 
part of a national GCP compliance program or to review the results of this study  in support of a 
regulatory  submission. The investigator should immediately  notify the sponsor if he or shehas
been contact[INVESTIGATOR_530] b y a regulatory agency  concerning an upcoming inspection.
17.11. Use of Information and Publication
All information, including but not limited to information regarding esketamine or the sponsor's 
operations (eg,patent application, formulas, manufacturing processes, basic scientific data, prior 
clinical data, formulation information) supplied by [CONTACT_43787], and any data, including pharmacogenomic orexploratory biomark er
research data, generated as a result of this study , areconsidered confidential and remain the sole 
propert y of the sponsor. The investigator agrees to maintain this information in confidence and 
use this information only to accomplish this study, and will not use it for other purposes without 
the sponsor's pr ior written consent.
The investigator understands that the information developed in the study will be used by [CONTACT_154988] , and thus may  be disclosed 
as required to other clinical investigators or regulatory  agencies. To permit the information 
derived from the clinical studies to be used, the investigator is obligated to provide the sponsor 
with all data obtained in the study .
The results of the study  will be reported in a Clinical Study  Report generated by [CONTACT_170195] . Recruitment 
performance or specific expertise related to the nature and the key assessment parameters of the 
study  will be used to determine a coordinating investigator . Results of pharmacogenomic or
exploratory biomarker analy ses performed after the Clinical Study  Report has been issued will 
be reported in a separate report and will not require a revision of the Clinical Study  Report. 
Study  subject identifiers will not be used in publication o f results. Any work created in 
connection with performance of the study  and contained in the data that can benefit from 
copy right protection (except any publication by [CONTACT_40999]) shall be 
the propert y of the sponsor as author and owner of cop yright in such work.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
112
Status: Approved , Date: [ADDRESS_385815] the right to publish such primary  (multicenter) data 
and information without approval from the investigator. The investigator has the right to publish 
study  site-specific data after the primary  data are published. If an investigator wishes to publish 
information from the study ,a copy  of the manuscript must be provided to the sponsor for review 
at least 60days before submission for publication or presentation. Expedited reviews will be 
arranged for abstracts, poster presentations, or other materials. If requested by [CONTACT_170196], theinvestigator will withhold such publication for up to an additional 60days to allow 
for filing of a patent application. In the event that issues arise regarding scientific integrity  or 
regulatory  compliance, the sponsor will review these issues with the investigator. The sponsor 
will not mandate modifications to scientific content and does not have the right to suppress 
information. Formulticenter study  designs and substudy  approaches, secondary  results generall y 
should not be published before the primar y endpoints of a study  have been published. Similarly , 
investigators will recognize the integrity  of a multicenter study by [CONTACT_41055], within 12 months of the availability  of the final data (tables, 
listings, graphs), or the sponsor confirms there will be no multicenter study  publication. 
Authorship of publications resulting from this study  will be based onthe guidelines on 
authorship, such as those described in the Uniform Requirements for Manuscripts Submitted to 
Biomedical Journals, which state that the named authors must have made a significant 
contribution to the design of the study  or analy sis and int erpretation of the data, provided critical 
review of the paper, and given final approval of the final version.
Registration of Clinical Studies and Disclosure of Results
The sponsor will register and disclose the existence of and the results of clinical studies as 
required b y law.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
113
Status: Approved , Date: 31 January 2018REFERENCES
1. Alphs L, Anand R, Islam MZ, et al. The international suicide prevention trial (InterSePT): rationale and design 
of a trial comparing the relative ability of clozapi[INVESTIGATOR_313302]. Schizophr Bull. 2004;30 (3):577 -586.
2. American Association of Suicidology. Depression and suicide risk 2014 . 
http://www.suicidology.org/Portals/14/docs/Resources/FactSheets/2011/DepressionSuicide2014.pdf (accessed 
7 September 2016 ).
3. American Red Cross. Blood Facts and Statistics. http://www.redcrossblood.org/learn -about -blood/blood -facts -
and-statistics (accessed 7 December 2016).
4. Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisf action, the Treatment 
Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health 
Qual Life Outcomes. 2004 Feb 26;2(1):12.
5. Ballard ED, Luckenbaugh DA, Richards EM, et al. Assessing measures of suicidal ideation in clinical trials 
with a rapid -acting antidepressant. J Psychiatr Res. 2015;68:68 -73.
6. Bazett HC. An analysis of the time -relationship of electrocardiograms. Heart. 1920;7:353 -380.
7. Beardsley PM, Balster RL. Behavioral dependence upon phencyclidine and ket amine in the rat. J Pharmacol 
Exp Ther. 1987;242:203 -211.
8. Beck AT, Steer RA, Kovacs M, Garrison B . Hopelessness and eventual suicide: a 10 -year prospective study of 
patients hospi[INVESTIGATOR_313303] . Am J Psychiatry. 1985;142(5):559 -563.
9. Beck AT, Steer RA . Beck Hopelessness Scale Manual. 1993 Edition.
10. Beck AT, Weissman A, Lester D, Trexler L . The m easurement of pessimism: the hopelessness scale. J Consult 
Clin Psychol. 1974; 42: 861 -5.
11. Bharmal M, Payne K, Atkinson MJ, Desrosiers MP, Morisky DE, Gemmen E. Validation of an abbreviated 
Treatment Satisfaction Questionnaire for Medication (TSQM -9) am ong patients on antihypertensive 
medications. Health Qual Life Outcomes. 2009;7:36.
12. Bickley H, Hunt IM, Windfuhr K, Shaw  J, Appleby L, Kapur N. Suicide w ithin two weeks of discharge from 
psychiatric inpatient care: a case- control study. Psychiatr Serv. 2013;64(7):653 -659.
13. Borges G, Nock MK, Haro Abad JM, et al. Tw elve-month prevalence of and risk factors for suicide attempts in 
the World Health Organization World Mental Health Surveys. J Clin Psychiatry. 2010 Dec; 71(12):1617 -1628.
14. Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS, Mazure CM. Measurement of 
dissociative states with the Clinician -Administered Dissociative State s Scale (CADSS). J Trauma Stress. 
1998;11(1):125 -136.
15. Brent DA, Greenhill LL, Compton S, et al. The Treatment of Adolescent Suicide Attempters study (TASA): 
predictors of suicidal events in an open treatment trial. J Am Acad Child Adolesc Psychiatry . 
2009; 48(10):987 -996.
16. Briefing Book, JNJ-54135419 -AAC (esketamine hydrochloride) . Esketamine for Rapid Reduction of 
Symptoms of Major Depressive Disorder, including Suicidality, in Patients who are Assessed to be at 
Imminent Risk for Suicide (25Aug 2016 ).
17. Cavan agh JT, Carson AJ, Sharpe M, Law rie SM. Psychological autopsy studies of suicide: a systematic 
review. Psychol Med. 2003 Apr; 33(3):395 -405. Addendum in: Psychol Med. 2003 Jul; 33(5):947.
18. Chang T, Savory A, Albin M, Goulet R, Glasko AJ. Metabolic disposition of tritium -labelled ketamine 
(Ketalar®, CI-581) in normal human subjects. Clin Res. 1970;18:597.
19. Clinical Study Report ESKETINTRD2003. A Double -Blind, Doubly -Random ized, Placebo -Controlled Study 
of Intranasal Esketamine in an Adaptive Treatment Protocol to Assess Safety and Efficacy in Treatment -
Resistant Depression (29 Apr 2016).
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
114
Status: Approved , Date: 31 January 201820. Collins GT, Woods JH. Drug and reinforcement history as determinants of the response -maintaining effects of 
quinpi[INVESTIGATOR_313304]. J Pharmacol Exp Ther. 2007;323:599 -605.
21. Collins RJ, Weeks JR, Cooper MM, Good PI, Russell RR. Prediction of abuse liability of drugs using IV self -
administration by [CONTACT_116434]. Psychopharmacology. 1984;82:6 -13.
22. Critchlow DG. A case of ketamine dependence with discontinuation symptoms. Addiction. 2006;101: 1212- 1213.
23. Curran HV, Morgan C. Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on 
the night of drug use and 3 days later. Addiction. 2000;95:575 -590.
24. Deisenhammer EA, Ing CM, Strauss R, Kemmler G, Hinterhuber H, Weiss E M. The duration of the suicidal 
process: how  much time is left for intervention betw een consideration and accomplishment of a suicide 
attempt? J Clin Psychiatry. 2009; 70(1):[ADDRESS_385816] in patients with treatment -resistant major depressive disorder. J Clin 
Psychiatry . 2010; 7 1(12):1605 -1611.
26. Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential ther apeutic targets. Science. 
2012;338:68 -72.
27. EuroQol Group. About EQ -5D. http://www.euroqol.org/about -eq-5d.html (accessed 15 September 2016).
28. EuroQol Group. EQ -5D-5L User Guide: basic information on how to use the EQ -5D-5L instrument. Version 
2.1; Apr 2015. 
http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Folders_Flyers/EQ -5D-
5L_UserGuide_2015.pdf (accessed 15 September 2016).
29. Geisslinger G, Hering W, Thomann P, Knoll R, Kamp H -D, Brune K. Pharmacokinetics and 
pharmacodynamics of ketamine enantiom ers in surgical patients using a stereoselective analytical method. Br J 
Anaesth. 1993;70:666 -671.
30. Haas DA, Harper DG. Ketamine: a review of its pharmacologic properties and use in ambulatory anesthesia. 
Anesth Prog. 1992;39:61 -68.
31. Hagelberg NM, Peltoniemi MA, Saari TI, et al. Clarithromycin, a potent inhibitor of CYP3A, greatly increases 
exposure to oral S -ketamine. Eur J Pain. 2010;14:625 -629.
32. Hijazi Y, Boulieu R. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of 
ketamine in human liver microsomes. Drug Metab Dispos. 2002;30:853 -858.
33. Hodges M, Salerno D, Erlien D. Bazett’s QT correction review ed: evidence that a linear QT correction for 
heart rate is better. J Am Coll Cardiol. 1983;1:694.
34. Hunt SM, McKenna SP. The QLDS: a scale for the measurement of quality of life in depression. Health 
Policy. [ADDRESS_385817];22(3):307 -319.
35. Hurt PH, Ritchie EC. A case of ketamine dependence. Am J Psychiatry. 1994;151:779.
36. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for 
Human Use. ICH Harmonized Tripartite Guideline E14: Clinical evaluation of QT/QTc interval prolongation 
and proarrhythmic potential for non -antiarrhythmic drugs. ICH 12 May 2005.
37. Investigator’s Brochure, JNJ -54135419 -AAC (esketamine hydrochloride) (29 Feb 2016) . 
38. Ionescu DF, Swee MB, Pavone KJ, et al. Rapid and Sustained Reductions in Current Suicidal Ideation 
Follow ing Repeated Doses of Intravenous Ketamine: Secondary Analysis of an Open -Label Study. J Clin 
Psychiatry. 2016 Jun;77(6 ):e719 -725.
39. Jansen KL. Ketamine --can chronic use impair memory? Int J Addict. 1990;25:133 -139.
40. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA. 2004;292:338 -343.
41. Kessler RC, Berglund P, Borges G, et al. Trends in suicide ideation, plans, gestures, and attempts in the United 
States, 1990 -1992 to 2001 -2003. JAMA. 2005 May 25; 293(20):2487 -2495.
42. Ketalar 10 mg/mL solution for injection/infusion: Summary of Product Characteristics; Aug 2014. [COMPANY_007] 
Healthcare Ireland, Dublin, I reland.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
115
Status: Approved , Date: 31 January 201843. Ketalar® (ketamine hydrochloride injection, USP) [[LOCATION_002] Prescribing Information]. JHP 
Pharm aceuticals, LLC; March 2012.
44. Ketamine HCl Injection: US Prescribing Information; Mar 2012. JHP Pharmaceuticals, LLC. [COMPANY_002]ster, 
Minnesota, [LOCATION_003].
45. Ketan est-S [Summary of Product Characteristics]. Ankeveen, Netherlands: Eurocept BV; 2011.
46. Koffarnus MN, Hall A, Winger G. Individual differences in rhesus monkeys’ demand for drugs of abuse. 
Addict Biol. 2011;17:887 -896.
47. Larkin GL, Beautrais AL. A preliminary naturalistic study of low -dose ketamine for depression and suicide 
ideation in the emergency department. Int J Neuropsychopharmacol. 2011; 14 (8):1127 -1131.
48. Lim DK. Ketamine associated psychedelic effects and dependence. Singapore Med J. 2003;44:31- 34.
49. Lindenmayer JP, Czobor P, Alphs L, et al. InterSePT Study Group. The InterSePT Scale for Suicidal Thinking 
reliability and validity. Schizophr Res. 2003; 63:161 -170.
50. Mathew SJ, Shah A, Lapi[INVESTIGATOR_27562] K, et al. Ketamine for treatment -resistant unipolar depression: cu rrent evidence. 
CNS Drugs. 2012; 26 (3):189 -204.
51. McAuliffe CM. Suicidal ideation as an articulation of intent: A Focus for Suicide Prevention? Archives of 
Suicide Research, 2002; 6:325 -338.
52. McKenna SP, Hunt SM. A new measure of quality of life in depressio n: testing the reliability and construct 
validity of the QLDS. Health Policy. [ADDRESS_385818];22(3):321 -330.
53. Meltzer HY, Alphs L, Green AI, et al. Clozapi[INVESTIGATOR_313305]: International 
Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60(1):82 -91. Erratum in: Arch Gen 
Psychiatry. 2003;60 (7):735.
54. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 
1979;134:[ADDRESS_385819] sizes in depress ion. Eur Neuropsychopharmacology. 
1994;(4)283 -284.
56. Moore NN, Bostw ick JM. Ketamine dependence in anesthesia providers. Psychosomatics. 1999;40:356 -359.
57. Moreton JE, Meisch RA, Stark L, Thompson T. Ketamine self -administration by [CONTACT_313374]. J Pharmacol 
Exp Ther. 1977;203:303 -309.
58. Morgan CJ, Muetzelfeldt L, Curran HV. Ketamine use, cognition and psychological wellbeing: a comparison 
of frequent, infrequent and ex -users with polydrug and non -using controls. Addiction. 2009;104:77 -87.
59. Morgan CJA, Curran HV, Independent Scientific Committee on Drugs. Ketamine use: a review. Addiction. 
2012;107:27 -38.
60. Morgan CJA, Curran HV. Acute and chronic effects of ketamine upon human memory: a review. 
Psychopharmacology. 2006;188:408 -424.
61. Morgan CJA, Muetzelfeldt L, Curran HV. Consequences of chronic ketamine self -administration upon 
neurocognitive function and psychological wellbeing: a 1 -year longitudinal study. Addiction. 
2010;105:121 -133.
62. Muetzelfeldt L, Kamboj SK, Rees H, Taylor J, Morgan CJ, Curran HV. Journey through the K -hole: 
phenomenological aspects of ketamine use. Drug Alcohol Depend. 2008;95:219 -229.
63. Murrough JW, Soleimani L, deWilde KE, et al. Ketamine for rapid reduction of suicide ideation: a randomized 
controlled trial. Psychol Med. 2015 (16);3571 -3580.
64. Narendran R, Frankle WG, Keefe R, et al. Altered prefrontal dopaminergic function in chronic recreational 
ketamine users. Am J Psychiatry. 2005;162:2352 -2359.
65. National Institute for Health and Clinical Excellence (NICE) Depression in adults: recognition and 
management. Clinical Guideline 90. National Collaborating Centre for Mental Health, London: October 2009. 
https://www.nice.org.uk/guidance/CG90 (accessed 16 September 2016).
66. Pal HR, Berry N, Kumar R, Ray R. Ketamine dependence. Anaesth Intensive Care. 2002; 30:382 -384.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
116
Status: Approved , Date: 31 January 201867. Pam bianco DJ, Vargo JJ, Pruitt RE, Hardi R, Martin JF. Computer -assisted personalized sedation for upper 
endoscopy and colonoscopy: a comparative, multicenter randomized study. Gastrointest Endos c.
2011;73(4):765 -772.
68. Portmann S, Kwan HY, Theurillat R, Schmitz A, Mevissen M, Thormann W. Enantioselective capi[INVESTIGATOR_154894] P450 enzymes which metabolize 
ketamine and norketamine in vitro. J Chromatogr A. 2010;1217:7942 -7948. 
69. Posner, K, Brow n GK, Stanley B, et al. The Columbia -Suicide Severity Rating Scale (C -SSRS): Internal 
Validity and Internal Consistency Findings From Three Multi- Site Studies With Adolescents and Adults, Am J 
Psychiatry 2011;168:1266 -1277.
70. Price RB, Iosifesc u DV, Murrough JW, et al. Effects of ketamine on explicit and implicit suicidal cognition: a 
randomized controlled trial in treatment -resistant depression. Depress Anxiety. 2014 Apr;31(4):335 -343.
71. Price RB, Nock MK, Charney DS, Mathew SJ. Effects of intrav enous ketamine on explicit and implicit 
measures of suicidality in treatment -resistant depression. Biol Psychiatry. 2009; 66:522 -526.
72. Rasmussen KG, Lineberry TW, Galardy CW, et al. Serial infusions of low -dose ketamine for major 
depression. J Psychopharmac ol. 2013 May; 27(5):444 -450.
73. Reich DL, Silvay G. Ketamine: an update on the first twenty -five years of clinical experience. Can J Anaesth. 
1989;36:186 -197.
74. Sagie A, Larson MG, Goldberg RJ, Bengston JR, Levy D. An improved method for adjusting the QT interv al 
for heart rate (the Framingham Heart Study). Am J Cardiol. 1992;70:797 -801.
75. Simon GE, Savarino J. Suicide attempts among patients starting depression treatment with medications or 
psychotherapy. Am J Pyschiatry. 2007; 164:1029 -1034.
76. Sinner B, Graf BM. Ketamine. In: Schüttler J, Schwilden H, eds. Modern Anesthetics: Handbook of 
Experimental Pharmacology. Berlin: Springer -Verlag; 2008;182:313 -333.
77. Tuynman -Qua H, de Jonghe F, McKenna SP. Quality of Life in Depression Scale (QLDS). Development, 
reliability, validity, responsiveness and application. European Psychiatry. 1997;12:199 -202
78. Vesierra® [Summary of Product Characteristics]. Sandwich, Kent, [LOCATION_008]: [COMPANY_007] Limited; 2014.
79. Wasserman D, Rihmer Z, Rujescu D, et al. The European Psychiatric Associati on (EPA) guidance on suicide 
treatment and prevention. Eur Psychiatry. 2012;27: [ADDRESS_385820]. 
1975;24:260 -263.
81. Williams JB, Kobak KA. Development and reliability o f a structured interview guide for the Montgomery 
Asberg Depression Rating Scale (SIGMA). Br J Psychiatry. 2008 Jan;192:52 -58.
82. Yanagihara Y, Kariya S, Ohtani M, et al. Involvement of CYP2B6 in N-demethylation of ketamine in human 
liver microsomes. Drug Met ab Dispos. 2001;29:887 -890.
83. Young AM, Herling S, Winger GD, Woods JH. Comparison of discriminative and reinforcing effects of 
ketamine and related compounds in the rhesus monkey. NIDA Res Monogr. 1981;34:173 -179.
84. Young AM, Woods JH. Maintenance of behavior by [CONTACT_313375] -administration histories. J Pharmacol Exp Ther. 1981,218:720 -727.
85. Zarate C, Brutsche NE, Ibrahim L, et al. Replication of ketamine’s antidepressant efficacy in bipolar 
depression: a r andomized controlled add -on trial. Biol Psychiatry. 2012;71: 939 -946.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
117
Status: Approved , Date: 31 January 2018Attachment 1:Prohibited Therapi[INVESTIGATOR_313306], please contact [CONTACT_313376] r egarding any specific concomitant therapi[INVESTIGATOR_53301] a subject. 
The pharmacotherapi[INVESTIGATOR_313307] (Y) or excluded (N) due to potential impact on efficacy  
evaluation and/or subject safety or because they are indicated for exclusionary conditions.
Except where specifically noted in the protocol, the prohibited therapi[INVESTIGATOR_313308] 1 day (24 hours) after the last dose of intranasal study medication.
Drug ClassEpi[INVESTIGATOR_170407]
(PRN)Continuous 
Use Comments
ADHD medications (eg, 
atom oxetine, guanfacine)N Y See also “Psychostimulants” row
Amantadine N N
Anorexiants (eg, 
phenteramine)N N
Anticonvulsants N N Subjects with seizures are excluded. 
Anticonvulsants used for other indications may be 
allow ed (eg, valproate for migraine, lamotrigine 
for mood disorder). Approval for use can be 
discussed on a case -by-case basis with the 
sponsor’s medical monitor.
Antidepressants ( except
monoamine oxidase 
inhibitors)N Y While continuous use of tricyclic antidepressants 
(TCAs) is not prohibited, given the target 
population (patients at imminent risk for suicide) 
and the known risk of lethality in TCA overdose, 
caution should be used if they are prescribed.
Epi[INVESTIGATOR_81532] (PRN) of trazodone is permitted but 
should not be used within 8 hours prior to the start 
of each intranasal study drug administration.
Antidepressants: 
Monoamine oxidase 
inhibitorsN N Prohibited w ithin the past 2 weeks prior to 
intranasal study drug administration on Day 1 and 
are not permitted throughout the study.
Antipsychotics Y (for sleep 
only)Y Use of antipsychotics (except clozapi[INVESTIGATOR_050]) for 
treatment of depression is not excluded. It w ould 
be excluded if being used for psychotic symptoms.
Epi[INVESTIGATOR_81532] (PRN) of antipsychotics (exce pt 
clozapi[INVESTIGATOR_050]) for sleep is permitted but should not be 
used within 8 hours prior to the start of each 
intranasal study drug administration.
Benzodiazepi[INVESTIGATOR_1651] (at 
dosages equal to or less 
than the equivalent of 6 
mg/day lorazepam)Y Y Prohibited w ithin [ADDRESS_385821] intranasal study administration on 
Day 1 and within 8 hours of Day 2 assessments.
Chloral hydrate N N
Clonidine Y Y Prohibited w ithin 8 hours prior to the start of each 
intranasal study drug administration.
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
118
Status: Approved , Date: 31 January 2018Drug ClassEpi[INVESTIGATOR_170407]
(PRN)Continuous 
Use Comments
Corticosteriods Y N Inhaled, intranasal, topi[INVESTIGATOR_2855], and ophthalmic 
steroids are not prohibited.
Intermittent IM/ IV corticosteroids are permitted 
(chronic use prohibited). Epi[INVESTIGATOR_313309] a case -by-case basis 
with sponsor’s medical monitor.
Cough/Cold/Allergy 
preparations (except those 
containing 
dextromethorphan)Y Y Intranasally -administered decongestants 
(vasoconstrictors) should not be used from 1 hour 
prior to each intranasal study medication 
administration. 
Pseudoephedrine -containing products should not 
be used w ithin 12 hours prior to an intranasal 
treatment session.
Dextromethorphan N N
DHEA Y Y
Diphenhydramine Y N PRN use is permitted, but should not be used 
within 8 hours prior to the start of each intranasal 
study drug administration.
Hypnotics 
(Non -benzodiazepi[INVESTIGATOR_78531])Y Y Do not use within 8 hours prior to the start of each 
intranasal study drug administration.
Ketanserin N N
Lithium N Y Patients with bipolar disorder (ie, lithium use for 
bipolar disorder) are excluded. Lithium use for 
another indication (eg, augmentation treatment for 
treatment -resistant depression) is permitted.
Methyldopa N N
Metyrosine N N
Opi[INVESTIGATOR_2438] Y Y Prescription opi[INVESTIGATOR_2536](s) can be 
continued, per clinician’s judgment
Non-vitamin K antagonist 
oral anticoagulation 
agents (eg, dabigatran, 
rivaroxaban, api[INVESTIGATOR_3822])N N
Psychostimulants 
(eg, amphetamines, 
methylphenidate, and 
modafinil, armodafinil)N Y The use of amphetamines (including prescribed 
amphetamines) can be continued but must not be 
taken within [ADDRESS_385822]. John’s Wort N N
Thyroid hormone 
supplementN Y Subjects needing supplements must be on a stable 
thyroid supplement dose for at least 4 weeks prior 
to Day 1 of the double- blind treatment phase.
Warfarin N N
Abbreviations : ADHD, attention- deficit/ hyperactivity disorder; DHEA, dehydroepi[INVESTIGATOR_2119] ;IM, 
intramuscular; IV, intravenous; PRN, epi[INVESTIGATOR_81532]; TCA, tricyclic antidepressant 
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
119
Status: Approved , Date: 31 January 2018Attachment 2:Anticipated Events
Anticipated Event
An anticipated event is an adverse event (serious or non -serious) that commonly occurs as a consequence 
of the underlying disease or condition under investigation (disease related) or backg round regimen.
For the purposes of this study the following events will be considered anticipated events37for esketamine 
and major depressive disorder (MDD) (based on DSM -5): 
 Suicidal thinking, ideation, and behavior
 Sleep changes, difficulty sleepi[INVESTIGATOR_007], reduced sleep, abnormal sleep, tiredness, fatigue, and reduced 
energy
 Difficulty in sexual desire, performa nce or satisfaction
 Reduced appetite and weight changes (loss or increase)
 Activation or hypomania/ mania
 Irritability, anger, and impulsive behavior
 Agitation, tension, panic attacks, and phobia
Reporting of Anticipated Events
All adverse events will be recorded in the eCRF regardless of whether considered to be anticipated events 
and will be reported to thesponsor asdescribed in Section 12.3.1 , All Adverse Events . Any anticipated 
event that meets serious adverse event criteria will be reported to the sponsor as described in 
Section 12.3.2 , Serious Adverse Events. These anticipated events are exempt from expedited reporting as 
individual single cases to Health Authorities. However if based on an aggregate review, it is determined 
that an anticipated event is possibly related to study drug, the sponsor will report these events in an 
expedited manner.
Anticipated Event Review Committee (ARC)
An Anticipated Event Review Committee (ARC) will be established to perform reviews of pre-specified 
anticipated events at an aggregate level. The ARC is a saf ety committee within the sponsor’s organization 
that is independent of the sponsor’s study team. The ARC will meet to aid in the recommendation to the 
sponsor’s study team as to whether there is a reasonable possibility that an anticipated event is related to 
the study drug.
Statistical Analysis
Details of statistical analysis of anticipated events, including the frequency of review and threshold to 
trigger an aggregate analysis of anticipated events will be provided in a separate Anticipated Events 
Safety Monitoring Plan (ASMP).
[STUDY_ID_REMOVED]
JNJ54135419 (esketamine)
Clinical Protocol 54135419SUI3002 Amendment 2
120
Status: Approved , Date: 31 January 2018INVESTIGA TOR AGREEME NT
[STUDY_ID_REMOVED]